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Summary
The work submitted for examination concerns several aspects of stroke patient 
management.
Chapter one is a general overview of the relevant literature concerning prevention of 
stroke both primary and secondary. The rationale for acute therapy, pathophysiology and 
specific treatments such as thrombolysis, anti-platelet agents, anticoagulation and novel 
neuroprotective agents are discussed within the introduction.
In Chapter two I examined the effects of the ACE inhibitor perindopril on blood pressure 
and total cerebral blood flow in hypertensive patients with recent ischaemic stroke. At 
present it is unclear at what stage it is safe to initiate anti-hypertensive therapy but in 
most cases this is delayed at least 72 hours. Patients admitted to the Acute Stroke Unit 
of the Western Infirmary are generally discharged either to the care of their general 
practitioners or to a further in-patient facility within 5 to 7 days of admission, it is 
therefore important to devise a risk factor intervention plan prior to discharge. Deferring 
decisions can result in unacceptable delays or even failure in the initiation of anti­
hypertensive treatment. A total of 28 patients were recruited to the study with 24 
completing the protocol. With a sample size of 2 4 patients we would expect to detect a 
difference in cerebral blood flow of 16% with 80% power.
I hypothesised that the ACE inhibitor perindopril could be instituted within 3-7 days of 
ischaemic stroke onset, and this treatment would be effective and safe. I used 
transcranial and carotid duplex Doppler ultrasound to assess any effect on cerebral blood 
flow. Blood pressure was effectively reduced, but there was no drug associated 
neurological deterioration and cerebral blood flow was unaltered. Patients were screened 
for underlying hypertension and following informed written consent allocated either
perindopril 4 mg or placebo for a period of 2 weeks within a double-blind, randomised, 
placebo-controlled study.
Blood flow was calculated from bilateral internal carotid artery Doppler ultrasound coupled 
to a wall tracker device. Arterial flow was calculated equal to n x diameter2. Doppler 
recordings were undertaken pre-treatment and at 2, 4, 8 and 24 hours and again at 2 
weeks.
In chapter three I examined the relationship between cholesterol and outcome following 
stroke with surprising results. All patients admitted through the Acute Stroke Unit of the 
Western Infirmary had total serum cholesterol measured routinely. 1,165 patients were 
included in the analysis. The results of the study suggested a clear dose dependent effect 
of elevated cholesterol on survival following stroke. The results were, however, counter­
intuitive with those patients with a significantly higher cholesterol having a better chance 
of survival. As the data linking cerebrovascular disease and elevated cholesterol is not 
wholly convincing appropriate placebo controlled intervention studies in patients with 
cerebrovascular disease are indicated before elderly patients should be routinely 
prescribed lipid lowering agents. I am currently involved in setting up such a placebo 
controlled study.
In chapter four I assessed the relationship between poor stroke outcome and 
hyperglycaemia. A number of studies have suggested a relationship between poor 
functional outcome and hyperglycaemia. 811 patients with computed tomography 
confirmed acute stroke and plasma glucose data were included in the study. The analysis 
was carried out retrospectively and represent consecutive admissions for which CT and 
immediate blood glucose data were available. Our results were consistent with the 
hypothesis that hyperglycaemia exerts a direct and independent effect predisposing to 
poor stroke outcome. These results have been confirmed by other investigators and there 
are a number of postulated mechanisms which have been put forward to explain this
trial of insulin therapy to correct hyperglycaemia versus standard observation in patients 
with acute stroke.
Chapters five, six and seven were phase II placebo controlled trials of novel 
neuroprotective compounds currently being evaluated as treatment for acute stroke. The  
studies were not powered to demonstrate efficacy but rather to evaluate tolerability, safety 
and clinical pharmacology prior to phase III studies.
In chapter five we evaluated the safety and tolerability of GV150526 (a glycine receptor 
antagonist) in patients with acute stroke. This drug was found to be extremely well 
tolerated when compared with other neuroprotective agents and the results suggest that 
putative neuroprotective concentrations can be achieved in patients with good tolerability. 
W e observed a hitherto unrecognised effect on liver function. These observations lead to 
further toxicology studies. The results of the study and pharmacokinetic analysis have 
been utilised in the design of a phase III clinical efficacy study.
Chapter six evaluated the safety and tolerability of remacemide hydrochloride, a 
neuroprotective NMDA antagonist with anticonvulsant activity. While putative 
neuroprotective levels were reached pharmacokinetics suggested that the active 
metabolite took some time to attain ‘therapeutic” levels and that rises in metabolite were 
associated with poor tolerability. Nausea, vomiting and CNS side effects such as 
hallucinations and agitation were commonly reported at the higher doses. In part due to 
the poor clinical tolerability but also because of the pharmacokinetic profile remacemide 
has not gone on to phase III evaluation in stroke patients, although it continues to be 
developed as an anticonvulsant.
In chapter seven we evaluated the tolerability of bolus single doses of aptiganel. Having 
predicted an appropriate infusion rate from the initial bolus pharmacokinetic data we 
assessed the effect of bolus followed by an appropriate infusion to maintain plasma levels 
at a steady state. Aptiganel is known to cause dramatic CNS effects and occasional 
hypertensive responses. The original dose selected for bolus and infusion was not well 
tolerated due to the frequency of CNS and significant hypertensive effects. A second 
dose and infusion regimen was then investigated. While there were CNS and blood 
pressure adverse events reported the results were deemed encouraging enough to 
proceed to a phase III efficacy study.
All studies within the thesis were approved by the W est Ethics Committee. Written 
informed consent was obtained from all patients entering into chapter two. In chapters 
five, six and seven informed consent was obtained wherever possible although informed 
assent was also considered acceptable in patients with speech or comprehension 
difficulties. The studies in chapter three and four were epidemiological and consent was 
not required.
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Introduction
This chapter will review stroke as a medical problem, discuss risk factors and 
their management, and introduce the background to neuroprotective 
interventions.
Stroke diagnosis, prevention and management of hypertension
1.01 Diagnosis
Stroke is responsible for 12% of all deaths in England and W ales1 with 2339 males and 2720  
females dying in the UK in 1992.2 It is the third greatest cause of mortality in Britain, 
superseded only by ischaemic heart disease and all cancers combined and has a profound 
social and economic effect not only on individuals who become disabled, but on society as a 
whole. The prognosis of patients with stroke is worse than for many forms of cancer, with 
half of all patients dead or dependent on carers after one year. The outcome is even more 
bleak for patients with severe stroke with 96% patients dead or dependent following a total 
anterior circulatory syndrome (TACS).3 Despite recent encouraging results with rt-PA, there is 
presently no widely applicable treatment for the majority of patients with acute ischaemic 
stroke.4 Effective means of secondary prevention: i.e.aspirin; anticoagulation in patients with 
atrial fibrillation; and carotid endarterectomy in patients with high grade carotid stenosis are 
now well established and are proven to reduce stroke recurrence.
The process of stroke diagnosis begins with recognition that a focal neurological deficit of 
sudden onset has arisen. The main differential diagnoses include epilepsy and migraine; 
these are distinguished from stroke mainly on the basis of the clinical history. Rarer 
possibilities include hypoglycaemia, intracerebral tumour, demyelination, syncope, subdural 
haematoma, malignant hypertension and giant intracerebral aneurysm.5 The diagnosis of a 
vascular event is therefore largely based on the clinical history and examination findings.
The importance of reaching an accurate diagnosis in the cases with good recovery is
14
paramount, to enable appropriate secondary preventive measures to be planned. It is no 
longer acceptable clinical practice to diagnose a cerebrovascular event without defining this 
further, and identifying the likely aetiology.6 The first distinction that must be made is 
between intracerebral haemorrhage and infarction. Despite the promulgation of clinical 
scoring tools to distinguish between the two, 7 9 scoring systems remain equivocal in a 
substantial proportion of patients and may be dangerously misleading in others.10 Since anti 
-thrombotic and anticoagulant treatments are increasingly recognised for secondary 
prevention of ischaemic stroke, it is essential to exclude haemorrhage in most cases.11 
Computed tomography (CT) scanning is the most reliable clinical tool currently available6 but 
should not be delayed beyond 2 weeks after the cerebrovascular event, since the 
appearances of a cerebral haemorrhage gradually alter and may become indistinguishable 
from infarction. Magnetic resonance imaging (MRI) may be a better option when a prolonged 
delay in investigation has occurred, but is more expensive and not freely available in all 
centres.
In ischaemic stroke the second element of diagnosis is to establish the vascular territory 
which has been affected.12 Carotid territory stroke should be distinguished from ischaemia in 
the posterior circulation, since patients with symptomatic carotid disease may benefit from 
carotid endarterectomy. Patients with infarctions in the watershed regions between major 
vessels (posterior, middle and anterior cerebral arteries) may have suffered systemic hy­
potension with or without occlusive disease in a proximal artery.13 These patients should be 
investigated for a precipitating cause e.g.silent myocardial infarction or arrhythmias.
The third element of diagnosis is to establish the pathophysiological processes which have 
eventually lead to cerebral ischaemia and correct as many of these modifiable risk factors as 
possible.
15
Hypertension predisposes to both large and small vessel disease. Hypertension is the major 
risk factor for small vessel cerebrovascular disease, which is probably neithert influenced by 
hyperlipidaemia nor amenable to surgical intervention. Small vessel disease predominantly 
leads to so-called ‘lacunar’ strokes. These may be recognised clinically as causing pure 
motor or pure sensory involvement of at least two adjacent elements of the face, arm and 
leg, or by the ‘dysarthria clumsy hand syndrome’ or an ataxic hemiparesis.
Cortical strokes, i.e. those involving higher cerebral dysfunction (neglect or dysphasia) often 
accompanied by hemiparesis and /  or hemianopia can be attributed to large vessel or 
embolic disease. The practical distinction that must be made is between those strokes 
caused by carotid stenosis, causing occlusive or embolic symptoms, and those due to 
cardioembolic disease. Patients with significant (>70%) stenosis should be considered for 
carotid endarterectomy, as this is now an established and effective secondary preventitive 
measure (figure 1.01.1). Unfortunately both may coexist making a firm diagnosis impossible.
Carotid disease is best diagnosed and quantified by colour flow duplex ultrasound (figures
1.01.2 and 1.01.3). The presence or absence of carotid bruits should be disregarded as they 
are not reliable indicators of underlying haemodynamic compromise. Cardiac investigations 
seeking embolic sources or cortical stroke in particular should be considered where clinical 
features suggest atrial fibrillation, a structural cardiac abnormality or recent myocardial 
ischaemia. Echocardiography should be reserved for patients with clinical or 
electrocardiographic evidence of a cardiac abnormality and for patients with no other risk 
factor for stroke. Patients with recurrent episodes of ischaemia in different cerebrovascular 
territories may have a central source of embolism, e.g. arising from the heart or arch of the 
aorta, and should be investigated with trans-thoracic and even trans-oesophageal 
echocardiography.
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The secondary prevention issues which arise primarily concern three approaches: 
anticoagulation for atrial fibrillation or presumed cardioembolic stroke; carotid 
endarterectomy for symptomatic ipsilateral carotid stenosis of 70% or more (but excluding 
carotid occlusion); and antihypertensive treatment.
Primary prevention of stroke by antihypertensive treatment is well established.14 Secondary 
prevention is likely to achieve even greater benefits since the absolute risk of stroke is 
substantially higher in such patients. Blood pressure management early after acute stroke is 
controversial. These issues will be discussed in detail.
1.02 Stroke Risk And Hypertension
The association between hypertension and the incidence of cerebrovascular disease and in 
particular acute stroke is now well established. A blood pressure reduction of 10-12/5-6 
mmHg confers a 38% reduction in stroke incidence.14 Unfortunately evidence suggesting 
that treating hypertension is an effective secondary preventative measure in patients 
following stroke or TIA is still scanty but the focus of current research interest.
The epidemiological evidence isolating hypertension as an independent risk factor for the 
primary incidence of both stroke and coronary heart disease came from nine prospective
15-23non-randomised observational studies. These studies involved almost 420 000 patients 
followed up, on average, for a period of 10 years. Thus, a 5 mmHg reduction in diastolic BP 
anywhere in the range of BP is associated with a 30%  reduction in stroke incidence while a 
10 mmHg BP reduces this by 50%. Furthermore the relationship between BP and incidence 
of stroke is approximately log linear,24 with no apparent 'threshold' level of blood pressure 
below which the association is lost (figure 1.02.1).
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Collins and MacMahon have suggested the initial strength of this association may have been 
significantly underestimated as a result of sampling errors. Many of these trials took blood 
pressure measurements as a baseline value prior to entry into the study. These values took 
no account of random fluctuations in the blood pressure and errors in blood pressure 
estimation itself. The result of this 'regression dilution bias'25 is usually an underestimation of 
the strength of association between two variables, in this case blood pressure and disease 
incidence.24 Data from the Framingham study21 suggest correction for this form of error 
increases the gradient of association between blood pressure and stroke by 60%.
The relationship between BP and the secondary incidence of stroke has not as yet been fully 
established. The UK TIA  trial suggested a continuous direct association between BP and
26stroke recurrence across the range of blood pressures similar to the primary incidence data. 
Again there was no evidence of a threshold level of BP below which the relationship was lost 
(figure 1.02.2). Other investigators have postulated a J-shaped relationship betwen BP and 
stroke recurrence rates, suggesting diastolic BP’s < 80 mmHg are associated with an 
increased risk of stroke recurrence27 (figure 1.02.3) A similar curve describes the 
relationship between BP and recurrent myocardial infarction.28 One possible explanation for 
the J-shaped curve is that patients with pathologically low blood pressures due to poor LV
29function have an increased risk of both stroke and myocardial infarction .
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1.03 Rationale for treating hypertension as a means of stroke 
prevention
Hypertension is an important precursor of both cerebrovascular disease and ischaemic heart 
disease. The incidence of cerebral infarction and haemorrhage are directly related to 
underlying hypertension while the relationship with subarachnoid haemorrhage is more
30complex with conflicting data from epidemiological, laboratory and clinical studies.
Although stroke is a heterogeneous condition with many different causes and pathologies 
hypertension accelerates and contributes to the development of many of these. Coronary 
heart disease, large vessel atheroma formation, aneurysmal dilatation intracerebral 
haemorrhage and arteriosclerosis of small vessels are examples.31 Large blood vessel 
changes induced by hypertension include hypertrophy of smooth muscle and elastic fibres, 
leading eventually to fibrous replacement.32 The vessel walls become increasingly thickened, 
rigid, elongated and tortuous with dilated lumina. Small vessel lumina are reduced due to 
intimal thickening and undergo hyaline arteriosclerosis, an age-dependent process acceler-
33ated by underlying hypertension. Cerebral arteries develop lipohyalinosis and miliary 
aneurysms which can rupture leading to primary intracerebral haemorrhage.34 This most fre­
quently affects the perforating arteries of the basal ganglia, cerebellum and periventricular 
white matter.
Severe hypertension also leads to thrombotic occlusion of arterioles. The overall effect of 
these changes increases cerebrovascular resistance and therefore reduces cerebral 
perfusion.32
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Patients with hypertension also have a reduced ability to maintain cerebral perfusion in the 
face of fluctuating systemic blood pressures. Cerebral autoregulation is a dynamic 
homeostatic system which maintains cerebral perfusion at a constant level despite changes 
in systemic blood pressure by altering the cerebral vascular resistance. In a normotensive 
individual the lower limit of autoregulation is 60-70 mmHg (mean arterial BP). Below this 
level, but between pressure levels of 40-60 mmHg the brain can compensate by increasing 
its extraction of O2. When BP falls further brain hypoxia develops and cell death will occur.35 
In hypertensive patients the autoregulation thresholds are set at an abnormally high level, i.e. 
85 mmHg,36 thus predisposing the individual to hypoperfusion of brain tissue should blood 
pressure fall dramatically.37 It is likely but unproven that the extent of autoregulatory resetting 
depends on the severity of the hypertension. Autoregulatory resetting could theoretically 
increase the likelihood of watershed infarction in the event of a hypotensive episode and 
cases of neurological deterioration have been documented following sudden lowering of BP 
to ‘normal' values. Recent research in animals has shown that correction of blood pressure
o o  OQ
can lead to correction of the autoregulation set-point. Similar studies in humans have 
however as yet failed to demonstrated significant resetting of the autoregulation threshold in 
either normotensive or hypertensive subjects.40 Hypertension consequently contributes to 
the development of a myriad of pathological mechanisms all of which make cerebral 
infarction or haemorrhage more likely.
It is logical to assume that control of hypertension may reduce the future risk of stroke by 
halting or reversing these mechanisms.
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1.04 Benefits of primary prevention
Thus far 17 randomised placebo-controlled trials of antihypertensives have been performed, 
involving 47,000 patients known to be hypertensive but without symptomatic cerebrovascular 
disease.24 A total of 1360 strokes were detected over a follow-up period of, on average, 5 
years. The reductions in stroke risk associated with a particular drop in BP were even more 
impressive than extrapolation of the epidemiological evidence might have predicted. A  
reduction in diastolic BP of 5mmHg was associated with a 38%  reduced risk of stroke 
(figurel .04.1): while epidemiological evidence from the the Framingham study suggested 
only a 30% reduction was likely. The results of these trials also suggested that most, if not 
all, of the benefits associated with blood pressure reduction are apparent within 2-3 years of 
treatment commencing.
The proportional reductions in stroke risk were similar for trials using higher or lower blood 
pressures as inclusion criteria, i.e. there appears to be no additional benefit from lowering BP 
in patients with higher baseline values. If these group risk reductions are applicable to 
individual patients, it could be concluded that maximal benefit in terms of numbers of strokes 
prevented per patient treated would be observed in those patients at higher risk of stroke. 
Middle-aged hypertensives have an annual incidence of stroke of approximately 0.5% 14 
whereas older hypertensives have a greater risk of 1.5%.41 If treated for a period of 10 years 
50 low-risk patients compared to 17 high-risk would be required to prevent one stroke.
Recent studies emphasing the importance of treating hypertension in the elderly population 
have lead to a new awareness of the potential benefit from active antihypertensive 
intervention in this group of patients. The SHEP investigators42 demonstrated reduced total 
mortality, cardiovascular mortality and morbidity and stroke in patients aged over 60 years of
21
age with isolated systolic hypertension. The relative reduction in stroke risk was 36%, 
demonstrating that, at least in the elderly, systolic blood pressure has prognostic implications 
independent of diastolic values (figure 1.04.2).
1.05 Benefits of antihypertensive therapy as secondary prevention of 
stroke
It might be postulated that the greatest benefit from anti hypertensive treatment would be 
derived from patients who have suffered either a TIA  or stroke, where the risk of recurrence 
is at least 5% per annum.43 While it is hoped that the benefits of treating hypertension 
observed in large clinical trials in patients asymptomatic for cerebrovascular disease might 
be mirrored in this group of patients, as yet no definitive study has been conducted. 
Retrospective observational analysis of mortality and stroke recurrence in Rochester, Minne­
sota, USA, failed to reveal an association between blood pressure and stroke recurrence 
rates, throughout a 30-year follow-up period in a total of 1600 patients.44 In a more recent 
study in patients following a transient ischaemic attack a direct continuous association 
between blood pressure and the secondary incidence of stroke was observed.45 The 
epidemiological evidence is therefore not as conclusive or complete as the data linking the 
primary incidence of stroke and hypertension.
Secondary prevention data are available from a mere two trials including a total of only 549  
hypertensive patients.14 Two further studies have been carried out treating normotensives 
following a TIA with atenolol. These trials recruited 2193 patients but only modest reductions 
in blood pressure were demonstrated (2-3 mmHg diastolic).45,46 Patient numbers were, as a 
result, inadequate to demonstrate the epidemiologically predicted benefits in lowering stroke 
risk (20%). If all four studies data are pooled together, the results suggest a benefit in stroke
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risk reduction of 19%, but with wide confidence intervals (95% CI:-49%, +11% ) (figure
1.05.1). Future studies in hypertensive patients where BP is more conclusively lowered may 
reveal a greater reduction in the stroke incidence.
A large placebo-controlled trial (PROGRESS) is currently underway assessing the efficacy 
of a thiazide diuretic and/or the angiotensin converting enzyme (ACE) inhibitor perindopril as 
secondary prevention for stroke in mildly hypertensive and normotensive individuals.47 48 It is 
hoped that by recruiting 6000 patients and following them up for a prolonged period (5 years) 
the trial will be sufficiently powered to demonstrate the benefit of anti hypertensive therapy in 
patients with cerebrovascular disease.
W hile trial and epidemiological evidence suggests the greatest benefits to individuals are 
gained in those patients at highest risk, the potential for reducing the overall population 
stroke incidence in younger mild hypertensives and even normotensives is, nevertheless, 
substantial as numerically they make up most of the population. While it would be 
inappropriate to intervene pharmacologically with all these individuals, public health 
measures to reduce blood pressure, e.g. by promoting exercise, reducing obesity, or lowering 
salt intake, could conceivably be hugely effective in reducing the future stroke risk of 
millions.
As yet, no specific group of antihypertensive agents have been identified as more effective 
than any other. Comparative studies of thiazide diuretics and beta-blockers have been 
performed in four trials involving 23,000 hypertensive patients.49 A statistically insignificant 
13% greater reduction in stroke risk was noted in the thiazide group. As yet, a comparative 
trial with sufficient statistical power to elucidate the effects of different antihypertensive 
medications on mortality and stroke recurrence has not been performed.
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1.06 Management of hypertension in acute stroke
Assessment of hypertension after an acute stroke is complicated by physiological changes 
which influence the level of blood pressure itself and the effects of blood pressure lowering 
therapy on patients with cerebral ischaemia. First, cerebral autoregulation is impaired after
50stroke. Cerebral perfusion is proportional to systemic BP and reduction of BP acutely may 
impair perfusion to the ischaemic penumbra. The penumbra is defined as an area of brain 
tissue where electrical activity is lost but the potential to recover electrical activity and 
contribute to a useful functional recovery still exists.51,52 Any reduction in blood flow to such 
a critically perfused area could mean the difference between irreversible infarction and the 
resolution of symptoms and recovery.
Many case reports suggest lowering of BP acutely in patients with ischaemic stroke leads to 
a worsening of clinical outcome,53 and evidence from therapeutic trials of the calcium 
antagonist, nimodipine, supports this view. Early BP reduction in this study was associated 
with an adverse functional outcome54 (figure 1.06.1). Similar findings were noted in a small 
pilot study assessing the ion channel blocker lifarizine: in this case, a significant drop in the 
blood pressure of elderly females receiving active drug was associated with a poorer 
functional outcome.55
Blood pressure reduction may be specifically contraindicated in the presence of significant 
carotid and/or vertebral stenosis. The most obvious example would be a patient with wide­
spread vascular disease who has bilateral carotid stenosis, perhaps having progressed to 
unilateral occlusion, and severe systolic hypertension. Just as BP reduction may impair renal 
function in the presence of bilateral renal artery stenosis, the risk of ischaemic stroke may be 
increased by reduction of BP.13 There little scientific evidence to support this theory but a
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significant number of hypertensive patients have antihypertensive therapy withheld because 
of these concerns.
Dose dependent increases in blood pressure are seen with the NMDA antagonist aptiganel, 
with rises of mean arterial blood pressure up to 30mmHg. This has not been shown to affect 
total cerebral blood flow but MCA velocity is increased.56 These blood pressure effects have 
now been reported in stroke patients (chapter 7). It is conceivable that rises in systemic 
blood pressure could lead to exacerbation of cerebral oedema or even haemorrhagic 
transformation of infarction, but it is equally possible that moderate rises in BP are beneficial 
to outcome by increasing local perfusion and improving blood flow. Deliberate attempts are 
made to increase BP and reduce delayed cerebral ischemia after subarachnoid haemorrhage 
by a combination of hypervolaemia, hypertensive agents, and hyperventilation.
Drugs lowering BP are therefore likely to have any neuroprotective effect obscured by an 
adverse BP lowering effect, while the effect of modest rises in blood pressure is as yet 
unknown and requires further research.
There is no doubt that in cases of severe hypertension especially if associated with 
papilloedema, retinal haemorrhages and soft exudates (accelerated or malignant phase 
hypertension) blood pressure should be reduced. Severe hypertension is characterised not 
only by cerebral autoregulatory failure but also by fits and focal neurological damage. At 
present few clinicians would intervene to lower blood pressure by pharmacological means 
unless blood pressure was sustained for several hours at over 120 mmHg diastolic and or 
220 mmHg systolic, or in patients with other clinical features of accelerated phase 
hypertension.57 There are some circumstances when cautious blood pressure reduction 
should be considered at a lower threshold. These include patients with other cardiovascular 
events such as aortic aneurysm, acute myocardial infarction, heart failure, primary
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intracerebral haemorrhage or haemorrhage due to arterial dissection or aneurysmal 
rupture.657
Approaches to the management of raised blood pressure in acute stroke are complicated by 
the well documented rise in blood pressure which commonly occurs in patients within the first 
48-72h of admission to hospital after stroke.58,59 This rise and subsequent spontaneous fall 
appears to be related to the physical and psychosocial stresses of admission to hospital and 
not to the acute ictal event59 (figure 1.06.1). Short-term blood pressure elevation may be 
associated with bladder distension, and pain. Systematic studies have revealed evidence of 
activation of the renin-angiotensin system and sympathetic nervous system in patients with 
acute stroke. This activation is likely to contribute to the observed transient elevation of blood 
pressure. The rise in blood pressure occurs in those who were previously normotensive as 
well as in patients with a history of hypertension. In the case of the latter they start from a 
higher baseline, rise to higher levels and subsequently fall to their hypertensive baseline. 
W hile it is widely believed that this transient rise in blood pressure is not of pathological 
significance, it must be acknowledged that this conclusion is not based on any formal 
randomised observation or intervention study. It is therefore important to recognise that 
many stroke patients with hypertensive BP readings on admission will spontaneously 
normalise their BP within the next 5-7 days. Decisions about long-term treatment of mild to 
moderate hypertension in stroke patients should therefore be based on blood pressure 
recordings weeks or months after the stroke and on other considerations such as evidence of 
target organ damage (electrocardiographic and echocardiographic left ventricular 
hypertrophy, renal impairment, proteinuria, etc.). There is probably more justification in 
treating hypertension in association with lacunar infarction, particularly where other 
cardioembolic or associated risk factors are absent.
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It may be justifiable to manage hypertensive patients with intracerebral haemorrhage more 
aggressively as this may contribute to continued bleeding and further rises in intracranial 
pressure. These patients tend to show a more marked acute hypertensive reaction after
59stroke with a more protracted period of elevated blood pressure.
As discussed above, it is only on infrequent occasions that blood pressure requires urgent 
reduction in patients with acute stroke. In our Acute Stroke Unit with over 700 admissions 
each year, such treatment is indicated less than once a month. Unfortunately, there are few if 
any adequately controlled studies to guide the choice of drug therapy in acute stroke. 
Extrapolation of experience from other hypertensive emergencies and urgencies is probably 
not justified in view of the particular haemodynamic circumstances of acute stroke discussed 
above.
The choice of drugs and formulations varies widely between countries. If patients are 
unconscious or have swallowing difficulties, an intravenous preparation will usually be re­
quired further limiting the choice. Ideally blood pressure should be reduced in a predictable 
and controlled manner to intermediate levels of 160-170/90-110 mmHg for the first 5-7 days. 
Uncontrolled, excessive falls or prolonged reductions in pressure should be avoided. 
Intravenous infusion of sodium nitroprusside or nitrates in the short-term offers the optimal 
potential for control of the fall in blood pressure with rapid reversal of the effect should that 
be necessary. Diazoxide or hydralazine intravenously were formerly used but may cause 
excessive falls in blood pressure or marked reflex tachycardia, while intravenous clonidine or 
labetalol have been used in some North American and European clinics.
In the absence of sound evidence from clinical trials the choice of drugs is largely empirical 
and likely to be influenced by other associated medical conditions. Amongst the newer drugs.
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angiotensin-converting enzyme (ACE) inhibitors deserve formal evaluation in acute stroke 
not least because preliminary evidence suggests that unlike many older antihypertensive 
agents ACE inhibitors do not acutely reduce cerebral blood flow in ischaemic stroke.60 ACE  
inhibitors have been shown to reduce the incidence of recurrent myocardial infarction.61,62 
Studies in animals suggest possible additional benefits by reducing atheromatous plaques in 
both carotids and other vessels.63'65 The American Heart Association guidelines6 suggest 
that the ACE inhibitors or calcium antagonists can be used but warn of precipitous falls after 
sublingual' calcium antagonists.
Cerebrovascular disease remains a major complication of inadequately treated hypertension. 
Physicians who manage hypertensive patients should acknowledge the challenges which 
face them. The optimal management of BP is not known, either immediately following stroke, 
or in normotensive survivors of stroke. Primary prevention could also be improved by 
greater attention on the part of cardiovascular physicians to anticoagulation in patients with 
atrial fibrillation since few other groups of doctors are in a position to provide advice and 
follow-up on the scale which is required. Further research is required to establish the optimal 
treatment of the hypertensive patient with cerebrovascular disease.
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1.07 Rationale for acute intervention in stroke
In the United States the American Heart Association has published guidelines on the 
management of stroke patients with particular regard to blood pressure control, the need for 
CT scanning, and the indications for carotid endarterectomy as secondary prevention. In the 
UK these guidelines are not widely practised and a recently conducted survey of consultant 
opinion in the UK demonstrated widely differing views on management, even on the 
necessity for CT scanning.66 This reflects the lack of concrete trial evidence supporting any 
form of interventional therapy and a degree of apathy within the medical profession. There 
has however been an explosion of knowledge regarding the pathophysiology of cerebral 
ischaemia and infarction and a rigorous effort is in progress to develop drugs which may 
preserve brain tissue by interfering with the processes that give rise to and exacerbate 
ischaemia.
Physicians treating stroke patients have taken heart from the results of the National Institute 
of Neurological Disorders and Stroke rt-PA Stroke Study Group (NINDS) study of rapid 
thrombolysis of patients with CT confirmed stroke. The results show a reduction in mortality 
and morbidity in patients receiving thrombolysis within 3 hours of onset of symptoms.4 This 
is the first good evidence that an as yet undefined time window of opportunity exists for the 
treatment of stroke not only in animal experimental models, but also in humans. To decide 
on a strategy for the development of any potential new treatment we must first consider the 
processes that lead to stroke, and the pathophysiological changes that take place within 
ischaemic brain tissue and that contribute to the eventual extent of the infarct.
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1.08 Pathophysiology of ischaemic stroke and its influence on 
treatment strategies
Stroke is a heterogeneous condition most commonly precipitated by large or small vessel 
atherothrombosis; it may also result as a consequence of embolism from the heart, the arch 
of the aorta or carotid vessels; and a number of other rarer causes e.g. trauma leading to 
vertebral artery dissection, haematological problems such as hypercoagulation or 
hyperviscosity states, and neurovascular abnormalities e.g.Moya Moya disease. A further 
15%-20% of strokes are due to primary intracerebral or subarachnoid haemorrhage. Since a 
variety of different insults can precipitate cerebral ischaemia, it is unlikely that any one mode 
of treatment will be of benefit to all patients.
The brain is dependent on a rich supply of both oxygen and glucose. W hen blood flow to the 
brain ceases abruptly i.e. following cardiac arrest, unconsciousness and irreversible neuronal 
damage rapidly ensue and infarction develops if adequate perfusion is not rapidly 
reinstated.67 Evidence from animal models of stroke suggest that following an ischemic insult 
neurological damage spreads out circumferentially from the central core of the infarct.68 If 
ischaemia is present for over an hour the volume of infarction gradually enlarges to its 
maximal size over a period of 3-4 hours in rodents69 and 6-8 hours in non-human primates70 
and an as yet undetermined time in humans.
Experiments in baboons investigating the effects of ischaemia on neurone membrane 
potentials indicate a critical blood flow threshold value <15 ml_ /100g per minute associated 
with electrical silence, despite normal membrane potentials and almost normal levels of 
ATP.71
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At flow rates <10 mL /1 0 0  mg per min total energy failure occurs and ATP becomes 
depleted resulting in the breakdown of normal ionic homeostasis. Potassium efflux and 
sodium influx follow associated with dramatic increases in the intracellular calcium 
concentration.72 The levels of flow between these two thresholds offer conditions in which 
tissue can either become irreversibly ischaemic or recover. It is this so-called ‘penumbral’ 
area which it is hoped will be amenable to therapeutic salvage.
In man positron emision tomography (P E T ) techniques have demonstrated reversible 
ischaemia up to 48 hours after stroke but it is not known whether this represents the true 
window of opportunity for treatment.73 This new technology now means it is possible to study 
changes in local cerebral metabolism and blood flow in humans. PET scanning gives details 
on the relative extraction fractions of oxygen, the quantity of oxygen and glucose 
metabolised, and the regional perfusion of ischaemic areas. Dense ischaemia is associated 
with irreversibly reduced metabolism of both oxygen and glucose. Results from these patient 
studies have confirmed what was already believed from the above primate studies. Regional 
cerebral blood flow of below 12mL/100g /min or regional metabolic rates for oxygen below 65  
(jjnol/100gr/min were associated with irreversible necrosis.74 When perfusion was less 
drastically reduced i.e. in those penumbral areas surrounding the densely ischaemic core, 
cerebral metabolism of glucose and oxygen was still maintained by a relative increase in 
oxygen extraction. The brain can therefore compensate for small reductions in perfusion by 
increasing its extraction of nutrients.
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Animal models of stroke
Before any potential treatment can be assessed within clinical studies in man a sound 
rationale for its use must be demonstrated. This inevitably involves preclinical testing within 
cell culture or animal models of stroke. Cell culture can be used to screen a large number of 
potentially neuroprotective compounds. A variety of neurotoxic insults has been used 
including hypoxia, excitatory amino acid agonists, and activators of sodium channels.75-77 
Since stroke is a neurological manifestation of a vascular disorder, reliable animal models of 
the vascular causes of stroke have been developed.
There are basically two in vivo animal models of cerebral ischaemia. Models of global 
ischaemia are more representative of conditions following cardiac arrest and prolonged 
anoxia whereas models of focal ischaemia, i.e.the middle cerebral artery occlusion (MCAo) 
model, mimic the effects of a large vessel occlusion in humans.78 Most studies have been 
conducted using small rodents i.e.rat or gerbil as these animals are inexpensive to maintain. 
Ischaemia can be induced artificially using a number of techniques to occlude large vessels 
like the MCA i.e. intraluminal filament insertion, electrocoagulation, or extraluminal 
compression. Embolic stroke can be simulated by injecting polystyrene microspheres into 
the cerebral circulation.76 In animal models of stroke very low flow caused by occlusion of 
major cerebral vessels leads to immediate weakness of limbs and infarction develops within 
5-10 minutes if blood flow is not re-established.79 Less dramatic reductions in blood flow can 
be induced by occluding the middle cerebral artery of animals (MCAo model). Infarction 
develops over 3-4 hours in rodents69 and 6-8 hours in non-human primates80 and an as yet 
undefined period in humans.
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A  large number of potentially neuroprotective as well as thrombolytic compounds have been 
evaluated using these models. Unfortunately due to the practical and ethical issues in 
conducting such experiments in higher primates, only limited data from old studies are 
available on species more closely related to man. Results of studies with thrombolytics and 
neuroprotective agents in rodent models are encouraging with substantial reductions in
81infarct volume when drug is administered before, during or even after the vascular insult.
Results in human trials have failed to demonstrated efficacy for treatment other than 
thrombolytics. There are a number of reasons why this may be so: the anatomical difference 
between rodent brain and man, the predominant use of relatively young healthy animals 
unrepresentative of human patients with stroke, and the careful control of oxygen saturation, 
blood pressure and temperature. Furthermore, pre-clinical investigators can, to a large 
extent, control the ratio of densely ischaemic tissue /  ischaemic but viable tissue. The 
methods used to generate cerebral ischaemia within these models are therefore more 
controlled than in the clinical setting and may overestimate the potential benefit of therapy.
1.09 Mechanisms of neurotoxicity
Recent interest has focused on the potential role of the N-methyl-D-aspartate (NMDA) 
receptor and excitatory amino acids (EAA) in the development of cerebral infarction. While 
the reduction in oxygen and nutrient supply to the brain provides the initial insult to ischaemic 
neurones, tissue damage is exacerbated by a complex cascade of receptor mediated events. 
In normal physiological conditions these receptors mediate essential neurological functions 
such as cognition, memory, movement and sensation. Varying insults may give rise to the
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same ‘common pathway’ of neurological damage i.e. hypoglycaemia, AIDS dementia 
complex, motor neurone disease and possibly Alzheimers disease.82
Excitatory amino acids are thought to have a crucial role in the development of neurological 
damage once cerebral perfusion is reduced to a level where metabolic activity is 
compromised but may potentially still recover.78 Recovery of perfusion through collateral 
circulation may lead to a resolution of neurological function, but further neurological damage 
may occur due to the subsequent build up of EAAs.69,73,80 The best evidence of this comes 
from animal models of stroke where antagonism of the NMDA receptor reduces infarction 
volume by as much as 50%.
Glutamate is the most abundant EAA in the human brain and is stored in presynaptic 
vesicles. Normally its release from presynaptic terminals is mediated by exocytosis and 
diffusion across the synaptic cleft where it exerts an excitatory effect on post-synaptic 
neurones. Glutamate is physiologically cleared from the extracellular space and deposited in 
astrocytes and presynaptic neurones by energy dependent uptake systems. It is then 
converted to glutamine through a further energy requiring enzyme system. These 
mechanisms are dependent on the normal physiological gradient of sodium and potassium 
across the cell membrane. During ischaemia, the resultant energy loss leads to these
83-87transport and conversion systems failing or even acting in reverse. Amino acids are also 
produced by injury to neighbouring cells initiating a further potent positive feedback loop of 
increasing excitotoxicity and rising glutamate levels. Activation of EAA receptors lead to 
influxes of sodium, chloride and water which lead to cellular swelling but it is the entry of 
extracellular calcium and mobilisation of intracellular calcium which lead ultimately to 
neuronal death.
There are two main groups of glutamate receptors: ionotropic receptors are coupled directly 
to membrane ion channels controlling calcium or sodium influx and metabotropic receptors
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are linked to intracellular phosphatidyl inositol enzyme systems, lonotropic receptors can be 
split into three groups according to their selective agonists: N- methyl-D-aspartate (NMDA), 
alpha-amino-3-hydroxy-5-methyl-isoxazolepropionate (AMPA) and kainate.81 Thus far, 
antagonists of the two former ionotropic receptors have been developed and assessed as 
potential neuroprotectives in animal models of stroke while little is currently known regarding 
the detail of metabotropic receptor function. A threshold relationship between excess 
glutamate release and cerebral blood flow exists whereby elevations in glutamate are 
triggered by flow rates below 20 ml_ per 100g of brain tissue per minute.88 This is a similar 
flow rate to the threshold associated with ischaemia i.e. 17 mLs /  100g /min89 and is 
substantially higher than flow rates leading to hypoxic energy failure and cell death (10mL / 
100g /min).72 This suggests a grey zone between the onset of the increase in EAA’s and 
irreversible neurotoxicity. It is hoped that neuroprotective drug therapy could salvage part of 
this ‘penumbral’ brain tissue by antagonising EAA’s and their effects.
The role of calcium in neurotoxicity
There are two subsets of voltage sensitive calcium channels of importance in mediating 
excitotoxic damage. Activation of L-type receptors leads to a post-synaptic calcium leak that
90may be blocked by conventional calcium blocking drugs, such as nimodipine. Drugs in this 
group are neuroprotective both in cell culture and in in-vivo animal models of stroke.91 N-type 
calcium channels are mainly found in neuronal tissue and control the release of a number of 
synaptically stored neurotransmitters, including the excitatory amino acids glutamate and 
aspartate. Opening of these channels and the resultant calcium influx add to the cycle of
92excitotoxic amino acid release in another positive feedback mechanism. These channels 
can be blocked by a class of short peptides known as conotoxins, but these have not yet
93been evaluated as potential neuroprotectives. Intracellular calcium is also mobilised during
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excitotoxic overstimulation and inhibitors of the release of intracellular calcium, such as 
dantrolene, are neuroprotective in tissue culture. Increases in intracellular calcium may 
activate lipases, proteases and endonucleases resulting in the condensation of nuclear 
chromatin and DNA fragmentation, leading to apoptosis or cell death. Other potentially cell 
damaging systems initiated include protein kinase C, phospholipases, and nitric oxide 
synthase. Activation of phospholipase A2 generates arachidonic acid and its metabolites as 
well as platelet activating factor. This in turn potentiates the glutamate induced potentials,
94reducing astrocyte glutamate reuptake mechanisms and increasing neuronal calcium. Thus 
self perpetuating mechanisms of increasing levels of intracellular calcium and glutamate lead 
to exacerbation and expansion of the area of neuronal injury and cell death. The 
homeostasis and pathological effects of excess glutamate and calcium are summarised in 
figure 1.09.4.
Nitric oxide and cerebral vasculature
Nitric oxide has a complex role in the regulation of the cerebral circulation. It may act as a 
neurotransmitter and also controls vascular tone. Vasodilatation to carbon dioxide and 
neurotransmitters such as acetylcholine, serotonin, substance P, and ADP are dependent on 
the generation of NO.95'102 NO is produced by a variety of cells within the cerebral 
circulation. Neurones, glia and endothelium can all produce NO mediated by the enzyme 
nitric oxide synthase (NOS) which converts L- arginine to citrulline and NO. In conditions of 
L-arginine deficiency NOS may however lead to the production of toxic free radicals such as 
superoxide. NO acts on local target cells by activating guanylate cyclase (GC). NO may be 
present and active under basal conditions in a constitutive form, the generation of which may 
be further stimulated by increases in intracellular calcium. Much larger quantities of inducible 
NO can be produced and this may mediate more pathological effects.103104
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In vivo administration of inhibitors of NO synthase, i.e. the L-arginine analogues L-NMMA, L- 
NNA and L-NAME, all reduce local cerebral blood flow by increasing local vascular tone. 
Impaired endothelium dependent relaxation is also observed in pathological states such as 
hypertension105'108 and diabetes.109111 This appears to be due to the production of an 
endothelium derived contracting factor that counteracts the normal physiological dilator 
effects of NO. Activation of the NMDA receptor complex induces production and 
extracellular release of NO by neurones.112 Administration of excitatory amino acids such as 
glutamate also induces cerebral arteriolar dilatation through a NO dependent pathway.113-116 
Nitric oxide may have both beneficial and toxic effects in cerebral ischaemia, as 
demonstrated by the conflicting reports of neuronal culture and in-vivo experiments. On the 
benefit side NO increases local perfusion, by inducing vasodilatation and inhibiting 
aggregation and adherence of platelets and polymorphs.117 Higher levels may however be 
toxic and it is postulated that the beneficial or toxic effect is determined by the redox state of 
NO. Oxidised NO produces the nitrosonium ion which reacts with the thiol group on the 
NMDA receptor’s modulatory site. This reaction acts as a negative feedback mechanism  
downregulating the NMDA receptor and preventing excess stimulation and excitotoxicity. The 
reduced form however may react with superoxide anions to produce a neurotoxic 
peroxynitrite ion (O N O O - ).118
In short, processes involving NO are important regulators of the cerebral circulation and in 
addition have a paradoxical role in the amelioration and exacerbation of excitotoxic mediated 
neurotoxicity dependent on redox state.
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1.10 Thrombolysis
In patients with acute myocardial infarction thrombolysis is now known not just to improve 
mortality but also to preserve left ventricular (LV) function,119,120 with a window of opportunity 
of at least 12 hours. The idea of restoration of blood flow as soon as possible following the 
onset of symptoms forms the basis for the current management of myocardial infarction and 
it was hoped that the same ‘open artery hypothesis’ could be applied to patients with acute 
stroke. A number of trials of thrombolytic treatment have now been concluded and the 
results are discussed below.
Prospective analysis of spontaneous reperfusion rates in patients with stroke suggests early
121reperfusion of viable tissue is associated with smaller infarcts and a better prognosis. The 
data published thus far are confusing in part because inclusion criteria and concomitant 
anticoagulant therapy affected the rate of haemorrhagic transformation and consequently 
altered outcome. The overall picture suggests that early thrombolysis, within 3 hours of the 
onset of symptoms is associated with a better long term (after 3 months) outcome than no 
treatment at all.
The NINDS study was a multicentre randomised placebo controlled study of thrombolysis 
with recombinant tissue plasminogen activator (rt-PA) within 3 hours of onset of symptoms in 
patients with CT confirmed ischaemic stroke. Results reported that patients receiving 
thrombolysis were 30% more likely to have minimal or no disability at three months (figure
1.10.1). This improvement in outcome was partly offset by a 10 fold increase in the rate of 
symptomatic intracerebral haemorrhage (6.4% vs 0.6%). Despite this high incidence of 
secondary haemorrhage the mortality figures were similar in the two groups (17% in the 
thrombolysed group vs 21% in the placebo group).4
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Other studies evaluating either a longer time window with rt-PA or streptokinase therapy at 
any stage have reported either negative results or at best a trend towards efficacy. W hat has 
been reported consistently is an increase in the number of symptomatic cerebral 
haemorrhages in the treated groups and a resultant increase in early mortality (figures 1.10.2 
and 1.10.3).
The Multicentre Acute Stroke Trial-Europe (MAST-E) was discontinued prematurely because 
of safety concerns.122 These results precipitated early analysis and discontinuation of the 
Australian Streptokinase (ASK) study. In both cases, administration of streptokinase (within 
4 hours in the case of ASK and 6 hours in MAST-E) was associated with an increased 
incidence of intracerebral haemorrhage. In the ASK study the odds ratio of an adverse 
outcome (death or poor functional outcome) was 2.65 in patients treated 3-4 hours after
123stroke. MAST-E reported an increased rate of symptomatic haemorrhage in thrombolysed 
patients (17.5% vs 5%) and this corresponded with a significantly higher early mortality rate 
in actively treated patients (44% higher mortality at 6 months). In this study there was a 
particularly high rate of concomitant prescription of anticoagulants (65% in the active and
12475% in the placebo arm) and this may have influenced outcome adversely.
The MAST-I study was designed to assess both aspirin and thrombolysis as potential acute 
stroke therapies. The study had a 2 x 2 factorial design with patients randomised to 
streptokinase with or without aspirin, aspirin alone, or placebo. This study was terminated 
after safety analysis of data from 600 patients out of a total of 1500 proposed. Again there 
were safety concerns as early death was more common in the thrombolysed patients with an 
additive effect in those patients also receiving aspirin (10 day fatality odds ratio 2.7). A  small 
beneficial effect on late mortality and severe disability was noted but this may reflect the 
higher early death of more severe stroke patients. This positive effect was at best marginal 
and could not be used to advocate thrombolytic treatment. Aspirin alone was not associated
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with poor outcome, early or late and there was a non significant trend toward efficacy in this
125,126group.
The European Cooperative Acute Stroke Study (ECASS) failed to demonstrate a benefit of 
rt-PA (according to the study’s predesignated primary hypothesis) in patients within 6 hours 
of stroke but the study did raise a number of issues of relevance to the interpretation of other 
trial results. This study intended to recruit only patients with moderate-severe stroke but 
without signs of major early infarct on CT scanning. Despite strict entry criteria and only 
specialised centres being used for recruitment, 17.4% of patients were retrospectively 
excluded from the target population analysis. Forty out of sixty of these exclusions in the 
actively treated group were due to ineligible CT scan criteria i.e.31 major infarcts, 2 
haemorrhages and 7 unavailable. It is notable that this subgroup had the worst survival 
outcome.
There was no improvement in functional outcome in the intention to treat analysis but 
exclusion of ineligible patients in a target population analysis demonstrated a significant 
improvement in functional outcome in rt-PA receiving patients (P = 0.035) with no difference 
in mortality in either analysis.127 Significantly there was a far higher proportion of patients 
with complicating intracerebral haemorrhage in both placebo and actively treated patients 
within the ECASS study compared with NINDS. This may have been due to better patient 
selection in NINDS but may simply have occurred by chance. The result was higher absolute 
numbers of complicating haemorrhages in the ECASS rt-PA group, and a statistically 
insignificant increase in patient deaths.
It could be argued that the longer time window in the ECASS study allowed entry of patients 
beyond a therapeutic window of opportunity, thereby diluting any beneficial effect and making 
haemorrhagic transformation more likely. Further analysis of the ECASS data however do 
not demonstrate poorer functional outcome in patients treated between 3 and 6 hours
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compared with those treated within 3 hours, but this represents a post-hoc analysis, and as 
such is not wholly reliable.
NINDS used a lower dose of rt-PA than ECASS and this also may have contributed to the 
higher incidence of haemorrhages in the ECASS study. If we examine the outcome criteria 
assessed in the two trials we find a crucial difference. NINDS dichotomised outcome 
measures into categories of good outcome vs poor outcome. Good outcome was defined as 
a Barthel128 of at least 95/100, a Rankin score of < 1, or a NIH Stroke Scale129 of < 1 (all 
equivalent to minimal deficit). Poor outcome was defined as anything else. The ECASS  
study however set out to prove the hypothesis that rt-PA would improve functional outcome 
by > 15 points on the Barthel or > 1 on the Rankin scale at 90 days. W hen the data acquired 
from the ECASS study are reanalysed using the NINDS hypothesis to assess outcome there 
is a significant benefit from rt-PA in terms of Rankin and NIH stroke scale but only a non­
significant trend to improvement in Barthel index (figure 1.10.4). A further ECASS study is 
underway investigating the lower dose of rt-PA and with more cautious selection of patients.
In a recent meta-analysis of thrombolytic therapy the authors suggest there is little evidence 
that rt-PA is safer than SK and suggest further trials of SK are merited. This conclusion is 
surprising as all the evidence suggests that SK increases early mortality and that the
130incidence of complicating cerebral haemorrhage is substantially increased.
W e could postulate from these results that while very early thrombolysis may be of benefit 
any delay beyond 3 hours tips the balance towards an unfavourable outcome. PET scans in 
stroke patients demonstrate that reperfusion of areas of brain which do not extract oxygen or 
metabolise glucose does not lead to smaller infarcts compared with the beneficial effect of 
reperfusion in areas which have increased levels of extraction. Reperfusion of ischaemic 
brain where there is no increase in the extraction fraction of oxygen conversely reflects
131reperfusion of unsalveagable tissue, or ‘luxury perfusion’. This paradoxically leads to
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additional necrotic damage or ‘reperfusion injury’ due to the influx of free radicals and 
polymorphs. Single Positron Emission Computed Tomography (SPECT) studies suggest 
reperfusion of areas with low residual cerebral blood flow is associated with an increased risk 
of haemorrhagic transformation132 and this may explain the poorer outcome in patients 
thrombolysed beyond the 3 hour time window. W hat is therefore required is a form of 
diagnostic imaging which can predict whether or not tissue is potentially salvageable prior to 
the administration of thrombolysis. At present PET scanning is not routinely available and 
certainly could not be performed within the 3 hour time window postulated. W e  are left with 
the conclusion that as current evidence stands thrombolysis is not a practicable treatment for 
the majority of patients with acute stroke. The NINDS study does however demonstrate for 
the first time in a randomised, controlled study, that therapeutic intervention can benefit 
outcome in patients with stroke. In the United States rt-PA is now licensed as treatment for 
acute stroke within 3 hours of presentation but is not in general use in Europe.
1.11 Aspirin, antiplatelet agents and anticoagulation 
Aspirin
Two recently completed controlled trials of immediate aspirin therapy recruiting 40,000  
patients have demonstrated a small but significant benefit from early aspirin use in acute 
stroke. The International Stroke Trial (1ST)133 and Chinese Acute Stroke Trial (CAST)134 
together suggest a benefit of about 10 deaths per 1000 if aspirin is commenced immediately. 
This benefit was offset by a small increase in the incidence of complicating intracerebral 
haemorrhage (2 per 1000). There was also a modest improvement in functional outcome in 
the aspirin receiving patients, with 11 (SD 6) fewer patients dead or dependent at discharge 
within the CAST study and 13 per 1000 less at 6 months in the 1ST. The conclusion of both 
trial groups was that aspirin was safe and efficacious within the first weeks after stroke. The  
results reassure stroke physicians, most of whom have been prescribing aspirin acutely after
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the exclusion of cerebral haemorrhage. It is therefore unlikely that the results of these 
studies will have a significant impact in terms of altering current patient management.
The International Stroke Trial also examined the effect of acutely prescribed heparin (12500u 
bd or 5000u bd). There was no reduction in deaths at 14 days or death and dependency at 6 
months. Again a small benefit in recurrent early stroke was offset by an increase in the risk 
of haemorrhagic stroke. Crucially, entry to the trial was left to the discretion of the physician 
with no detailed inclusion and exclusion criteria. This introduces potential bias which could 
mask a significant risk or benefit in the patients excluded from the study.
A number of trials of fractionated heparin are underway. Two doses of nadroparin were 
assessed in a recently reported study. The higher was equivalent to full anticoagulation for 
DVT and the lower equivalent to prophylactic use. The results suggest benefit of high dose 
low molecular weight heparin with a 30% reduction in the relative risk of a poor outcome 
compared with the placebo group (death or dependency at 6 months). This corresponded 
with a risk ratio of 0.69 (95%CI 054-0.90). There was an trend toward reduction in poor 
outcome within the lower dose group. No increase in the overall incidence of adverse events 
was reported in the active treatment arms and there was no evidence of a substantial risk of
135haemorrhagic transformation.
This study raises some interesting issues for future research. Are fractionated heparins 
effective and safe in stroke patients and is there a significant dose effect? This could 
partially explain the failure of the 1ST to produce a beneficial effect.
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Anticoagulants and secondary prevention for stroke
The reported results of five recent trials suggest the relative safety and benefit of 
anticoagulation in patients with non-rheumatic atrial fibrillation. Warfarin reduced the risk of 
stroke from 4.5%  to 1.4% per year (risk reduction 69% )136-140 This was associated with a 
small increase in the incidence of haemorrhage. The second Stroke Prevention in Atrial 
Fibrillation Trial (SPAF II) compared aspirin (325 mg) and warfarin (INR 2- 4.5) in patients 
with non-rheumatic atrial fibrillation. Aspirin appeared as effective as warfarin in preventing 
large disabling strokes. Warfarin did reduce the total number of strokes but was associated 
with a higher incidence of intracerebral haemorrhage.141
In younger patients with few risk factors for thromboembolism, the absolute risk of stroke is 
low and there is little additional benefit in full anticoagulation compared with aspirin. In 
contrast, older patients and those with previous TIA or stroke, hypertension, heart failure, 
previous thromboembolism or an abnormal echocardiogram have a higher annual incidence 
of stroke and would probably benefit from warfarin treatment. A trial of warfarin (target INR 
3.0 - 4.5) versus aspirin for secondary prevention of patients without cardioembolic disease 
was abandoned when the risk of haemorrhage within the warfarin-treated group was found to 
be excessive (KR Lees, personal communication). A  further trial (ESPRIT) is now underway 
in more cautiously selected patients, testing lower dose warfarin (target INR 2.0 - 3.0) versus 
low dose aspirin, versus aspirin plus dipyridamole.
Patients with atrial fibrillation without cerebrovascular disease therefore require individual risk 
factor assessment for both stroke and complicating haemorrhage and before allocation to 
either warfarin or aspirin therapy as appropriate. Once patients have suffered even a 
transient ischaemic neurological event they immediately become high risk and should benefit 
from full anticoagulation.
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Other anti-platelet agents
Ticlopidine and clopidogrel inhibit the binding of the platelet agonist ADP. This is turn 
inhibits the activation of the GP llb-llla complex, the major receptor for platelet activation. A 
recent study compared ticlopidine with placebo in patients with known peripheral vascular 
disease but crucially did not compare ticlopidine with current accepted therapy (aspirin). A 
dramatic reduction in the incidence of myocardial infarction resulted in a 29%  reduction in 
mortality in the ticlopidine receiving patients (p=0.015), but 2% of patients developed 
significant haematological abnormalities and there was also an excess of gastro-intestinal 
upset in the actively treated patients.142 While ticlopidine is likely to be an effective anti­
platelet agent the side effect profile and additional expense has precluded its introduction to 
the UK though it is commonly prescribed in the U.S.
Clopidogrel, while acting by the same mechanism, does not appear to cause haematological 
abnormalities. A recent direct comparison between clopidogrel and aspirin in patients with 
vascular disease suggested a significant annual relative risk reduction of 8.7%  (95% Cl 0.3- 
16.5). At present the additional expense of clopidogrel will prevent its use in place of aspirin 
as a first line anti-platelet. It may find use, however, as an add-on therapy in patients at high 
risk of vascular events.143
The potential benefits of combination therapy were also examined within the second 
European stroke prevention study (ESPS-2).144 This study suggested the combination of 
aspirin + dipyridamole was more effective in reducing the secondary incidence of stroke than 
either drug alone (additional risk reduction of 23.1%  from combination therapy compared with 
aspirin alone). Dipyridamole and aspirin have different modes of action; dipyridamole 
inhibits aggregation by raising platelet levels of c-AMP and c-GMP whereas aspirin acts by 
irreversibly inhibiting platelet cyclo-oxygenase which in turn reduces thromboxane 
production. Since the ESPS-2 results support the hypothesis that antiplatelet agents with
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different modes of action have additive effects it is likely that combination therapy will be 
increasingly researched and prescribed, as evidenced by the protocol of the ESPRIT study.
1.12 Neuroprotection
Preclinical Evidence
The most conclusive evidence that glutamate mediated activation of receptors is responsible 
for expansion of the infarct volume comes from animal models of acute stroke. In these 
studies, drugs antagonising the NMDA receptor complex consistently reduce the size of 
infarction induced by a standardised vascular or hypoxic brain insult.78 The receptor complex 
itself is made up of several integral parts. Glutamate binds at a specific recognition site on 
the NMDA receptor. Competitive blockers of this site include CGS 19755 (selfotel) or cis-4- 
phosphomethyl-2-piperidine carboxylic acid and D-CPPene. Other potential sites for 
antagonism of the receptor include the ion channel that is blocked physiologically by 
magnesium or pharmacologically by aptiganel (chapter 7), remacemide (chapter 5) and 
dizocilpine (MK801); and the glycine site, since glycine binding is required for the activation 
of the receptor, blocked by GV150526 (chapter 6)and ACEA1021. Clinical studies are 
currently underway to assess tolerance and efficacy of these drugs in patients with stroke. In 
addition, a polyamine site distinct from the ion channel but part of the NMDA receptor
complex (possibly the NR2B subunit) has been identified and antagonists are currently in
81clinical development. GABA-A receptors have important inhibitory functions within the 
CNS and a number of agonists have been assessed in models of focal ischaemia. GABA  
administration blocks the excitotoxic effects of glutamate including depolarisation and 
calcium influx. GABA-mimetic drugs such as chlormethiazole or muscimol are 
neuroprotective and combination therapy with the NMDA antagonist MK 801 has been shown 
to be more effective than treatment with chlormethiazole alone. Unfortunately the high 
incidence of respiratory depression with cholmethiazole was also potentiated by MK
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801.145,146 Potential sites of pharmacological interaction with the NMDA receptor are shown 
in figure 1.12.1.
Neuronal Vacuolation
Despite being shown to be effective in animal models of cerebral ischaemia there remain 
some safety concerns regarding this group of drugs: PCP and other NMDA antagonists have 
been shown to induce a neurotoxic reaction within the cingulate and retrosplenial cortex of 
the adult rat.147 Mitochondria and endoplasmic reticulum are acutely transformed into large
148intraplasmic vacuoles. It has been claimed on the one hand that these changes are
149completely reversible and on the other that prolonged administration may result in
150neuronal death. Reassuringly no NMDA antagonist currently in development for stroke has 
been associated with permanent neuropsychiatric effects or pathological changes in humans. 
Partly because of these pathological findings and the recognised physiological role of 
glutamate in neurological function there is concern that administration of NMDA antagonists, 
particularly if prolonged, may lead to impaiment of learning and cognition.
The NMDA antagonist remacemide (chapter 5) has however been used in the treatment of 
epilepsy chronically with no significant permanent neurological or psychological effects. It is 
therefore unlikely that this effect will prejudice the development of therapeutic agents.
Neuroprotection in stroke patients
Stimulation of the NMDA receptor leads to the initiation of the excitotoxic positive feedback 
system and a large number of inhibitors of the receptor complex are in various stages of 
development. Trials with selfotel in traumatic brain injury and stroke were abandoned in late 
1995 due to lack of a favourable risk-benefit profile.151 Theoretically the competitive block
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induced by these drugs can be overcome by increasing concentrations of glutamate within 
the ischaemic brain, which could potentially cause a reduction in efficacy. The prototypic 
compound MK 801 and other subsequently developed blockers aptiganel or phencyclidine 
(PCP) do not suffer from this potential drawback but at high doses may give rise to 
psychotomimetic or hallucinatory side effects.81
Another potential hazard of this group of NMDA antagonists is haemodynamic changes. 
These issues are discussed in detail above and also in chapter 7. Any drug being evaluated 
as a stroke therapy must have its haemodynamic side effect profile assessed.
Glycine is a co-agonist at the NMDA receptor and antagonists of the glycine binding site are 
currently in clinical trials. GV150526 appears to be well tolerated with a favourable side 
effect and safety profile compared with glutamate site inhibitors (chapter 6). Glutamate 
release itself may also be inhibited and the Wellcome release inhibitor 1003C87 has been
shown to be neuroprotective in a MCA occlusion rat model without being associated with the
81vacuolation changes noted with NMDA antagonists. The Glaxo Wellcome compound 
619C89 blocks veratrine-induced release of glutamate. It has been evaluated in animals and 
has now progressed to phase II clinical trials.152'154 Other drugs may inhibit glutamate 
release indirectly via their action on sodium channels i.e; phenytoin, riluzole, lamotrigine, 
lifarizine.81 Adenosine inhibitors may also have neuroprotective activity through this same
155mechanism but there are no details as yet on tolerability at experimentally effective doses.
The polyamine site (made up of the molecularly isolated NR2B subunit) is a further allosteric 
site within the NMDA receptor complex. Ifenprodil and eliprodil (SL 82.0715) are antagonists 
at this binding site. Development of eliprodil was halted due to a lack of clinical efficacy, 
though at high doses drug was noted to cause QT prolongation due to its mode of action 
(blocking voltage sensitive calcium channels).156
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The opening of the NMDA receptor ion channel that facilitates the influx of calcium is voltage 
dependent and is blocked in physiological conditions by magnesium. Ischaemia induced 
excitotoxic depolarisation removes the magnesium dependent block. Magnesium in the form 
of the chloride and sulphate salts has been shown to be neuroprotective in permanent MCA  
occlusion models of cerebral ischaemia.157 It is cheap to produce, and appears well tolerated 
in initial pilot studies in stroke patients.158'160 It has already been safely given to over 50,000  
patients with acute myocardial infarction161 and is currently being evaluated in a multicentre 
randomised, placebo controlled trial (IM AG ES).162 Results in stroke patients suggest it is well 
tolerated with no adverse effects on blood pressure.159
AMPA receptors are also activated by excess excitatory amino acids and antagonists are 
currently being developed. AMPA receptor blockers are more effective than NMDA receptor 
agonists in some animal models of global cerebral ischaemia163,164 and combination blockade 
of NMDA and AMPA together appears to be synergistic, although associated with respiratory 
depression.165
Free radicals are thought to have a role in mediating ischaemic neurone damage and in 
particular reperfusion injury. A free radical is a reactive species with an unpaired electron. 
Once generated, free radicals rapidly react with other molecules forming more free radicals 
and setting up a damaging chain reaction. Free radicals may react with cellular constituents 
i.e. nucleic acids, lipids, and particularly the polyunsaturated fatty acids within neuronal 
membranes, damaging both the membranes themselves and associated receptors.165 The 
combination of ischaemia, a rich supply of metal complexes (i.e iron from haemoglobin), and 
a paucity of free radical neutralising enzymes (superoxide dismutase, catalase and 
glutathione peroxidase) within the brain predisposes to neurone damage mediated by free 
radicals. Vitamins C (ascorbate) and E (alpha-tocopherol) are naturally ocurring free radical 
scavengers, but are also unfortunately relatively deficient within the central nervous 
system.166
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Various means of reducing free radical damage during and after cerebral ischaemia are 
being preclinically and clinically evaluated. The synthetic 21-amino-steroid tirilazad has free 
radical scavenging activity, analogous to Vitamin E. It also has anti-oxidant effects, 
inhibiting the generation of hydrogen peroxide and blocking the release of arachidonic acid 
from injured cell membranes. It is effective in animal models of stroke, reducing the volume 
of infarction in the rat MCA occlusion model, but so far phase III clinical trials have been 
disappointing.167 Enzymes like superoxide dismutase (SOD) can convert unstable free 
radicals to more stable, less harmful molecules. Unfortunately these do not directly cross the 
blood brain barrier, but conjugation to lipid soluble agents i.e.polyethylene glycol may allow 
blood brain barrier penetration. These mechanisms are currently undergoing preclinical 
evaluation.168
Neutrophils also have a role in the development and maturation of cerebral infarction and 
mediate some aspects of reperfusion injury.169 Neutrophil adhesion is mediated by specific 
adhesion molecules which are essential in initiating the release of cytotoxins and in 
controlling cellular activation. Monoclonal antibodies to these adhesion molecules (i.e anti- 
C D 11 and anti-CD18) also reduce infarction volume but are unsuitable for clinical use, due to 
their immunogenicity.170'172 A recent study has shown the effectiveness of a recombinant 
neutrophil inhibitory factor derived from hookworms in reducing infarct volume following 
MCA occlusion in rats. This correlated with a reduction in the number of neutrophils found 
within the infarcted tissue.173 Unfortunately, results of a phase-3 trial with the anti-ICAM drug 
enlimomab, are reportedly negative; indeed, mortality was higher in the actively treated 
group, perhaps due to increased inflammation (D Sherman, oral communication). It is 
possible that immunological therapies will also have a broader window of opportunity as they 
modulate more delayed effects of infarction. Studies have evaluated treatment following 2 
hours of middle cerebral artery occlusion in rats. Further studies should evaluate the
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possibility of significant neuroprotection beyond the time window already established for 
NMDA antagonists in animal models.
1.13 Therapeutic window of opportunity and duration of therapy
PET studies suggest ischaemic but still potentially viable infarct zone tissue may be present 
up to 48 hours after stroke, but it is not yet proven that ischaemic brain tissue is potentially 
salvageable beyond the 3 hour time window demonstrated in the NINDS trials of 
thrombolysis. Forty eight hours may be an overoptimistic time window and 6-12 hours is 
probably nearer the true time limit for useful neuroprotection in patients. The outer limit of 
the therapeutic time window will be established only by large scale trials of a proven therapy 
which does not carry the risks that attach to thrombolysis. It is likely that neuroprotective 
treatment will not be the two edged sword that thrombolysis has proven to be. W hile it is true 
that excitotoxic damage appears to be initiated rapidly after stroke onset delayed 
administration of these drugs should not be associated with the reperfusion complications of 
cerebral oedema and cerebral haemorhage which are responsible for poor outcome in 
patients thrombolysed beyond 3 hours.
As discussed above, a number of neuroprotective compounds are in advanced stages of 
clinical development following encouraging results from preclinical studies. There is however 
no consistent approach to dosing schedules for these novel treatments and as a result 
ongoing phase three clinical studies of effficacy are using differing and possibly inappropriate 
durations of drug therapy. In most phase three efficacy studies, drug is administered as soon 
as possible after stroke within a predetermined but arbitrary time window. Drug is then often 
continued for a variable time depending on the pharmacological properties of the individual 
compound. For example, studies with tirilazad or selfotel (CGS19755) have restricted 
recruitment to cases that can be treated within 6 hours. In the case of selfotel, the drug was 
given as a single intravenous bolus174, whereas tirilazad administration was repeated for 72
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175hours. In contrast, piracetam efficacy was assessed when commenced within 12 hours 
and continued for up to 12 weeks after the onset of symptoms.176
It is clear that in both animal models of stroke and humans the effects of cerebral ischemia 
are manifest on the cerebral metabolism rapidly, within a timescale measured in minutes or
67 79 177hours. Any form of potential neuroprotective treatment should therefore be given by 
the most rapidly effective route. In practice, this means intravenously. In an ideal scenario, 
neuroprotective plasma and CNS levels of drug would be attained immediately. This is 
widely recognised, and is supported by the results of the recent thrombolysis trials [NINDS, 
ECASS, MAST, MAST-1]4,122,126,127 and by meta-analysis of nimodipine trial results.178 
Questions which remain, and which require attention before that magic bullet is found, 
concern the issues of how late after stroke can treatment of any kind be usefully 
administered and how long and by what route subsequent therapy should be given.
The available human PET data suggests a rationale for initiating and continuing 
neuroprotective treatment up to at least 48 hours after stroke onset, as within this time 
window metabolically compromised ischaemic brain has been shown to return to normal.
Also regional blood flow abnormalities tend to resolve in most cases within 3-4 days due to 
reperfusion via collateral vessels which develop in the intervening time. During this time 
cerebral autoregulation is deranged and as a result cerebral perfusion is determined by 
systemic BP. There is new evidence that suggests EAA’s remain grossly elevated for at 
least 6 days after stroke.179 These data were gathered using a microdialysis probe inserted 
into an area of infarcted tissue during a neurosurgical procedure to relieve raised intracranial 
pressure following a large cerebral infarct. The conditions of the study were therefore 
atypical and the results require confirmation. If we consider this evidence we can conclude 
that for 3-4 days the cerebral circulation is in a state of turmoil whereby autoregulation is 
deranged and collateralisation and reperfusion may occur. It would seem logical to protect 
patients with some form of neuroprotective therapy during this period i.e.for at least 3-4 days.
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If further evidence confirms elevated EAA’s at 6 days or beyond a case could be put for more 
prolonged treatment.
The precise timing of these events and the status of the patient’s cardiovascular, respiratory 
and cerebral circulation will determine the extent of the eventual stroke deficit. W hile early 
collaterisation may lead to improved outcome and late collateralisation to reperfusion injury 
physicians cannot yet predict which outcome is likely in individual patients. It is 
predominantly this inability which makes thrombolysis such a hazardous treatment.
The route and means of administration of treatment will depend on the individual 
pharmacokinetic properties of the neuroprotective compound, on the adverse effect profile of 
the drug, and on the nature of the insult giving rise to the stroke. For example, it would be 
desirable to maintain neuroprotection throughout recurrent episodes of cerebral ischemia as 
seen in association with recurrent cardiac embolism. While this risk may vary from patient to 
patient, phase three studies should address the safety and efficacy of durations of treatment 
that are likely to be utilised subsequently in routine clinical practice.
Pharmacological properties
Ideally, any compound for the treatment of stroke should adequately cross the blood brain 
barrier, and obtain sufficiently therapeutic levels rapidly within the brain and CSF. Highly 
lipid soluble drugs will penetrate the cerebral tissues more rapidly than hydrophilic agents 
and will also be cleared more slowly from neural tissue. Although there are scant data 
available in human subjects, investigations of the pharmacokinetics of the lipid soluble 
neuroprotective agent selfotel in human volunteers, suggest that the brain half life of drug is 
significantly longer than the plasma half life. Selfotel was present in the CSF after 16 hours 
in contrast to its plasma half life of 2-3 hours.180 The central nervous system effects were 
also prolonged: up to 60 hours in patients with stroke. The active drug pool need not
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necessarily be within the CSF, however, and tissue levels are likely to be more important 
since CSF may equilibrate only slowly with brain tissue.
Drugs with slow clearance from the brain tissue are more likely to accumulate and lead to 
toxic side effects if given by constant i.v infusion but conversely may give prolonged 
protection if given by single bolus injection.180 Overall, lipid soluble agents are more likely to 
exhibit in-vivo activity at relatively lower plasma levels than water soluble agents and drug 
doses required for neuroprotection may be overestimated by plasma level calculations and 
pharmacokinetic modeling. Maintenance doses may not even be required to sustain 
neuroprotective drug levels within the brain.
At present little is known about the effect of stroke on the integrity of the blood brain barrier, 
which is crucial in determining the penetration of less lipophilic compounds. In acute cerebral 
ischemia it is possible that hydrophilic compounds may cross the blood brain barrier and thus 
enter infarcting or ischemic tissue. It is also important to consider the limitations of 
calculating maintenance drug doses from data based on plasma levels of drug and or 
metabolite, which of course give no indication of CSF and brain levels of drug during 
treatment. Studies in which patients are subjected to frequent removal of CSF via lumbar 
puncture following infusion of neuroprotective agents are unacceptable to most physicians 
and patients. There are limited data regarding the CSF or brain penetration of these 
compounds in man and thus the quantity of drug actually reaching the brain is unknown. 
Positron emission tomography (PET) studies using isotope-labelled drug may give some 
indication of drug distribution in man, but there are considerable practical difficulties 
involved. Patients must be recruited, examined, scanned with CT or MRI, treated and then 
undergo PET scanning, all within several hours of stroke onset.
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Binding properties
At a cellular level the mechanism of action of any particular agent will also determine 
whether constant exposure to drug is necessary or indeed desirable. In the case of non­
competitive high affinity NMDA antagonists such as aptiganel, binding occurs rapidly if the 
ion channel is open and the drug dissociates slowly.81 Thus after dosing, increasing numbers 
of ion channels become blocked over time until steady state is reached. Conversely, lower 
affinity blockers such as remacemide (chapter 5) will dissociate from the receptor more 
readily and thus may require a higher loading dose followed by a maintenance infusion to 
achieve effective ion channel blockade.
The clearance and volume of distribution of any given compound will influence the doses 
required but not necessarily the duration of treatment. W here the half life of drug is relatively 
long (e.g selfotel) it may be more acceptable to patients and medical staff to give treatment 
in the form of single or intermittent iv bolus, rather than a constant iv infusion. The exception 
is in the case of drugs which have a narrow therapeutic index, i.e. for which the minimal 
effective plasma concentration is close to the maximum tolerated plasma concentration. In 
this case, despite a long half-life, it may be impossible for patients to tolerate the peak 
concentrations achieved after each bolus unless doses are so low that the trough 
concentrations may be ineffective. An example is aptiganel which in phase II studies was 
given as initial bolus followed by constant i.v infusion, as initial peak concentrations following 
higher single bolus injection were associated with intolerable side effects. Tolerability may 
therefore be improved by minimising fluctuations in drug concentration. Initial dosing 
schedules for the glutamate release inhibitor 619C89 utilised intermittent dosing whereas 
more recent studies have relied on constant rate infusion.154
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Most compounds investigated as possible treatments for stroke in animal models are 
maximally effective given as initial bolus followed by constant i.v infusion. The selective 
competitive NMDA antagonist EAA090 paradoxically is maximally effective after single i.v 
bolus only (Dr P Danjou, personal communication). The significance of these differences in 
humans is unknown and may be marginal or even irrelevant but may influence the dosing 
schedules that are chosen for the evaluation of therapies in future clinical trials.
The therapeutic range, and thus the desirable duration of therapy, is also influenced by the 
steepness of the dose-response relationship. The effects of aptiganel in healthy volunteers 
include subjective oral paraesthesia and at higher doses, objective evidence of nystagmus. 
The dose - response curves differ for these two effects (figure 1.13.1). Which of these effects 
is more closely related to neuroprotection is unknown, though the paraesthesiae appear to 
occur at plasma levels lower than have been associated with experimental neuroprotection. If 
neuroprotection were associated with the paresthaesiae, then frequent or repeated dosing 
may be unnecessary, since a degree of neuroprotection would persist for many hours after a 
single bolus dose of aptiganel. Conversely, if neuroprotection is associated with nystagmus, 
then it is likely that plasma concentrations would fall below those required for efficacy within 
minutes to a few hours of ceasing aptiganel infusion.
Orally active drugs with good bioavailability characteristics may be suitable for longer term 
post-ischaemia treatment in patients with a high risk of imminent cerebral infarction. It is 
however common clinical practice to withhold food, drink and oral medications until speech 
and swallowing have been adequately assessed by a trained speech and language therapist, 
as swallowing is frequently compromised in patients with recent stroke.55 It is therefore likely 
that early treatment of acute cerebral ischaemia will be limited to iv therapy.
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It is likely that the lack of efficacy of thrombolysis beyond 3 hours is at least in part due to 
reperfusion injury. As both free radical scavengers and leucocyte adhesion inhibitors may 
reduce reperfusion injury, they should be considered as possible adjuvant therapy in 
combination with thrombolytic treatment. Reperfusion promoted by thrombolytic drugs 
probably occurs within at most a few hours of drug administration and spontaneous 
reperfusion up to a few days after occlusive stroke. If combination therapy with a 
neuroprotective agent and a thrombolytic drug is contemplated, then it should be sufficient to 
administer both drugs together, and to maintain treatment with the neuroprotective agent for 
two to three days.
Side effect profiles and safety
While it may be appropriate in some cases for neuroprotective therapy to be continued for 
hours, days or even weeks following acute ischaemic insult a paramount consideration is the 
tolerability and patient acceptance of any potential therapy. A number of neuroprotective 
agents have already been shown to have dose and duration-limiting side effect profiles. In 
particular, the more potent NMDA antagonists are associated with severe psychotomimetic 
effects. Aptiganel may cause lightheadedness, dizziness, paraesthesiae, sedation, and even 
paranoia;56,181 selfotel has been associated with agitation, confusion and hallucinations.
These symptoms have sometimes been reported as intolerable by patients receiving bolus or 
short infusion doses in clinical trials. Any clinically effective treatment even if poorly tolerated 
in the short term could potentially still be justified bearing in mind the poor prognosis of 
patients with moderate or severe stroke. Some of the NMDA antagonists may however be 
unsuited to maintenance infusion or repeated dosing because of the likelihood of prolonged 
severe side effects. Other NMDA antagonists in development, such as remacemide (chapter
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5), appear better tolerated and have been given successfully with more acceptable levels of 
patient tolerability.182
The glycine site antagonist GV150526 has a ‘clean’ side effect profile compared with 
antagonists acting at the ion channel pore of the NMDA receptor i.e.aptiganel. It may 
therefore be a suitable drug for longer term administration, although concerns regarding its 
effect on liver function remain (chapter 6).
Another potential neuroprotective agent with good tolerability is magnesium. Although the 
Intravenous Magnesium Efficacy in Stroke study (IMAGES)162 will be using only a 24-hour 
infusion, there is no reason why more prolonged treatment could not be administered.
Prolonged therapy for certain patients ?
The risk of further cerebral ischaemia following stroke or TIA is highest immediately after the 
initial event. Results from the Oxfordshire Community Stroke Project suggest the absolute 
risk of a further cerebral ischaemic episode is 4.4%  during the first month and 8.8% in the 
first two months. The odds ratio of a stroke in these patients compared with age matched 
controls without recent symptoms of cerebral ischaemia is 80.0 within the first month and
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27.0 within the second. Thereafter the odds ratio diminishes to 4.7 between 1 and 2 years. 
While the risk of further stroke is relatively high in these patients, extrapolation of these 
results suggests that between 50 and 100 patients would require treatment for one week or 
alternatively 25 patients for one month to provide neuroprotection during a single recurrent 
event.
Patients with high grade stenosis of the internal carotid artery awaiting endarterectomy have 
a significantly higher risk of further recurrent stroke. In the control arm of the North American 
Symptomatic Carotid Endarterectomy (NASCET) trial the risk of stroke over a two year
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period in patients with high grade ulcerative lesions was 30% .184 The risk of recurrent brain 
embolism in the 14 days following cardioembolic stroke has been reported as 13.7% with the 
highest risk found in the 2 days immediately following stroke.185 There are therefore 
subgroups of patients that can be identified as being at higher than average risk of further 
ischaemic events, who potentially could benefit from longer term neuroprotection. For 
prolonged treatment to be practicable it would ideally be available in an orally active form 
and have an acceptable side effect profile. Drugs could be given over a period of several 
days through the intra-venous route since anticoagulants are frequently administered in this 
way following a thrombo-embolic event. Potential interactions with drugs commonly used in 
the management of stroke patients, i.e.warfarin and aspirin, would however have to be 
assessed.
Practical issues of administration
For neuroprotective treatment to be effective it is likely that patients will require to have 
therapy initiated within at the most 12 hours after the onset of symptoms. Thus the 
healthcare infrastructure must facilitate the rapid referral, transfer to hospital, emergency 
assessment and treatment of such patients. Until now, with no proven therapy available for 
acute stroke, referral practices and assessment times are extremely variable both 
internationally and locally. The recent results with rt-PA are unlikely to change this situation, 
but should neuroprotection be demonstrated to be effective it is likely that this would 
improve, possibly with the development of a fast track referral system analogous to that in 
operation for patients with suspected myocardial infarction. It is conceivable that general 
medical practitioners or even paramedical staff could give an initial bolus dose of treatment 
prior to hospital transfer. Preparations of such drugs would need to be easy to administer
and safe in patients with intracerebral haemorrhage, as clinical signs are unreliable in the
10diagnosis of this condition. The same caveat would apply to any form of therapy being
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considered for use in smaller hospitals and isolated communities where there is no access to 
CT scanning facilities.
Potential problems
W hen considering how long intra-venous treatment may be continued, the potential effect on 
patient rehabilitation should be taken into consideration. Patients receiving intra-venous 
infusions are often immobilised as a consequence and this in itself may reduce the 
effectiveness of early attempts at rehabilitation. Furthermore, any treatment that immobilises 
patients following stroke is likely to lead to an increase in risk of thrombo-embolic 
complications, such as DVT. Prolonged infusions are associated with a risk of local phlebitis 
and indeed several agents under development are locally irritant.175 It would therefore be 
ideal if treatment could be administered initially in an iv preparation and later converted to an 
oral formulation as soon as the patient was mobilised.
Drugs with potential respiratory depressant or sedative effects e.g. the AMPA antagonists186 
may cause practical problems in the management of stroke patients, in addition to increasing 
the risk of complicating aspiration pneumonia. It may be impossible to distinguish between 
the sedation caused by a complication of the initial stroke (eg secondary haemorrhage 
leading to raised intra-cranial pressure) and the sedation induced by the neuroprotective 
drug. Care must be taken that whenever possible appropriate concentrations of drug are 
prepared for the doses being considered, to avoid fluid overload: shortterm administration 
of high fluid loads (e.g 500mls in one hour) may be safe or even desirable in a dehydrated 
patient, but may precipitate incipient heart failure if prolonged in an individual with poor 
cardiac status.
In summary it is hoped that ongoing clinical trials will demonstrate efficacy of neuroprotective 
therapy in patients with acute stroke. When trials are conceived it is important to consider the 
way in which these drugs are likely to be utilised by physicians in the future and to design
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studies accordingly. Side effect profiles of these agents require accurate definition and are 
crucial to the way in which drugs may be prescribed in the future: for example agents with 
potent adverse side effects i.e. psychotomimetic effects, may be suitable only for a single 
bolus or short term infusion. W ell tolerated preparations could be given as repeat boluses or 
constant i.v infusion depending on the pharmacokinetic proprties of the compound in 
question. The optimal duration of treatment is probably at least 72 hours, ensuring 
neuroprotection while cerebral hemodynamics are compromised. New evidence suggests 
EAA’s may be grossly elevated for at least 6 days following large ischaemic stroke 
suggesting a possible rationale for more prolonged acute therapy.
Neuroprotective drugs may be combined in the future such that potent drugs with potentially 
upsetting side effects are given as an initial bolus and a better tolerated preparation used for 
prolonged therapy. Evaluation of the combination of rt-PA and neuroprotective therapy is 
inevitable now that rt-PA has become licensed within the U.S. Reperfusion injury may be 
reduced by administration of free radical scavengers or immunological modulators that 
reduce the influx and adherance of leukocytes in the infarct zone. Additional neuroprotection 
for high risk patients may continue if a suitable well tolerated orally active therapy was 
available. Ideally acute therapy would be available for administration by non specialist 
medical and paramedical staff as this would facilitate the earliest possible initiation of 
neuroprotection. Interactions of these agents with drugs frequently given following acute 
stroke will require assessment. Finally the relationship between acute changes in BP and 
stroke outcome requires further attention as some of these agents are likely to have 
haemodynamically significant effects.
61
1.14 Scope of thesis chapters
The work submitted for examination concerns several aspects of stroke patient management.
In chapter 2, I have examined the effect of the ACE inhibitor perindopri! on blood pressure 
and total cerebral blood flow in hypertensive patients with recent stroke. It is still unclear at 
what stage it is safe to initiate antihypertensives but in most cases this should be delayed at 
least 72 hours. Most patients admitted to the Western Infirmary Stroke Unit are discharged 
either to the care of their General Practitioners or to a further in-patient facility (often 
rehabilitation) within 5-7 days of admission. It is therefore important to devise a risk factor 
intervention plan prior to discharge. Deferring a decision on blood pressure treatment until 
after discharge can result in unacceptable delay or even failure in the initiation of 
antihypertensive treatment. I hypothesised that ACE inhibitor treatment within 3-7 days of 
stroke onset was safe, effective and not associated with either exacerbation of neurological 
deficit, or reduction in cerebral blood flow.
In chapter 3 , 1 have examined the relationship between cholesterol and outcome after stroke. 
This work initially began as an analysis of the risk factor profile of all admissions and 
outpatients under the care of our stroke service. This initial analysis suggested the incidence 
of raised cholesterol was identical to that of the local population. There appeared to be an 
excess of patients with very low cholesterol and intracerebral haemorrhage but this did not 
reach levels of statistical significance.187 I went on to assess the influence of some of these 
risk factors on patient prognosis, with surprising results.
Less controversial is the relationship between poor stroke outcome and hyperglycaemia, that 
is further examined within chapter 4. Unlike the described relationship between better stroke 
outcome and raised cholesterol there are established biological mechanisms which explain
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these observations. Again I found the relationship to be statistically significant and 
independent of other known prognostic variables.
Chapters 5, 6, and 7 were all phase II, placebo controlled trials of novel neuroprotective 
compounds being evaluated as treatment for acute stroke. The studies were not powered to 
demonstrate efficacy but rather to evaluate tolerability, safety and clinical pharmacology prior 
to a phase III study.
GV150526 is a glycine antagonist at the NMDA receptor complex. Prior to this study the 
compound had been administered to volunteers but not to patients. This early work had 
suggested good tolerability. The results confirmed this but suggested a drug effect on liver 
function. Remacemide has been extensively investigated as a potential anticonvulsant but 
also has significant neuroprotective effect in animal models of stroke. Unlike GV150526 it is 
known to have significant gastro-intestinal and CNS side-effects at high doses. A maximal 
tolerated dose was identified for further evaluation. Side effects were attributed to the build 
up of remacemide metabolites. W hile all the aforementioned work was solely conducted 
within the Stroke Unit of the Western Infirmary, the investigation of aptiganel in patients with 
acute stroke described in chapter 7 was carried out as a multi-centre study. This was an 
early phase II study. The work was carried out in two parts, the first to establish a safe and 
well tolerated loading dose, the second to examine tolerability of the selected loading dose 
followed by a constant infusion chosen from the pharmacokinetics established in part 1. 
Significant CNS dose limiting side effects were reported and furthermore haemodynamic 
effects requiring therapeutic intervention were observed.
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Figure 1.01.1: Angiography of surgically correctable high grade internal 
carotid artery stenosis.
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Chapter 2
Perindopril in patients with recent cerebral infarction
2.1 Introduction
Blood pressure is an established risk factor for the primary incidence of stroke. A reduction of 
5 mmHg confers a population risk reduction of stroke incidence of 30% .14 The potential 
benefit of antihypertensive therapy following cerebral infarction is undefined but it is likely 
that treatment will be of most benefit in those patients with a higher risk of future stroke i.e. 
those with underlying cerebrovascular disease. A definitive trial recruiting sufficient numbers 
of patients to demonstrate the efficacy of anti-hypertensive therapy as secondary prevention 
has not yet been performed but a large randomised multi-centre placebo-controlled study 
using perindopril and or /  a thiazide diuretic (PROGRESS) will enrol between 6-8,000  
patients with cerebrovascular disease and mild or moderate hypertension.47,48 It is hoped this 
study will clarify the relationship between blood pressure and the secondary incidence of 
stroke. Perindopril is an Angiotensin Converting Enzyme (ACE) Inhibitor with a gradual onset 
of action and a relatively long ty, allowing once daily dosing and is less likely to cause first 
dose hypotension than other shorter acting preparations such as captopril or enalapril.188 
ACE inhibitors may be particularly suited to patients with cerebrovascular disease as they do 
not adversely affect cerebral blood flow.60
Lowering blood pressure within hours of acute stroke can lead to dramatic neurological 
deterioration probably by reducing cerebral perfusion to the infarct zone.52,53 The INW EST  
study evaluated the effects of the calcium channel blocker nimodipine in patients within 72 
hours of acute stroke. Increased mortality was associated with a reduction in blood pressure
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in actively treated patients.54 A blood pressure lowering effect was also associated with a 
poor clinical outcome in a phase II study of the ion channel blocker lifarizine.55 In the first 
few days after acute stroke cerebral autoregulation and local cerebral perfusion is deranged 
and thus any change in systemic blood pressure may cause a critical reduction in local 
cerebral perfusion. In most cases these changes normalise within 3-4 days and cerebral
189autoregulation is restored. Immediate blood pressures are often elevated in patients with 
acute stroke and resolve within several days of hospital admission.190 It would therefore 
seem prudent to defer consideration of patients for anti-hypertensive therapy for at least 72 
hours following hospital admission. Following this time it is still unclear which patients should 
go on to receive antihypertensive therapy and exactly when this should be instituted.
2.2 Materials and Methods
A double blind randomised trial design compared 15 days of oral perindopril (4 mg daily) 
with placebo in patients admitted to our stroke unit with a clinical and CT diagnosis of 
cerebral ischaemia. Patients with normal CT scans were included in the study since CT is 
insensitive to early signs of infarction and to small subcortical infarcts. All patients had mild 
to moderate hypertension (170-250 /  95-120 mmHg) as defined by two blood pressure 
readings within the inclusion range at least 6 hours apart within the 24 hours prior to entry 
into the study. BPs at the the time of drug administration were therefore not identical to 
screening BP readings as the latter were recorded in the hour immediately prior to drug 
dosing.
Patients with severe carotid disease were excluded from the study for safety and technical 
reasons. Patients admitted on prescribed anti hypertensive therapy had treatment 
discontinued according to local treatment guidelines for at least 48 prior to entry into the 
study. Ethical approval was obtained from the W est ethical committee and patients gave 
written informed consent to participate. Clinical and neurological assessment using the NIH
191stroke scale was made prior to study entry and repeated on day 15. Blood pressure was
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measured semi-automatically using Marquette oscillometric equipment (Marquette 
Electronics Wisconsin) pre-treatment and then hourly up to 10 hours after first dosing. Blood 
pressure was repeated at 24 hours and at 2 weeks. Total cerebral blood flow was calculated 
from bilateral internal carotid artery Doppler ultrasound (Acuson 128, 5 megahertz probe 
Acuson, California) coupled to a wall tracker device (Wall Track System, Neurodata, 
Bilthoven, Netherlands). Arterial flow was calculated = n x  diameter2 x  mean velocity / 4. 
Details of Doppler methods employed have been published previously.56 MCA velocity and 
resistance index were measured by transcranial Doppler (Nicolet EM E TC2000, 2 megahertz 
probe; Nicolet, Warwick, UK). Doppler recordings were undertaken pre-treatment and at 2,
4, 8 and 24 hours and again repeated at 2 weeks. An additional recording of MCA velocity 
was made at 6 hours. Routine safety biochemistry and hematology were collected at entry 
and at the conclusion of the study period. Plasma renin activity, angiotensin II activity, 
angiotensin converting enzyme activity and drug plasma levels were assessed at 0, 4, 6, 8, 
12 and 24 hours, and at 2 weeks.
Laboratory Measurements
Plasma renin activity was measured by radio-immunoassay of generated angiotensin I 
(detection limit 0.54 ng /ml/hr; co-efficient of variation 6.7% ). Angiotensin II was determined 
according to Morton and W ebb192 (detection limit 2.0 pg /ml; co-efficient of variation 6.4%). 
Angiotensin converting enzyme was assayed by incubation of plasma/serum with the ACE 
substrate analogue hippuryl-histidyl-leucine. The hippuric acid produced is extracted, then 
quantified using high performance liquid chromatography. The limit of quantification using 
this assay is 0.05mMol/L. The limit of detection is 0.01 mMol/L.
Perindopril levels were assessed by the direct determination of ACE inhibitor in plasma by 
radioenzymatic assay using a modification of the method of Reydel-Bax et al and liquid 
chromatography-assisted assay for ACE in serum.193 The active metabolite perindoprilat is
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measured with a calibration range of 0.16-20 ng/ml. The limit of quantification is 0.16 ng/ml. 
The limit of detection is 0.1 ng/ml.
Statistical Analysis
Results were analysed using repeated measurements analysis of variance and co-variance 
using Statistica for Windows software version 5.0 (StatSoft Inc, Tulsa, OK, USA). W ith a 
sample size of 24 patients we expect to detect a difference in cerebral blood flow of 16% with 
80% power.
2.3 Results 
Tolerance and safety
A total of 28 patients were recruited to the study with 24 completing the protocol. Patients 
were aged between 52 and 89 years. Clinical and demographic details of patients entering 
the study are summarised in table 2.1 and 2.2 resprctively. Four patients failed to complete 
the protocol: one was withdrawn following an adverse event which was not felt to be related 
to drug action. This consisted of transient left arm paraesthesia while undergoing carotid 
Doppler imaging of the right internal carotid artery 9 hours after perindopril dosing.
Symptoms lasted 5 minutes and did not recur. A further patient in the perindopril group was 
withdrawn after only one dose when his renal function was found to be mildly impaired prior 
to drug treatment. Two patients receiving placebo did not complete the study: One was lost 
to follow up after transfer to an outlying hospital while another had inadequately documented 
data to allow analysis. All withdrawn patients were contacted and were well at the conclusion 
of the study.
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Perindopril was therefore well tolerated with no serious adverse events. Biochemistry and 
haematology results were unremarkable. Mean NIH scores in placebo and treatment groups 
improved in a clinically and statistically similar manner but with no difference between the 
two groups (table 2.2).
Systolic, diastolic and mean blood pressures were significantly reduced in the perindopril 
treated patients from 2 - 24 hours after perindopril (p < 0.004) and remained reduced after 2 
weeks treatment (perindopril 168 ± 1 7 / 91± 9 at baseline to 150 ± 21 /  79 ±  14 mmHg at 4  
hours cf placebo 172 ± 26 / 92 ± 14 to 173 ± 23 /  91 ± 1 3 , i.e.a placebo corrected fall of 19 /
11 mmHg). Blood pressure changes are summarised in figures 2.1 and 2.2. There was no 
associated change in heart rate in either group. Despite the reduction in blood pressure there 
was no reduction in total internal carotid artery flow or middle cerebral artery velocity, even at 
the time of peak drug effect (figures 2.3 and 2.4). Internal carotid artery flow was increased at 
8 hours in the perindopril receiving patients(p< 0.004). Neither common nor external carotid 
artery flow was significantly different between treatment and placebo-receiving groups. 
Determinations of velocity and blood vessel diameter in common, internal and external 
carotid vessels similarly showed no difference between perindopril and placebo groups. In 
addition there was no difference in the MCA resistance index (a measure of artery tone and 
distensibility). Renin activity and All levels were not significantly different between perindopril 
and placebo groups but angiotensin converting enzyme was inhibited by perindopril ( p< 
0.001) The AUC 0-24 for perindoprilat was 135 h.ng/ml (data not shown).
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2.4 Discussion
Perindopril was well tolerated in patients following an acute ischaemic stroke. The study was 
not designed to demonstrate any long-term effect on neurological outcome but the results are 
reassuring as no patient suffered a drug associated neurological deterioration.
ACE inhibitors are thought to lower blood pressure without adversely affecting total cerebral 
blood flow. The role of angiotensin in the physiological control of the cerebral circulation has 
not been adequately defined. The configuration of the ACE gene may be important in the 
generation of accelerated atherosclerosis in the coronary and cerebral circulations, although 
there is conflicting evidence that ACE genotype is relevant in the development of 
cerebrovascular disease. Angiotensin 2 (AT2) receptors regulate cerebral blood flow in rats. 
Large cerebral arteries containing AT2 receptors ameliorate increases in blood flow in 
response to a rise in blood pressure.194 Treatment of hypertensive animals with ACE  
inhibitors resets cerebral autoregulation at a lower level but this effect may be shared with 
other antihypertensive agents. In hypertensive humans without a history of stroke, captopril 
increases cerebral blood flow, measured by a single positron emission computed 
tomography scanning (SPECT) radionuclide Xe -133 technique, with an inverse correlation 
between BP fall and mean cerebral blood flow.195
Two single dose studies in healthy volunteers by Demolis assessing blood flow with carotid 
and transcranial Doppler following ACE inhibitor administration demonstrated similar results 
to our study, with BP effectively lowered and an increase in bilateral common carotid artery 
flow.196 197 Middle cerebral artery flow velocity was unchanged but there was an increase in
196cerebral vascular resistance index suggesting vasoconstriction in the cerebral arterioles.
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Hypertensive stroke patients have only been assessed in two uncontrolled studies (each 
recruiting 12 patients). Both studies used SPECT scanning and a Xe 133 inhalation 
technique. In one study drug effectively lowered BP and increased cerebral blood flow to
197both hemispheres while in the other study a fall in blood pressure was not associated with 
a significant blood flow effect.60
Doppler data support the hypothesis that perindopril does not adversely affect cerebral blood 
flow or alter cerebral hemodynamics in a clinically significant way. The results, however 
cannot be considered relevant to all patients with severe carotid disease. It is conceivable 
that the presence of hemodynamically significant carotid lesions may lead to a reduction in 
cerebral perfusion distal to a site of stenosis following the lowering of systemic blood 
pressure. This may be particularly relevant in the hours and days immediately following acute 
stroke where cerebral autoregulation is deranged and consequently perfusion is directly 
dependent on systemic blood pressure levels. W e  did not consider it ethical to treat patients 
prior to 48 hours of onset of stroke symptoms as there is good trial evidence that lowering 
blood pressure at this time results in adverse outcome.54,55 Further research is required to 
assess whether these patients are indeed more prone to neurological deterioration following 
BP reduction before treatment guidelines can be advised. It is also possible that while total 
internal carotid artery flow is preserved, local ischaemic areas may become increasingly 
compromised as a result of a reduction in blood pressure. Other forms of brain imaging 
techniques such as SPECT (Single Photon Emission Computed Tomography) or PET  
(Positron Emission Tomography) scanning may give further information on the effects of 
blood pressure lowering treatment on regional perfusion particularly in the area surrounding 
the cerebral infarct.
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Our data suggest that starting perindopril treatment within 2 and 7 days of the onset of 
cerebral ischaemia can successfully and safely lower blood pressure without adversely 
affecting total cerebral blood flow in patients without severe carotid stenosis.
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Figure 2.1: Systolic blood pressure (± SE of the mean) v. time in patients 
receiving perindopril or placebo. Systolic blood pressures were significantly 
reduced in the actively treated group from 2 -24  hours after perindopril (p < 
0.004) and remained reduced after 2 weeks treatment.
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Figure 2.2: Diastolic blood pressure v. time in patients receiving perindopril 
or placebo. Diastolic blood pressure (± SE of the mean) v. time in patients 
receiving perindopril or placebo. Diastolic blood pressures were significantly 
reduced in the actively treated group from 2 -24 hours after perindopril (p < 
0.004) and remained reduced after 2 weeks treatment.
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Figure 2.3: ICA flow (± SE mean) vs time in patients receiving perindopril 
or placebo ICA (internal carotid artery flow rate mL/minute) vs time in 
patients receiving perindopril vs placebo. Increase in flow in the actively 
treated group at eight hours (p<0.004)but no significant changes at other time 
points.
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Figure 2.4: MCA (middle cerebral artery) mean velocity cm/s (± SE mean) vs 
time in patients receiving perindopril or placebo. There was no significant 
changes over time and no difference between placebo and perindopril 
receiving groups.
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Chapter 3 
Influence of cholesterol on survival after stroke
3.1 Introduction
The association between total serum cholesterol and coronary artery disease is well 
established but the relationship between stroke and cholesterol remains less clear. Large 
epidemiological studies in Japanese198,199 and Japanese Americans200 failed to associate 
cerebral infarction with raised cholesterol but found an inverse relationship with the incidence 
of intracerebral haemorrhage. The M RFIT study examined middle aged men in the US and
noted a positive association between raised cholesterol and ischaemic stroke and a negative
201association with haemorrhagic events.
Meta-analysis of the prospective follow up of 450,000 patients within 45 separate cohorts 
over an average follow-up period of 16 years detected no relationship between cholesterol 
and the overall incidence of stroke.202 In most cohorts however there was no differentiation 
between stroke type i.e. cerebral infarction or intracerebral haemorrhage and competing 
associations with infarction and a negative association with haemorrhage could not be 
excluded.
A post mortem study in Japanese stroke patients did suggest an association between low 
cholesterol and cerebral haemorrhage and between high cholesterol and large carotid vessel 
atherothrombotic infarction. There was no association between subcortical lacunar events
203and raised cholesterol.
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Meta-analyses of published trials of lipid lowering treatment and incidence of stroke are 
fraught with potential bias and pitfalls but not all studies support the hypothesis that lowering 
cholesterol effectively reduces the incidence of stroke. In the W O SC O PS (West of Scotland 
Coronary Prevention Study) pravastatin successfully reduced cholesterol and the primary 
incidence of coronary events but not stroke in a middle aged population204. The CARE study 
was a large placebo controlled study recruiting 4159 patients study investigating the effect of 
pravastatin treatment for 5 years on patients with previous myocardial infarction and average 
cholesterols. The results suggested a significant reduction in total mortality and a reduction 
in the incidence of stroke by 31% (P= 0.03)205. Patients in the simvastatin receiving group of 
the 4S study (lipid lowering as secondary prevention of coronary heart disease) also had a 
significantly reduced number of cerebrovascular events206.
Lipid lowering therapy particularly with statins have been shown to reverse carotid artery 
atheroma formation with an associated reduction in cerebrovascular events. Lovastatin and 
pravastatin have both been shown to reversed intimal medial thickening in the carotid
arteries.207' 208
There are a number of possible explanations as to why a reduction in stroke incidence has 
not been consistently reported in studies of lipid lowering therapy. Many large trials of 
cholesterol lowering treatment were designed to detect a reduction in coronary deaths in 
middle aged patients with and without coronary artery disease. Coronary events are 10 times 
more common than stroke in this age group of patient and as a result few stroke endpoints 
per study were reported. The few studies that have been conducted in elderly patients do 
however suggest a reduction in stroke incidence with lipid lowering treatment. It is also likely 
that cholesterol influences certain subtypes of stroke and any effect is likely to be diluted if 
strokes are not divided into the appropriate diagnostic grouping. Distinction between cerebral
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haemorrhage and infarction is absolutely essential as available evidence suggests there is a 
positive association with cerebral infarction and a reverse relationship with haemorrhage.
As yet there are no published data regarding the effect of cholesterol on survival or prognosis 
following stroke. W e  considered the hypothesis that hypercholesterolaemia would 
predispose to a poorer outcome and an increased mortality from stroke but infact our 
analysis demonstrated a counter-intuitive ‘protective’ effect of relatively higher cholesterol.
3.2 Subjects and methods
The admission criteria and protocol of the acute stroke unit of the Western Infirmary, 
Glasgow, are described in detail elsewhere.209 Briefly, all patients within a well-defined 
geographical region suffering a new focal or global neurological deficit are admitted, 
regardless of age or severity of neurological deficit. CT or MRI is performed routinely within 
72 hours of admission. Total serum cholesterol is measured on a fasting sample on the 
morning following admission. Details of each patient’s risk factors, presenting complaints, 
neurological examination, results of investigations, and final diagnosis are prospectively 
recorded and transferred to a computerised database. The patients included in this study 
represent a series of consecutive admissions to our unit. Patients whose symptoms were 
found to be caused by a condition other than stroke are excluded from the analysis.
Total serum cholesterol was measured by a standard cholesterol oxidase method. Subtype of 
stroke (primary intracerebral haemorrhage [PICH] or infarction) was diagnosed from the early 
CT or MR scan. Stroke was classified according to the system used by the Oxfordshire 
Community Stroke Project.3 This describes patients as having total anterior circulation 
infarction (TACI), partial anterior circulation infarction (PACI), posterior circulation infarction 
(POCI) or lacunar infarction (LACI).
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Outcome follow-up was by record linkage210 to death records from the Registrar General of 
Scotland, and to hospital discharge records to obtain information on medical events after
stroke. This technique has been validated previously in an epidemiological study of
211 212 hypertension and has also been used for endpoint monitoring in a large clinical trial.
The method of record linkage is a reliable one; however, admissions to private hospitals or
institutions outwith Scotland are not detected. Outcome was categorised as alive at home,
alive in care, or dead at 2, 3, 6 and 12 months after stroke; only the 3-month data were used
in our study, with good outcome defined as alive at home versus alive in care or dead. This
subdivision at 3 months is a marker for 3-month functional outcome, an endpoint commonly
used in trials of therapeutic agents in stroke.
W e  assessed the effect of serum cholesterol on survival using Cox’s proportional hazard
213model in which we controlled for known confounding factors affecting outcome (stroke 
type, i.e. haemorrhage or infarction; symptom duration, i.e. transient ischaemic attack (TIA) 
or reversible neurological deficit versus sustained stroke; Oxfordshire classification of stroke; 
plasma glucose concentration; and age). Since stroke subtype may not satisfy the 
proportionality assumption of the Cox proportional hazard model, we stratified the analysis 
into 5 groups for sub-type of stroke and Oxfordshire category (PICH, TACI, PACI, POCI and 
LACI). Age and serum cholesterol were entered as continuous independent variables. 
Plasma glucose did not satisfy the proportionality assumption and was entered as a 
dichotomous variable (<8 mmol/L versus >8 mmol/L). Estimates of survival for 1000 days in 
example cases are provided from the Cox proportional hazard model. The model predictions 
were checked by comparison with Kaplan-Meier survivorship functions for selected 
subgroups of patients. Dichotomous outcome at 3 months was assessed by logistic 
regression, using the same independent variables as above. W e  performed the statistical 
analysis using Statistica for Windows Version 5.0 (StatSoft Inc, Tulsa, OK, USA) on a PC. 
Statistical significance is declared at P < 0.05. Normally distributed data are expressed as 
mean ±  SD.
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3.3 Results
One thousand one hundred and sixty five patients were included in this study, after exclusion 
of 227 admissions in 1990 and early 1991 for whom Oxfordshire classification and/or CT  
scan results were unavailable. Of these 1165 patients, 102 had suffered a transient 
ischaemic attack and 43 a reversible neurological deficit; the duration of symptoms was not 
recorded in 9. Thus, complete data were available for 1011 patients with acute stroke. The  
average age was 69.9+12.4 years (range 23-94); the average total serum cholesterol 
concentration was 5.91±1.43 mmol/L; and plasma glucose was 7.3±2.7 mmol/L. In survivors, 
the mean follow up was 895 days, range 105-2032, with total mortality during the follow up 
period of 39.4%: median survival could not be estimated but the 25th percentile was 254 
days. There were 109 patients with primary intracerebral haemorrhage (1000 day survival 
38%), 198 with TACI (1000 day survival 38%), 326 with PACI (1000 day survival 63% ), 91 
with POCI (1000 day survival 71%) and 287 with LACI (1000 day survival 64%). Mortality 
was also significantly influenced by the presence of hyperglycaemia (plasma glucose > 8 
mmol/L): 1000 day survival was 60% if normoglycaemic versus 43%  if hyperglycaemic. Age 
significantly influenced outcome, with 1000 day survival of 71%  in patients aged < 69 years 
and 46%  for the older patients. Serum cholesterol concentration did not correlate with 
plasma glucose (r2 = 0.002) or with age (r2 = -0.004).
Figure 3.1 shows the Kaplan-Meier cumulative survival curves for patients with above or 
below average cholesterol concentrations in our population. Within the Cox proportional 
hazard model after adjustment for stroke type and Oxfordshire group, higher plasma glucose, 
lower serum cholesterol and higher age were independent predictors of mortality after stroke 
(table 3.1). The relative hazard was 8% lower for each 1 mmol/L rise in serum cholesterol 
concentration. The effect of cholesterol appeared similar within each stroke subgroup,
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though it reached statistical significance only within the larger subgroups: patients with total 
or partial anterior circulation infarcts (table 3.2).
Within logistic regression, when outcome at 3 months was coded as good (alive at home) or 
bad (alive in care, or dead) and after adjustment for age, plasma glucose, stroke type and 
Oxfordshire group, increasing levels of serum cholesterol were still associated with better 
outcome (P=0.024).
Examples of the predicted 1000-day survival for patients with low or high cholesterol at 
different ages are shown in table 3. 3.
Table 3.1: Cox proportional hazard model for mortality after stroke in 1011 
patients, adjusted for stroke type and Oxfordshire classification (PICH, TACI, 
PACI, POCI or LACI): %2 = 70.0, df = 3, P<0.00001.
H H H lH a m
plasm a glucose  
(>8 versus <8 m mol/L)
1.60 1.30, 2.00
|
0.0002
serum  cholesterol 
(p e r m mol/L)
0.92 0.84, 0.98 0.017
age
(p er year)
1.028 1.018, 1.038
!
0.00001
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Table 3.2: Relative hazard associated with serum cholesterol within each stroke 
subtype/Oxfordhire category.
■
PICH 0.97 0.78, 1.20 109
TACI 0.88 0.78, 1.03 198
PACI 0.88 0.76, 1.00 326
POCI 0.99 0.71, 1.38 91
LACI 0.95 0.82, 1.12 287
Table 3.3: Predictions from Cox proportional hazard model according to age 
and total serum cholesterol concentration, after adjustment for stroke subtype 
and Oxfordshire classification.
50 5.2 73
50 7.5 78
75 5.2 51
75 7.5 59
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3.4 Discussion
Our data suggest that the level of cholesterol independently influences survival in patients 
with acute stroke. Higher levels of cholesterol were associated with improved survival. The 
effect appears greatest in elderly patients e.g. 1000 day survival would be 51% for a 75 year 
old patient and a cholesterol of 5.2 mM, and 59%  if the cholesterol is 7.5mM, an absolute risk 
reduction of 8% and a relative risk reduction of 16%. Cholesterol did not correlate with either 
blood sugar or age. The prognostic effect was robust following adjustment for known 
prognostic indicators such as stroke type, Oxfordshire group, blood sugar and age. 
Extrapolation of our results suggests that the reduction in cholesterol of 25%  achieved within 
the 4S study204 would result in a 13% increase in stroke mortality.
There is no established biological mechanism that explains these results but cholesterol is 
known to have effects on the vasculature and is essential for normal membrane fluidity.
High cholesterol modifies the action of platelets such that exposure to cholesterol LDL 
enhances platelet aggregation by its action on platelet activating factor [PAF].214 Rabbits fed 
on a high cholesterol diet therefore have larger experimentally induced infarcts associated 
with an increase in platelet thrombi deposition within the infarct.215 Exposure to high levels of 
cholesterol also reduces the responsiveness of large but not small vessels to vasodilatory 
stimuli.216 All of these effects would therefore suggest that a higher cholesterol would 
predispose to a poorer outcome from a stroke event.
High cholesterol may exhibit a neuroprotective effect by modulating the action of the enzyme 
gamma-glutamyl transpeptidase (GGT) and acetylcholinesterase ( AChE). GGT activity is
217increased while AChE activity is reduced following a high cholesterol diet.
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GGT has a role in amino acid uptake and transport. Thus its increase in patients with higher 
cholesterol could reduce the neurotoxic effects of excitotoxic amino acids. Early survival 
does not however appear to be affected by cholesterol, rather it appears that the difference in 
the respective survival curves increases gradually over time. This suggests that the 
protective mechanism may have a more prolonged effect. Cholesterol therefore appears to 
be a marker for long term rather than short term survival. W hy this should be so is unclear 
as all conventional rationale suggests that patients with higher cholesterols would have an 
increased risk of coincidental cardiac disease, of subsequent sudden cardiac death and of 
larger cerebral infarctions. Low cholesterol is however known to be associated with 
underlying serious illness and it might be expected that these patients would have a poorer 
outcome than those with higher cholesterol. Alternatively a lower cholesterol in these 
relatively elderly patients (average age 69.9 ± 12.4 years) may simply reflect poor nutritional 
status which could predispose to a poor stroke outcome.
Trials of lipid lowering agents have concentrated on middle aged patients with a low risk of 
stroke, and as a result it is unknown whether lipid lowering treatment is beneficial in older 
patients with elevated cholesterol and cerebrovascular disease. Epidemiological data suffer 
from failure of sub-classification of stroke types which could mask a positive relationship 
between infarction and cholesterol and a negative relationship with cerebral haemorrhage. 
Post mortem pathological data also suggest cholesterol may only increase the risk of certain 
sub-groups of infarcts e.g. large vessel atherothrombosis, but not lacunar events. Evidence 
from trials of statins suggest suggest regression of carotid artery atheroma is possible with 
effective lipid lowering but whether this is clinically significant in terms of reducing 
cerebrovascular events is not entirely clear.
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A prospective study of the incidence and outcome of stroke in relation to cholesterol in older 
patients (with appropriate CT and clinical diagnosis) is therefore required to define this 
relationship accurately. A randomised, controlled trial of lipid lowering treatment in the elderly 
would evaluate the safety and cost-effectiveness of lowering cholesterol in this age group 
and could reveal effectiveness in terms of the reduction of the incidence of both stroke and 
coronary events. Current practice recommends reducing cholesterol in patients > 55 years 
with a high risk of vascular disease despite the lack of evidence for benefit in patients > 70 
years. As all previously conducted trials of lipid lowering treatment have demonstrated the 
benefit of lipid lowering treatment in middle aged patients these results cannot be 
extrapolated to the elderly population. Our data suggest lower cholesterol may have an 
adverse independent influence on survival following stroke but further studies to investigate 
and confirm this relationship are required. The efficacy of cholesterol lowering therapy as 
primary or secondary prevention of coronary and cerebrovascular events in the elderly 
remains unproven.
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Figure 3.1: Kaplan-Meier cumulative survival curves for patients with stroke 
according to quintiles of serum cholesterol concentration: < 4.8 mmol/L (group 1, 
lowest curve); > 4.8 and <5.6 mmol/L (group 2, second lowest curve); > 5.6 and 
< 6.1 mmol/L (group 3, middle curve); > 6.1 and < 7.0 mmol/L (group 4); and > 
7.0 mmol/L (group 5, top curves). Time is shown in days since stroke onset.
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Chapter 4 
Hyperglycaemia independently predicts poor outcome 
following acute stroke
4.1 Introduction
Diabetic patients have worse survival and recovery prospects after acute stroke than their 
non-diabetic patients. In addition, hyperglycaemia in the acute phase of stroke has been 
established as a predictor of poor outcome in non-diabetics.
Data from the Copenhagen Stroke Study, suggested that raised blood sugar on admission 
predisposed to poorer functional recovery and a significantly higher mortality.218 Smaller 
studies in the UK have confirmed these findings.219 There is some dispute as to whether 
plasma glucose is independently associated with a poor outcome. Some investigators have 
noted that while admission blood glucose correlates with poor outcome, HbA1c levels and 
fasting or random blood sugars after the acute event have no prognostic value220,221. Many
investigators have gone on to suggest that hyperglycaemia itself is merely a marker of a
221 228stress response with more severe strokes eliciting a more dramatic rise in blood sugar.
This theory appears credible since poor stroke outcome correlates with increased activation
229of the cortisol and adrenal axis. No investigation into the relationship between 
hyperglycaemia, cortisol axis activation and poor outcome has been carried out howeyer.
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Others have suggested that hyperglycaemia influences outcome independently of stroke
218 230 231severity. If the latter is correct, we should investigate whether reversing
hyperglycaemia in the acute phase of stroke influences its adverse effect on survival.
Rehncrona and colleagues speculated as long ago as 1981 that cerebral infarction following 
ischaemia is exacerbated by the build up of lactate within the brain. They demonstrated that 
animals exposed to global cerebral ischaemia and hyperglycaemia had larger pathological 
infarctions than those maintained at euglycaemic levels. They went on to postulate that the 
build up of acidity within the brain was an important determinant of the outcome of any
232vascular insult. Berger and Hakim demonstrated an increased rate of cerebral oedema in 
hyperglycaemic stroke patients and suggested this mechanism may contribute to a poor
233clinical outcome.
There is now good evidence from animal studies in cat and rat models of stroke that 
hyperglycaemia induced artificially and therefore independent of any stress response, leads 
to an exacerbation of the effects of cerebral ischaemia.234,235 In the rat MCAo model animals 
rendered hyperglycaemic by glucose infusion and animals infused with both insulin and 
glucose to maintain normoglycaemia had similar outcomes whereas those animals with blood 
sugar lowered to 3.4 ± 0.2 mmol (±SE of the mean) had 50% smaller infarcts on histological 
examination. This would suggest it was the correction of hyperglycaemia that had the 
neuroprotective effect rather than insulin itself.
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The same group went on to examine the effect of insulin directly infused into the 
intraventricular cisterns of rats brains. They found a significant reduction in volume of 
cerebral infarction following transient forebrain ischaemia in animals administered low and 
high dose insulin, compared with placebo infused animals, with a more dramatic effect in the 
high dose group. The high dose regime had a systemic blood sugar lowering effect but the 
low dose did not. The available animal evidence therefore suggests that both 
hyperglycaemia itself and possibly a reduction in insulin (or even a downregulation of insulin 
receptor activity within the brain) could exacerbate cerebral ischaemia by an as yet 
undefined mechanism, and crucially that this may be amenable to therapeutic manipulation.
W e  studied the effect of hyperglycaemia on stroke mortality and morbidity by assessing the 
effect of hyperglycaemia on outcome after adjusting for known prognostic factors. W e  
describe our findings in a cohort of unselected patients admitted to our acute stroke unit.
4.2 Patients and Methods
The acute stroke unit of the Western Infirmary, Glasgow, serves a catchment area of 220 
000. All patients who present within 72h of the onset of an acute neurological deficit, with no 
known alternative to a vascular cause, are admitted irrespective of age or the severity of the 
deficit. All patients have clinical data and results of investigations prospectively recorded. 
Patients undergo computed tomography to establish a diagnosis of ischaemic or 
haemorrhagic stroke. Magnetic resonance imaging is considered as an additional diagnostic 
tool, particularly in patients with suspected posterior circulation events. The aim is to 
complete all investigations within 72h of admission. All patients have their stroke subtype 
categorised on the basis of clinical features according to the Oxfordshire Community Stroke 
Project classification.3 This clinical classification divides patients into the following four
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groups: total anterior circulation syndrome, partial anterior circulation syndrome, posterior 
circulation syndrome or lacunar syndrome.
Biochemistry is analysed routinely in all patients on the day of admission and early the 
following morning. Plasma glucose is measured on both these occasions, giving one random 
and one fasting glucose measurement. In this study we used the random glucose 
measurement for each patient if it was taken; if not, we used the fasting measurement. 
Glucose level was recorded both as a continuous variable and a binary one (< 8 mmol/L, 
normoglycaemic; > 8 mmol/L, hyperglycaemic). The upper limit of the normal range for 
fasting plasma glucose level is 6.5 mmol/L. Since not all glucose measurements taken in our 
study were fasting, 8 mmol/L was used as the cut-point for hyperglycaemia. Other potential 
prognostic variables which we considered were: age, stroke type (ischaemic or 
haemorrhagic), admission blood pressure (systolic and diastolic), smoking status (non- 
smoker, ex-smoker or current smoker), resolution time of symptoms (< 72h or > 72h), and 
Oxfordshire community stroke project category.
The subjects in this study presented to our acute stroke unit between June 1990 and 
December 1993. Previously diagnosed diabetics were included in the study but the data 
from these patients were analysed separately since there is evidence that hyperglycaemia 
affects outcome differently in diabetic patients.218
210Survival and placement follow-up were by record linkage to the Scottish Deaths Register
and to a national database of hospital discharge records. The method of record linkage has
211been validated previously in an epidemiological study of hypertension, and has also been
212used for monitoring end-points and adverse events in a large clinical trial. Record linkage 
provides reliable patient follow-up; however, admissions to private hospitals or institutions 
outwith Scotland are not detected. Outcome placement was coded as: alive at home, alive
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in care, or dead. This placement information was recorded at two, three, six and twelve 
months after admission.
Baseline variables in diabetic and non-diabetic patients were compared using %2 tests for 
discrete variables and Mann-Whitney tests for continuous variables. Differences in the 
distributions of potential prognostic variables between placement categories at three months 
were assessed by % test for discrete variables and Kruskal-Wallis analysis of variance for 
continuous variables. The main analysis used Cox’s proportional hazards regression 
model213 to estimate the effect of hyperglycaemia on survival after stroke. A separate 
baseline survival function was fitted for each of the four Oxfordshire community stroke 
project categories since including Oxfordshire classification as an explanatory variable was 
unlikely to fulfil the proportional hazards assumption. The effect of plasma glucose level was 
determined after entering other significant prognostic variables (selected from age, stroke 
type, resolution time of symptoms, smoking status, and systolic and diastolic blood pressure). 
The assumption of proportional hazards was checked for all variables included in the model. 
The effect of hyperglycaemia on outcome was further explored by coding three-month 
outcome as good (alive at home) or poor (alive in care, dead) and then performing a 
stepwise logistic regression analysis.236 W e tested whether hyperglycaemia was 
independently associated with this outcome after adjusting as necessary for age, time to 
resolution of symptoms, stroke subtype, Oxfordshire classification category, smoking status, 
and systolic and diastolic blood pressure. In the proportional hazards and logistic regression 
analysis, a quadratic relationship between blood pressure and outcome was permitted.
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4.3 Results
811 patients with computed tomography confirmed acute stroke and plasma glucose data 
were included in the study. In 624 cases (77%) of patients the plasma glucose was 
measured on admission; in the remaining 23%  the measurement was taken early on the 
morning after admission. Plasma glucose was measured at a mean of 3.6 hours after 
admission to the stroke unit, and a mean of 14.4 hours after stroke onset. Sixty-one (8%) 
patients were diabetic, seven (1%) being insulin-dependent. The characteristics of these 
patients are compared with those of non-diabetic patients in table 4.3.1. As expected median 
plasma glucose level and the proportion of patients with hyperglycaemia was higher in the 
diabetic group. Our main analysis was restricted to the 750 non-diabetic patients. Fifteen 
patients were lost to follow-up for placement (due to failure of hospital discharge record 
linkage) but not for survival. Mean follow-up time was 1.65 years. Table 4.3.2 shows the 
number of patients in each outcome category over time. Table 4.3.3 gives the distributions 
of patient variables across the three placement categories. Table 4.3.4 shows the results of 
the proportional hazards modelling. Hyperglycaemia led to higher mortality, even after 
adjusting for other prognostic variables. Increased systolic and diastolic blood pressure were 
not significant linear or quadratic predictors of poor survival and were not included in the final 
proportional hazards model. Similarly, smoking status did not predict survival and was 
excluded from the model. The assumption of proportional hazards held for all variables 
except plasma glucose level (continuous). This variable was therefore removed from the 
model and plasma glucose was considered as a binary variable. Figure 4.3.1 gives the 
Kaplan-Meier survival curves for patients with and without hyperglycaemia, at each level of 
the Oxfordshire classification.
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Hyperglycaemia also predicts poor outcome at three months: this variable significantly 
(p=0.0003) improved prediction of three month outcome (alive at home vs in care or dead) 
by logistic regression after adjusting for age, time to resolution of symptoms, stroke subtype, 
and Oxfordshire classification category. Systolic and diastolic blood pressure were not 
included in the logistic regression model since they were neither linear nor quadratic 
predictors of outcome. Smoking status did not predict outcome and was excluded from the 
logistic regression model.
4.4 Discussion
Our results show that hyperglycaemia is a predictor of higher mortality and morbidity after 
acute stroke, independently of other adverse prognostic factors such as older age, type and 
severity of stroke, and non-reversibility of neurological deficit. The effect of hyperglycaemia 
on mortality is large: the estimated relative hazard of 1.87 is greater than that for 
haemorrhagic versus ischaemic stroke, and equivalent to adding more than twenty years to a 
patient’s age.
Our results suggest that hyperglycaemia is not solely a stress response to neurological insult, 
since it predicts outcome after taking other prognostic factors into account. Indeed, the 
relative risk conferred by hyperglycaemia is greatest in patients with lacunar stroke.
Previous studies which concluded that hyperglycaemia was a stress response, based on a 
correlation between stroke severity and plasma glucose level,226,227 did not consider whether 
hyperglycaemia independently predicted outcome after adjusting for stroke severity. Van
230Kooten et al demonstrated that norepinephrine levels were associated with stroke severity, 
but could not find significant relationships between catecholamine and plasma glucose level 
or between glucose level and stroke severity. They concluded that elevated plasma glucose 
in non-diabetic stroke patients could not be explained by a stress response. Jorgensen et
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218al found a correlation between glucose level and stroke severity but found that glucose 
level independently predicted outcome after adjusting for stroke severity.
W e sought to correct for admission blood pressure in our modelling of survival, since 
elevated blood pressure after stroke admission may be due to both mental stress of 
hospitalisation59,190 and physical stress of neurological damage. However, neither systolic 
nor diastolic blood pressure was associated with outcome. In addition, diastolic blood 
pressure was not significantly correlated with plasma glucose level (Spearman’s rank 
correlation coefficient rs = 0.053, p = 0.0819) while systolic blood pressure was only weakly 
correlated with plasma glucose level (rs = 0.131, p = 0.0003). This further indicates that 
elevated plasma glucose is not due to a stress response after acute stroke.
It is likely that in many of the hyperglycaemic patients in our study, the elevated plasma 
glucose was of a long-standing nature. Other studies218,223,224,230,231 investigated this by 
measuring glycosylated haemoglobin HbAic and inferred that elevated HbAic levels indicated 
a long pre-stroke history of hyperglycaemia. HbAic is not routinely monitored in our stroke 
unit and we were thus unable to estimate the prevalence of previously undiagnosed diabetes.
The mechanism by which hyperglycaemia might influence stroke outcome is uncertain. Both
237acute and chronic hyperglycaemia are associated with increased oedema and infarct size,
238and with reduced cerebral blood flow and cerebrovascular reserve. Ischaemia leads to a 
slowing of the oxidative glucose metabolism and an increase in anaerobic glycolysis. The 
concentration of lactic acid increases locally as a result. Hence intracellular pH is lowered
232 239 240and cells die or become dysfunctional. Hyperglycaemia exacerbates such changes. 
Experimental evidence suggests hyperglycaemia may increase lactate production in two 
ways: either directly in the severely ischaemic brain by increasing available glucose, or 
indirectly in the case of incomplete cerebral ischaemia by inhibiting mitochondrial respiration 
and glucose oxidation.240 Such increased lactate production in the ischaemic penumbra may
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lead to poorer outcome. The above mechanisms may also cause a worse outcome in 
hyperglycaemic primary intracerebral haemorrhage, the excess lactate generation occurring 
in the area of ischaemia around the site of the haemorrhage.
Our results suggest that a randomised trial of glucose control in hyperglycaemic stroke 
patients is warranted. Randomisation should be soon enough after stroke onset to allow 
treatment during the “window of opportunity” for pharmacological intervention. Recently 
reported studies suggest that this time window lasts for up to three4 or even twelve178 hours 
after stroke onset.
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Table 4.3.1 Comparison of diabetic and non-diabetic patients
Diabetic
n=61
Non-diabetic
n=750
Median age 69 70
Male sex (%) 34 (56) 371 (49)
Median plasma glucose (mmol/L) * 11.1 6.5
Hyperglycaemia ( % ) t 42 (69) 162 (22)
Smoker (% )1 11 (18) 326 (43)
Median diastolic blood pressure 
(mm Hg)
90 90
Median systolic blood pressure 
(mm Hg) *
170 160
Haemorrhagic stroke (%) 4 (7 ) 105 (14)
Symptoms resolved within 72h (%) 7(11) 92 (12)
Oxford classification
Total anterior circulation syndrome 12 (20) 173 (23)
Partial anterior circulation syndrome 22 (36) 259 (35)
Posterior circulation syndrome 4 (7 ) 78 (10)
Lacunar syndrome 21 (34) 217 (29)
Other 2 (3 ) 23 (3)
Figures are numbers of patients (percentage of patients) unless otherwise stated 
* Mann-Whitney test significant at p<0.0001 
t  Chi-squared test significant at p<0.0001 
$ Mann-Whitney test significant at p<0.05
Table 4.3.2: Numbers of patients in each outcome category over time
2 months 3 months 6 months 12 months
Alive at home 410 (56) 441 (60) 453 (62) 444 (60)
Alive in care 173 (24) 129(18) 91 (12) 68 (9)
Dead 152(21) 165 (22) 191 (26) 223 (30)
Figures are number of patients (percentage of patients at each time) 
Fifteen patients were lost to follow-up for placement
Table 4.3.3 Distribution of variables with three month placement
Variable Alive at home 
(n=441)
Alive in care 
(n=129)
Dead
(n-165)
Median age1 68 75 72
Male sex* (%) 239 (54) 51 (40) 78 (47)
Median plasma glucose* (mmol/L) 6.2 6.7 7.3
Hyperglycaemia* (%) 68 (15) 27(21) 66 (40)
Smoker (%) 206 (47) 50 (39) 63 (38)
Median diastolic blood pressure (mm Hg) 90 90 90
Median systolic blood pressure (mm Hg) 160 164 160
Haemorrhagic stroke* (%) 36 (8) 21 (16) 45 (27)
Symptoms resolved within 72h* (%) 82(19) 4 (3 ) 5 (3 )
Oxford classification* (% within outcome group)
Total anterior circulation syndrome 47(11) 44(35) 80 (50)
Partial anterior circulation syndrome 167 (39) 38 (31) 46 (29)
Posterior circulation syndrome 60(14) 2 (2 ) 15 (9)
Lacunar syndrome 154 (36) 40 (32) 19 (12)
f Kruskal-Wallis analysis of variance showed significant differences between 
outcome groups, p<0.001
* Chi-squared test showed significant differences between outcome groups,
p<0.01
* Chi-squared test showed significant differences between outcome groups, 
pcO.OOOl
Table 4.3.4: Proportional hazards modelling of mortality
Variable Relative hazard 95% confidence 
interval
p-value
Hyperglycaemia 1.87 1.43 to 2.45 <0.0001
Increasing age (per decade) 1.36 1.21 to 1.53 <0.0001
Symptoms remaining after 72h 2.15 1.15 to 4.05 0.015
Haemorrhagic stroke 1.67 1.22 to 2.28 0.001
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Chapter 5
The safety and tolerability of GV150526 (a glycine receptor antagonist) 
in patients with acute stroke 
[A double blind, randomised, placebo controlled, parallel group, 
ascending dose study] 
5.1 Background
G V150526 is a novel antagonist at the glycine site of the NMDA receptor complex. 
Antagonism at this site specifically and selectively blocks activation of the NMDA receptor 
complex. The structure of GV150526 is shown in figure 5.1.1. GV150526 has been 
evaluated in animal models of stroke which have demonstrated efficacy in reducing infarct 
volume and improving neurological outcome.
5.2 Preclinical pharmacology
In the rat model of middle cerebral artery (MCA) occlusion GV150526 is a potent 
neuroprotective agent, with a putative neuroprotective concentration of 10-30 ng/mL241 
(figure 5.2.1). It is free from cardiovascular and behavioural effects at doses of up to 
30mg/kg in rat or mouse and 12 mg/kg in dogs.242,243 Animal and human volunteer studies 
suggest GV150526 is less likely to cause the adverse effects seen in studies of NMDA  
antagonists (sedation, agitation, catatonia, nausea, Gl upset, dyspepsia). Adverse reactions 
noted in animal toxicity testing included local injection site irritation, mild sedation, 
discoloured red urine, and renal tubular dilatation in rats at a dose of 200mg/kg (Glaxo 
laboratories, Verona, unpublished data). This was considered to be the maximal tolerated 
dose in rodents. Doses up to 30 mg/kg had no effect on memory or muscle tone in mice
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with no evidence of neuronal vacuolation.244 Toxicology studies in dogs demonstrated 
increases in hepatic enzymes with concomitant increases in liver weight and minimal bile 
duct proliferation associated with mean systemic exposure of 210 ng/mL. These changes had 
diminished by the end of the recovery period.
Pre-clinical pharmacokinetics from animals indicate the clearance and volume of distribution 
of GV150526 are low suggesting limited tissue distribution. The plasma elimination half-life in 
the rat was estimated as 6.5 hours and in the dog 2.5 hours with the major route of 
elimination by biliary excretion. In-vitro plasma protein binding studies confirm high protein 
binding (> 99%) mainly to albumin.
5.3 Clinical experience
Prior to this study GV150526 had been given to 17 young healthy volunteers and 24 elderly 
volunteers, in doses ranging from 1 to 400mg (Glaxo laboratories, Verona).
Only minor adverse events were reported and there was no change in vital signs or 
laboratory safety data attributable to treatment. Symptoms potentially attributed to treatment 
included tiredness, headache, neck-ache, flatulence, loose bowels and sore throat. 
Pharmacokinetic data from these studies (dose range 1-400mg) suggest clearance and 
volume of distribution are low in humans with an elimination half life of 19 hrs. Cmax was 
linearly related to dose throughout the 1-400 mg range.
5.4 Aims and objectives
Part A 
Primary
•  To assess safety and tolerability of ascending doses of GV150526 in patients with acute 
stroke (doses 50, 100, 200, 400, 800mgs).
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•  To assess clinical pharmacokinetics of GV150526 in patients with acute stroke.
Secondary
•  The power of the study was not sufficient to assess the therapeutic efficacy of GV150526  
but preliminary data on stroke outcome were gathered.
Part B 
Primary
The objectives of the second study were to assess the safety and tolerability of a bolus dose 
selected from the initial study and followed by repeated infusions selected to maintain 
putatively neuroprotective concentrations during 60 hours.
Secondary
Preliminary outcome data were collected but the study was not powered to demonstrate 
efficacy.
5.5 Patients and methods
5.5.1 Study design
Part A
This was a double blind randomised (ratio of 3:1 active: placebo) placebo controlled, parallel- 
group, ascending single intravenous dose study in acute stroke patients. Eight patients were 
to be enrolled into each dosage group.
97
PartB
This was a double blind, randomised, placebo controlled, parallell-group, ascending multiple 
intravenous dose study. Each patient received a loading dose of 800mg GV150526 followed 
by 5 repeat infusions at 12 hourly intervals.
Ethics and consent
The study design and consent form were approved by the W est Ethics Committee of the 
Western Infirmary, Glasgow. Written informed consent was obtained from the patient or 
relatives before subjects were randomised to receive either active drug or placebo. W here  
written consent could not be obtained, consent was accepted verbally, but only in the 
presence of an independent witness unconnected to the trial. On rare occasions when 
patients were unable to give written or verbal consent, consent was accepted from the next 
of kin in the presence of an independent witness.
5.5.2 Patient selection 
Inclusion criteria
•  Males aged over 18 years, and post menopausal or surgically sterilised females.
•  Patients suffering acute ischaemic stroke within 12 hours of study entry. For patients with
night time stroke, time of waking was taken as time of onset.
Exclusion criteria
Patients with the following were excluded from the study
• Coma (unable to localise painful stimulus)
•  Known serious hepatic or renal abnormalities.
•  Receiving investigational drug within previous 3 months.
98
•  Acute unstable systemic illness other than acute stroke.
•  Known underlying seizure disorder.
•  Anti-coagulation with warfarin.
•  Patients taking > 1gram aspirin in the previous 24 hours.
5.5.3 Dosing regimen 
Part A
Within each study panel, 8 patients were allocated placebo or active treatment according to 
the randomisation code. The dose regimens are summarised below.
Part A: Bolus
■ I mmSEn]■M M
1 50 7.5 min 62
2 100 15 min 125
3 200 30 min 250
4 400 60 min 500
5 800 240 min 1000
N.B Group 5: 400mL in 500ml over 60 mins + 400mg in 500mL over 180 mins.
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Part B
Within each dosage group 8 subjects (6 active and 2 placebo) received treatment as 
allocated in the table below. All patients receiving active treatment were administered a 
loading dose of 800mg over 4 hours. The first maintenance infusion commenced 12 hours 
after the start of the loading dose. The maintenance dose was administered at a rate of 500 
m U  h. The duration of each infusion was therefore variable and is shown in the table below.
Part B: Bolus + 60 hour infusion
1 800mg /  4 hours 10Omg bd x 5 infusions 15 minutes
2 800mg /  4 hours 200mg bd x 5 infusions 30 minutes
3 800mg /  4 hours 400mg bd x 5 infusions 60 minutes
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5.6 Study procedures
5.6.1 Screening
Following admission to the acute stroke unit patients underwent initial clinical and 
neurological assessment by a member of the medical staff. Only patients who met the 
inclusion criteria and for whom consent was obtained were entered into the study.
5.6.2 Safety
The fo llow ing analyses were carried out
Haematology Biochemistry Urinalysis
haemoglobin sodium glucose
white cell count chloride protein
red cell count potassium blood
platelet count bicarbonate
haematocrit urea
creatinine
coagulation calcium
prothrombin time phosphate
activated partial thromboplastin time albumin
thromboplastin time protein
fibrinogen bilirubin
alkaline phosphatase
AST
ALT
GGT
Blood samples were taken for biochemical screening, urinalysis performed and 12 lead ECG  
recorded pre-dosing and at 4, 60 and 96 hours. Continuous ECG monitoring was performed 
throughout all infusions. CT or MRI scanning was carried within 3 days on all patients to
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confirm the diagnosis of stroke. Scanning was not a prerequisite to study entry but patients 
with CT findings inconsistent with a diagnosis of stroke had study drug discontinued and 
remained within the study for collection of safety data.
Coagulation was assessed using prothrombin time at baseline, 24 and finally 72 hours. 
Biochemistry was analysed by the routine laboratory analyser at the Biochemistry 
Department, Gartnavel General Hospital, Glasgow. Haematology was performed by 
automatic counter at the Western Infirmary Haematology Department. Urinalysis was carried 
out using Multistix SG (Bayer Diagnostics, Basingstoke, Hampshire UK) and the presence of 
blood, protein and glucose noted.
5.6.3 Tolerability
Adverse event enquiries
Adverse event reports were collected at the start of the infusion and at the following intervals: 
2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 1 week, 1 month. Brief general physical examinations 
were carried out at baseline, 24 h, 3 days, 1 week and 1 month wherever possible. A 
functional assessment (Barthel index) was recorded at 1 month.
5.6.4 Vital signs
Blood pressure and pulse recordings were made using Marquette semi-automatic 
oscillometric monitoring equipment (Marquette Electronics Inc. Wisconsin U S A ) and 
repeated at frequent intervals during drug dosing.
5.6.5 Pharmacokinetics
Blood samples (2mL) were taken from a cannula sited in the ante-cubital fossa of the non­
infusion arm, at regular and frequent intervals for assay of the main metabolite of GV150526
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(GV150526X). The sampling times varied according to the dose administered. All time 
points were nominal and precise times of sampling were documented in the case report 
forms.
Samples were stored on ice immediately after collection and centrifuged (3000rpm for 15 
mins at 4°C). Plasma was then transferred to a plastic vial and frozen (< -1 8 °  C) within 3 
hours of collection.
Urine was continuously collected where possible over the 0-24 and 24-48 hr period and 
assayed for GV150526X and creatinine. At the end of the collection period urine was stored 
frozen (<-18°C) in a plastic container. The pharmacokinetic analysis was performed in the 
Drug Metabolism Department Glaxo S.p.A., Verona.
Plasma and urine were transported from the Acute Stroke Unit on dry ice. Samples were 
stored at < -18° C pending analysis. Plasma concentrations of GV150526X, the main 
metabolite of GV150526 were determined using an online solid phase extraction, with fully 
automated cartridge exchange with HPLC separation and UV detection. The validated limit 
of quantification for this analysis was 0.2(xg/mL.
The binding of GV150526X to plasma proteins was determined in the Cmaxsamples from all 
patients. Protein binding was determined by equilibrium dialysis and assay of free fractions 
by HPLC.
GV150526X in urine was assayed using a HPLC separation with direct injection of diluted 
urine and UV detection. The validated limit of quantification for this method in the calibration 
range was 0.025p.g/mL.
103
Part A
Standard non-compartmental methods were applied for the pharmacokinetic analysis. The 
maximum concentration (C max ) ,  the time taken to reach maximum plasma concentration 
( tm a x ) . the area under the plasma concentration time curve from zero to the time of the last 
measurable plasma concentration (AUC ia s t ) ,  the area under the curve from zero to infinity 
(AUCco), the terminal rate constant (Xz ), the associated terminal half-life ( t  1 /2 ) and the mean 
residence time corresponding to an intra-venous bolus dose (MRTiv) were calculated using 
PCNONLIN (release 4.2a, non-com partmental model 202).
AUCiast was calculated by the linear trapezoidal method, Xz was estimated by log-linear 
regression of those data points that describe the terminal log-linear decline in the plasma 
concentration /  time profile, and 11/2 was calculated as In2 / Xz. AUC„ was calculated as 
AUCiast+ Ciast/ K  where Ciast was the last measurable concentration; the mean residence 
(MRTiv) was calculated as (AUMC„ /AUCoo)-T/2 where AUMCW is the area under the first 
moment of the curve and T was the infusion time.
The percentage of AUC«, obtained by extrapolation (%AUCex) was calculated as
Ciast * 100 /  (VAUCoo). Total plasma clearance (CL) was calculated as Dose/ AUC*. 
apparent volume of distribution (Vd) as CLAZ, volume of distribution at steady state (Vdss) as 
CL*MRTiv. G V150526X excreted in the urine were estimated from the concentrations 
measured in urine samples and the collected urine volume. Renal clearance (CLr) was 
calculated as Ae/AUC* where Ae is the total amount of GV150526X excreted in the urine.
Protein binding was assessed, from samples taken at the end of the infusion, using 
equilibrium dialysis HPLC.
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The relationship between pharmacokinetic parameters and patient age and weight was 
explored using linear regression analysis. Regression analysis plots were generated together 
with the predicted regression line. The significance of the correlation was determined from 
the slope of the regression.
A compartmental analysis was also performed using a two compartment model with constant 
intravenous input and first order output. The volume of the central compartment V i, the 
elimination rate constants (ki2,k2i) were estimated by nonlinear reweighted least squares 
regression analysis (PC NONLIN 4.2 model 9, reweight -2).
Part B
In part B the appropriateness of a two or three compartment model with intermittent 
intravenous infusions and first-order output was assessed. Actual infusion and blood 
sampling times were used in the analysis.
The volume of central compartment (Vc), the elimination rate constant from the central 
compartment (kio) and the distribution rate constants (ki2, k2i, ki3, k3 i) were estimated by 
non-linear least squares regression analysis (WinNonLin 1.1 .Models 9 and 13).
Concentration data were weighted using either 1/Y, 1 /Y 2 or no weighting as appropriate, 
where Y  was the model predicted concentration value. Assessment of goodness of fit was 
based on observed/predicted concentration-time profiles, residual plots and Akaike 
Information Criterion(AIC). The results indicated that a two compartment model best 
described the concentration/time profile of GV150526X.
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The maximal plasma concentration (Cmax) was determined directly from the observed 
concentration data. Clearance (Cl), steady state volume of distribution (Vdss) and terminal 
half life (ty2) were determined as secondary parameters by WinNonLin. Intercom partmental 
clearance (CI12) was estimated from the product of Vc and ki2 . The average steady state 
concentration(Css) for each patient was determined from the maintenance dose infusion rate 
and clearance.
Microsoft ®  Excel v 5.0 was used for all calculations and descriptive statistics.
5.6.6 Outcome
NIH stroke scale (appendix 1) assessments were made at baseline, 24 hours, 72 hours, 1 
week and 1 month. Barthel index (appendix III) functional assessment was undertaken at the 
completion of the study i.e.1 month.
5.7 Results
5.7.1 Recruitment and demographics
A total of 66 patients were recruited to parts A and B of the study. 18 patients in total 
received placebo (12 within part A and 6 within Part B) and 6 each received bolus doses of 
50, 100, 400 and 800mg GV150526. Due to a dosing error only 5 patients received the 
200mg dose, (the sixth received 400mg over 30 minutes). In part B: 6 patients were 
administered 100 and 200mg bd and 7 patients received the highest dose of 400mg bd. The 
demographic details of patients entering parts A and B of the study are summarised in the 
tables below.
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Demographics: Part A
HI
num ber o f 
patients
12 6
’
5 6 6
sex
male 7 2 4 2 5 2 I
female 5 4 2 3 1
4
age (yrs)
mean 73.4 66.8 72.4 62.2 68.1 72.8
SD 13 22.1 17.8 5.7 9.9 11.3
w eight(kg)
i
I
mean 68.3 72.5 76.4 62.2 76.7 65.8
SD 7.3 8.2 23 13.5 17.8 18.7
height(cm )
mean 166.3 163.5 166 165 165.3 166.6
SD 7.2 10.2 14.8 8.5 6.6 9.1
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Demographics: Part B
mm g g
num ber o f patients 6 6 6 7
sex
male 3 4 2 2
female 3 2 4 5
age (yrs)
!
mean 78 67 69 71
SD 8.6 10.3 11.6 14.2
w eight (kg)
mean 69.5 64.5 63.2 61.4
SD 8.1 9.8 5.5 8.5
height (cm)
mean 169 166 163 162
SD 8.1 9.8 5.5 8.5
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5.7.2 Compliance
Protocol violations
Six patients were dosed after 12 hours of onset. In each case the patients had been 
assessed and consent obtained before 12 hours but the start of the infusion was delayed due 
to practical difficulties in obtaining venous access and setting up the infusions. These 
protocol violations are described in the tables below.
Part A
6 placebo time to treatment: 12 hours 55 minutes
23 placebo time to treatment: 12 hours 20 minutes
35 placebo time to treatment: 13 hours 30 minutes
3 50mg time to treatment: 12 hrs 15 minutes
Part B
96 200mg bd time to treatment: 15hrs 30 mins
103 400mg bd time to treatment: 12hrs 40 mins
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5.7.3 Serious adverse events 
Mortality
There were 8 deaths out of a total of 66 patients: 7 in part A and one in part B. The fatal 
events are summarised in the table below.
U
35 placebo further stroke 14 days
51 placebo further stroke /  bronchopneumonia 21 days
17 100mg bronchopneumonia 29 days
24 100mg myocardial infarction 20 days
65 800mg stroke + complicating infection 17 days
66 800mg stroke 49 days
71 | 800mg Gl haemorrhage < 1 hour
Part B
I
91 200mg bd extension of stroke 11 hours
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Deaths: Part A
Placebo
2/12 (17%) placebo patients died at 14 and 21 days after stroke as a result of extension of 
stroke and a combination of recurrent stroke + bronchopneumonia respectively: subjects 35 
and 51.
800mg bolus
Three patients in the 800mg group died as a result of
1. extension of stroke on day 49 (subject 66);
2. complicating infection on day 17 (subject 65);
3. gastrointestinal haemorrhage and myocardial infarction which presented 
less than 1 hour after the start of the infusion (subject 71).
A post mortem in the last patient revealed gastric erosions and a leaking aortic aneurysm. 
The plasma urea on admission was subsequently found to be elevated consistent with a 
recent prior Gl haemorrhage.
Deaths in part B
Patient number 91 (200mg bd dose group) died 11 days after the start of treatment. The 
patients deterioration was thought to be due to the CT confirmed large middle cerebral artery 
infarction.
Withdrawals 
Part A
Five patients were withdrawn from the study prior to their one month follow up assessments. 
Two were withdrawn prior to completion of drug infusion (subjects 17 and 71).
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During infusion
lOOmg
•  Subject 17 developed unstable atrial fibrillation immediately prior to the infusion being 
started and was subsequently replaced with subject 25.
•  Patient 21’s conscious level deteriorated 23 hours after infusion commenced and later 
recovered but this was consistent with the underlying diagnosis of a moderate sized 
cortical intracerebral haematoma.
Post infusion
50mg
•  Patient 5 in the 50mg dose group developed prolonged sinus pauses, requiring 
permanent pacemaker insertion 16 hours after the start of the drug infusion. A right 
bundle branch block pattern had been present on the ECG prior to the start of the 
infusion.
lOOmg
Patients 17 and 24 (both 100mg) developed acute left ventricular failure, 27 and 15 days
after treatment respectively.
Part B
Six patients were withdrawn prior to their 1 month assessments. Four withdrawals were prior
to completion of treatment.
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During infusion
Placebo
Patient 99 was withdrawn due to extension of stroke.
lOOmg bd
Patient 98 was withdrawn following the loading dose after the onset of vomiting and positive
faecal occult blood.
400mg bd
•  Patient 97 exhibited fluctuating levels of consciousness, neck stiffness, drowsiness, and 
confusion after 2 days infusion treatment and was subsequently withdrawn from the 
study.
•  Patient 102 developed an infusion site cellulitis 24 after commencing treatment and was 
withdrawn prior to completion of the infusion regimen.
Post infusion
200mg bd
•  Patient 91 was withdrawn 1 week after treatment due to deteriorating conscious level 
which led to death on day 11 of the study.
•  Patient 93 was discharged from hospital and subsequently failed to attend follow up 
visits.
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Other serious adverse events
Part A
There was one additional serious adverse event in part A of the study. Patient 72 suffered a 
recurrent transient ischaemic attack 3 days after enrolment.
Part B
All serious adverse events reported in part B of the study were either fatal or resulted in 
withdrawal from the study.
CNS effects
In contrast to other NMDA receptor antagonists e.g.remacemide (chapter 6) and particularly 
aptiganel (chapter 7), GV150526 was exceptionally well tolerated by patients even at high 
doses. There was no excess of CNS adverse events reported in the actively treated patients 
in either study.
Other adverse events
Headache was more commonly reported in the actively treated group of part A; 5/29 vs 1/12 
placebo. There were no other consistently reported side effects and no increase in reported 
adverse events in the actively treated groups.
In part B there was no excess of headache or other any other reported symptoms within the 
actively treated patients.
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No serious adverse events reported in either part A or B were thought likely to be the result 
of drug administration. The overall death rate of 12% over a 1 month follow up period is 
consistent with the prognosis expected in patients with stroke. Acute stroke unit mortality for 
1996 was 12.2%
Vital signs
No changes in blood pressure or heart rate consistent with drug effect were reported.
All deviations in ECG findings within 1 week of drug administration are reported in the table 
below.
35 placebo 24 new anterior Q wave
54 placebo 72 bradycardia : rate 52
56 400 mg 1 ventricular bigeminy
5 50 mg 1 sinus arrest requiring pacemaker insertion
71 800 mg 1 myocardial infarction following massive Gl bleed
22 100 mg 1 -7 2 generalised myocardial ischaemia
89 100 mg 
bd
60 myocardial ischaemia. ST elevation
98 100 mg 
bd
96 ventricular trigeminy
94 200 mg 
bd
60 sinus tachycardia
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An analysis of changes in ventricular rate, PR, QRS, and QT intervals at the time of maximal 
drug concentration revealed no difference before and during infusion in treated patients from 
part A. The results are shown in the table below.
HBHHHImgHm
before infusion mean 75 185 113 392
SD 23 18 18 20
during infusion mean 72 182 96 395
SD 19 20
....
24 18
5.7.4 Laboratory results 
Part A
There were no changes attributable to study drug on laboratory screening. Bicarbonate was 
mildly reduced in 4/6 patients in the 800 mg, 1/6 of the 400 mg 1/6 100mg 1/6 50 mg and 
2/12 placebo groups. This is likely to reflect the clinical condition of the patients within the 
higher (800 mg) dose group rather than any dose dependent drug effect. Minor disturbances 
in electrolytes were equally frequently reported in both the active and placebo groups 
consistent with the administration of intravenous fluids or dehydration. Increases in liver 
enzymes (G GT and ALT) were reported in 6/29 (21%) actively treated patients compared 
with 3/12 (25%) controls. In each actively treated subject the rise was transient and not 
severe. Mild anaemia was reported in a total of 4/29 (14%) actively treated patients 
compared with 1/12 (8.3%) placebo patients, but there was no increased frequency at the 
higher dose levels and in each case hematological indices were consistent with pre-existing 
iron deficiency. One patient in the 800 mg group developed a transient reduction in platelet 
count 72 hours after commencing drug infusion (142 at baseline 81, recovering to 164 at 1
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week). This was not associated with any abnormalities in total red or white cell count that 
may have suggested marrow failure.
Part B
Elevations in bilirubin, GGT and liver transaminases consistent with cholestasis were 
reported following repeated infusions. The effect was dose dependent and particularly 
prevalent at the highest dose (400 mg bd). Mean rises in liver function tests for each dose 
group are summarised in figures 5.7.4.1, 5.7.4.2 and 5.7.4.3. There were no changes in liver 
function in any placebo receiving patients.
One out of six patients receiving 100 mg had a 3 fold rise in G G T and ALT at 24 hours. This 
had resolved by 10 days. In the 200 mg group 2/6 patients had liver function abnormalities: 
one patient had an isolated 3 fold increase in ALT at 84 hours; a second patient had a 2 fold 
increase in bilirubin, AST and ALT at 84 hours, resolving by 10 days.
In the group receiving 400 mg bd 4/7 patients had significant rises in bilirubin and 3/7 had 
increases in GGT and alkaline phosphatase, consistent with a hepatic cholestatic effect. 
Changes in liver function tests in individual patients in the 400mg bd dose group are 
summarised in figures 5.7.4.4, 5.7.4.5 and 5.7.4.6.
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5.7.6 Pharmacokinetics
Part A
Detectable plasma levels of GV150526X were observed in all actively treated patients at all 
sample times post-infusion. GV150526X had a low clearance (0.27-0.39L/hr) and a terminal 
half life of approximately 25-35 hours. The central compartment volume of distribution was 
3-4 L, which is equivalent to plasma volume (~3L). The steady state volume of distribution 
was 7-10 L and is equivalent to the apparent volume of distribution for plasma proteins (~7L). 
The low distribution may result from high plasma protein binding (>99.9%) of GV150526X.
Pharmacokinetics appeared linear up to a dose of 100 mg. The Cmax for the 800 mg dose was 
less than the predicted value from the 400 mg dose. This may be due to saturation of protein 
binding at higher doses leading to increased penetration of peripheral tissues. The ti /2 was 
long varying between 34.9 hours in the 50 mg group and 23.0 hours in the 800 mg group. 
Urinary excretion was between 0.14%  and 0.27%  total dose and the volume of distribution 
was low (between 7.43 L in the 50 mg and 9.93 L in the 800 mg group) consistent with high 
protein binding noted in animal studies. Plasma concentrations predicted to be 
neuroprotective in humans from the rat MCA occlusion model were successfully exceeded, 
sustained and well tolerated.
Systemic clearance was consistent with results previously observed in healthy volunteers 
(0.3-0.42 L/hr). Renal elimination accounted for less than 1% of the total dose. The terminal 
tic was similar to that observed in previous volunteer studies i.e.25-35 hrs). G V150526 has 
a low volume of distribution at steady state i.e.7-13 L due to high protein binding (99.99%). 
Analysis of the AUC* and CL for each dose group suggests deviation from linear kinetics at 
doses of 400 mg and 800 mg. These observations may be the result of saturable protein 
binding.
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Regression of C max against dose following bolus injection is shown in figure 5.7.6.1.
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A summary of median pharmacokinetic parameters at each dose level is 
summarised below
BbiyQ iH ifiiT& l
H H S H I
n=4 n=4 n=4 n=6 n=5
Cmax (ng/mL) 16.5 28.9 69.2 101 106
(11.4-18.8) (22.6-35) (49.5-76.1) (95.3-126) (105-121)
AUCoo (^g/mL) 167 374 646 1096 2092
(138-211) (267-444) (503-998) (954-1272) (1399-3372)
CL (L/h) 0.3 0.27 0.32 0.37 0.38
(0.24-0.36) (0.23-0.37) (0.2-0.4) (0.31-0.42) (0.24-0.57)
V dss(L) 7.43 8.15 6.69 8.64 9.93
(6.28-9.27) (6.3-9.71) (5.37-7.91) (7.56-14.2) (9.14-16.96)
11/2 (h) 34.9 30.8 25.2 27.4 23.0
(25.4-46.2) (27.3-40.5) (21.3-26.6) (18.5-43.7) (19.6-52.2)
Urin. excr.(% 
dose)
0.24 0.25 0.27 0.14 0.21
(0.18-0.91) (0.22-0.61) (0.02-0.48) (0.05-0.55) (0.11-0.82)
CLr(L/hr) 0.0006 0.0008 0.0008 0.0005 0.0011
(0.0006-0.0033) (0.0006-
0.0018)
(0.0001-0.001)
j
(0.0002-
0.0022)
(0.0004-
0.0025)
% unbound at 
Cmax
ND ND 0.0015 0.0034 0.0045
(0.0011-0.0023) (0.0017-
0.0080)
(0.0028-
0.0070)
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Part B
G V150526 again was found to have a low clearance (0.31-0.40 L/hour) and low central (3.3- 
3.9L) and steady state volume of distribution (9.8-17L). The terminal t i /2 was 29-56 hours. 
The low distribution results from high plasma protein binding (>99.9% ). The clearance was 
30% lower in females. Volume of distribution was not related to patient demographics. The 
free fraction of drug increased in some patients during the 60 hour treatment period, 
particularly in those patients with elevated bilirubin. GV150526 and its conjugated 
metabolites altered the elimination process of bilirubin. A significant inverse relationship was 
noted betweeen patient age and clearance (p=0.02) and a significant direct relationship was 
noted between patient weight and clearance (p=0.02). Patient weight was highly correlated 
with patient age (p<0.001), thus the effects of age and weight on clearance could not be 
distinguished. No relationships were observed between volume of distribution and patient 
age or weight.
Concentrations achieved after administration of the three maintenance doses are shown in 
figures 5.7.6.2, 5.7.6.3 and 5.7.6.4.
A summary of the statistical analysis of the compartmental pharmacokinetics in part B is 
shown in the table below.
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Summary of geometric mean (95%CI) compartmental pharmacokinetic 
parameters for GV150526X.
dose 800mg/100mg bd 800mg/200mg bd 800mg/400mg bd
n=6 n=6 n=7
CL (L/hr) 0.4 0.31 0.33
(0.31-0.50) (0.25-0.37) (0.20-0.54)
CL12 (L/h) 0.53 0.73 0.48
(0.36-0.79) (0.59-0.91) (0.20-1.25)
Vc (L) 3.36 3.33 3.9
(2.71-4.17) (2.54-4.35) (3.35-4.54)
V dss (L) 11.5 9.84 17.0
(9.35-14.0) (7.94-12.2) (15.1-21.3)
tl/2a (h) 2.14 1.63
i
2.73
(1.50-3.04) (1.22-2.18) (1.23-5.63)
ti/2p (h) 28.9 26.7 55.9
(23.6-35.4) (18.4-38.9) (44.7-79.1)
Predicted Css 118 118 135
(ng/mL)
(101-137) (107-131) (118-144)
Urin. excr. (%dose) 0.35 0.19 0.29
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5.7.7 Clinical outcome
The power of the study was not sufficient to show any trend towards efficacy. The results of 
the NIH Stroke scale and Barthel index follow ups are documented in figures 5.7.7.1, 5.7.7.2, 
5.7.7.3  and 5.7.7.4 and not unexpectedly failed to demonstrate differences between drug and 
placebo treated patients. The overall outcome in the highest dose group was poorer due to 
the baseline severity and complications of stroke suffered by those particular individuals.
5.8 Discussion
G V150526 had no effect on blood pressure, heart rate or the electrocardiogram. No serious 
adverse events related to drug therapy were reported and there was no trend to altered 
functional outcome.
Plasma concentrations predicted to be neuroprotective in humans from the rat post MCA  
occlusion model were successfully exceeded and were well tolerated. Infusions of 200mg 
and 400mg bd sustained plasma levels of GV150526 above the concentration demonstrated 
to be neuroprotective in animal models of 10-39 pg/mL (figures 5.7.6.3 and 5.7.6A). 
Interestingly there were no significant adverse psychotomimetic or haemodynamic effects as 
frequently reported with other NMDA antagonists. W hile it has been suggested that the 
favourable side effect profile may be due to a lack of sufficient drug within the brain tissue, 
preclinical animal work with G V150526 did suggest that this compound would be better 
tolerated than conventional NMDA receptor antagonists. The lack of haemodynamic and 
CNS effects is consistent with the preclinical animal experimental findings.
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It may be that antagonism of the glycine binding site of the NMDA receptor complex rather 
than the ion channel leads to neuroprotection without haemodynamic and psychotomimetic 
effects. This would certainly give such a compound a significant advantage over other 
potential neuroprotectives which are less well tolerated. Therapeutic levels of drug could 
reliably be obtained and sustained and patient compliance would be enhanced. Significant 
numbers of patients are likely to ‘drop-out’ of any treatment which has a psychotomimetic 
side effect profile even if well motivated to receive treatment.
Haemodynamic effects are of particular concern to physicians attending stroke patients. 
Complications of haemorrhagic transformation and brain oedema (in those patients with 
hypertensive responses) and exacerbation of the infarction in those with blood pressure falls, 
either as a direct consequence of neuroprotective treatment or as a result of treatment given 
to reverse a hypertensive drug effect, will complicate the prescribing of any such drug. A 
clean haemodynamic side effect profile is a major benefit to any compound being evaluated 
as a potential neuroprotective. GV150526 was free from haemodynamic effects. 
Pharmacokinetic analysis suggests that G V150526 has a relatively long ti /2 which would 
make intermittent infusions feasible, i.e.several 1 hour infusions over several days. This is 
an advantage as it does not necessitate constant intravenous infusion of drug to maintain 
therapeutic levels, which would potentially restrict early rehabilitation.
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Constant infusions require regular supervision by nursing or medical staff and compliance is 
likely to be compromised by interruptions to the infusion regime which may rapidly cause a 
fall to sub-neuroprotective levels, particularly if the t i /2 is short.
The abnormalities in liver function reported in the prolonged administration phase of the 
study raise potential concerns regarding the overall safety profile.
Patients with elevated bilirubin had increased free fraction of GV150526X, suggesting protein 
binding displacement. GV150526X may alter the glucuronide conjugation and /  or biliary 
elimination of bilirubin as suggested from elevated levels of bilirubin and altered 
pharmacokinetics of GV150526X and its conjugated metabolite. These pharmacokinetic 
explanations for changes in bilirubin concentration cannot however fully explain 
accompanying rises in hepatic enzymes (AST and ALT) or moreover the rise in alkaline 
phosphatase.
It is likely that the changes observed in this study are analogous to the rise in hepatic 
enzymes associated with increases in liver weight and bile duct proliferation observed in 
studies in dogs. Reassuringly in these studies hepatic pathological changes were reversible 
and had largely resolved by the end of the 10 day recovery period.
W hile rises in liver function tests of 2-3 times the normal reference range in themselves may 
be of little clinical significance, particularly as all patients were asymptomatic and values 
returned to normal within 10 days, the cause and possible implications of these observations 
necessitate careful monitoring of liver function in future studies. Many useful and safe drugs 
exhibit similar properties, notably anticonvulsants. Asymptomatic rises in liver function are 
common and routine monitoring of liver function is neither required or advised. Even if 
future studies with GV150526 suggest mild hepatic toxicity this would not automatically 
preclude the clinical use of such a drug. The untreated prognosis of stroke patients is so 
poor that effective treatment would be acceptable to both patients and clinicians even if the 
drug was mildly hepatotoxic.
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In summary, GV150526 appears to be a well tolerated glycine antagonist with a favourable 
pharmacokinetic profile to permit twice daily infusion. Minor changes in hepatic biochemistry 
require further monitoring. The optimal dose for phase 3 studies appears to be 800 mg as a 
loading infusion, followed by 200 mg maintenance infusions twice daily. This dose will 
rapidly exceed and maintain concentrations in excess of 10 ng/ml, whilst minimising transient 
liver function abnormalities.
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Chapter 6
A phase II double blind, placebo controlled, dose escalation, group 
comparative study ofremacemide hydrochloride in patients with acute 
ischaemic stroke 
6.1 Background
Antagonists of the NMDA receptor inhibit the action of excitatory amino-acids on the post- 
synaptic neurones and in animal experimental models of stroke significantly reduce the size 
of cerebral infarcts. Remacemide hydrochloride is a high affinity NMDA antagonist which is 
currently being evaluated both as a neuroprotective agent and as an anti-convulsant.
6.2 Preclinicalpharmacology
Remacemide is an anticonvulsant in animal models and is being evaluated as an 
anticonvulsant in man. The anticonvulsant and neuroprotective effects have been attributed 
to its desglycinated metabolite ARL 12495, which is a low affinity antagonist at the ion 
channel of the NMDA receptor. The structure of remacemide hydrochloride and its 
desglycinated metabolite are shown in figure 6.2.1.
Remacemide has been shown to be neuroprotective in in-vitro rat cortical neurone cultures 
exposed to NMDA.245 Rats treated with remacemide after reperfusion in the 4 vessel 
ischaemia model had smaller infarctions affecting the CA1 and CA3 subregions of the 
hippocampus. Improvements in pathological findings were matched by improvements in 
functional outcome (assessed by ability to complete T- m aze).149 Similar results have been 
obtained in canine models of global ischaemia and in focal MCA occlusion models in rats 
(Astra unpublished data).
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Studies in cats confirm a neuroprotective effect after a focal ischaemic insult. Infusion of 
remacemide prior to permanent occlusion of the middle cerebral artery reduced the 
development of infarction in the cortex while the area of dense ischaemia within the caudate 
nucleus was resistant to neuroprotection.246 The results are summarised in figure 6.2.2. The 
plasma concentrations required for neuroprotection vary according to the animal model used. 
The results are summarised in the table below.
rat: 4VO intra-peritoneal 46 64
rat: MCA occlusion: pre- 
ischaemia
intra-peritoneal 46 64
rat:post-ischaemia intra-peritoneal 527 106
dog: global ischaemia iv 681 28
cat: focal iv 633 95
Preclinical pharmacokinetics suggest remacemide is rapidly absorbed and extensively 
metabolised with less than 1% excreted unchanged in the urine. In dogs the active 
desglycinated metabolite crosses the blood brain barrier and the CSF concentration mirrors 
the plasma concentration.
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The toxic effects were similar in mice, rats and rabbits with evidence of alterations in 
neurological function, particularly seizures and movement disorders. The median lethal dose 
in rodents for single doses was in the range of 580-993 mg/kg. The maximal tolerated dose 
in the rat was 160mg/kg. Low incidences of neuronal vacuolation with no evidence of 
neurone necrosis were reported at this dose.
Haemodynamic effects
Intra-venous infusions of remacemide in conscious beagles produced minor rises in blood 
pressure and heart rate at doses above 10 mg/kg and this effect was more marked at 30 
mg/kg.
In one study of anaesthetised dogs remacemide had no effect on blood pressure at doses of 
1,3 and 10 mg/kg. In a second study land 3 mg/kg again had no effect but 10 mg/kg 
produced a small rise in blood pressure: 10 mmHg between 5 and 15 minutes after 
administration.
Oral doses of 100mg/kg have no haemodynamic effect on the spontaneously hypertensive 
rat. The cardiovascular effects described in animals appear mild by comparison with the 
hypertensive effects of aptiganel described in chapter 7.
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6.3 Clinical pharmacology
Volunteer studies suggest good tolerability with this compound. In human volunteers the 
most common reported side effects were mild CNS disorders e.g.dizziness, headache, mood 
changes general fatigue and somnolence; or gastro-intestinal symptoms e.g.abdominal pain, 
dyspepsia, nausea and vomiting.
The clinical pharmacology of remacemide has been investigated in single and multiple dose 
studies in healthy volunteers and epilepsy patients. Intra-venous single doses (1-300 mg) of 
remacemide have been given to 19 healthy volunteers with minor adverse events reported 
only (headache, dizziness and diarrhoea).
Single oral doses (10-500mg) have been given to 68 volunteers within 7 different studies. 
Remacemide was well tolerated up to 400 mg with dyspepsia, nausea and dizziness reported 
between 325-400mg. Oral doses of 500mg were poorly tolerated with dizziness, nausea and 
vomiting reported as the dose-limiting side effects. Multiple oral doses were well tolerated up 
to 600mg per day. Dose-limiting side effects reported in subjects receiving 125-150 mg four 
times a day were consistent with those observed in single dose studies.
Pharmacokinetics
Plasma collected from these volunteer studies was used to describe the pharmacokinetics in 
man. Remacemide was rapidly absorbed orally and eliminated with a half-life (t 1/2) of 3-4 
hrs. Oral remacemide administration demonstrates good bioavailability with a degree of first 
pass metabolism. The active desglycine metabolite is eliminated more slowly (ti/2 12-18 hrs). 
The kinetics appear linear with first order elimination. Longer term dosing did not induce 
hepatic enzymes. Remacemide is concentrated in the brain (brain:plasma ratio 25).
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6.4 Aims and objectives
Primary
•  The purpose of this study was to assess the safety, tolerability and pharmacokinetics of 
ascending doses of remacemide in patients with acute stroke.
Secondary
•  Neurological and functional outcome data were collected but the power of the study was 
not powered to demonstrate drug efficacy.
6.5 Patients and methods
6.5.1 Study design
This was a placebo-controlled, escalating dose, single centre parallel group study. Groups of 
8 patients (6 active:2 placebo) received treatment, initially consisting of 2 intra-venous 
infusions, followed by twice daily oral treatment until day 7. Each treatment group was 
completed and safety data analysed prior to progresssion to a higher dose group.
Ethics and consent
Ethical approval was gained from the local W est Ethics committee. Patients gave written, 
witnessed informed consent whenever possible. W here patients were unable to write, 
witnessed verbal consent was accepted from the patient. All witnesses were independent 
and had no connection with the study. If the patient was unable to give consent verbally 
written informed assent was accepted from the next of kin or other close family member.
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6.5.2 Patient selection
Inclusion criteria
Patients within 12 hours of acute ischaemic stroke were considered for eligibility to the study. 
NMDA antagonists may be neuroprotective in patients with intra-cerebral haemorrhage and 
these patients were not excluded from the study.
Other entry criteria to be satisfied are listed below.
•  clinical signs of middle cerebral artery occlusion
•  male or non pregnant female
•  age > 40 and < 85 years
• written or verbal and witnessed informed consent
•  capable of attending for follow up as required by protocol
•  functionally independent prior to stroke
Exclusion criteria
Pre-clinical data suggest remacemide may cause Gl upset, thus patients with peptic ulcer 
disease were excluded, together with patients on regular NSAIDS or steroids. No information 
on possible interactions with warfarin was available at the time the study was performed and 
as warfarin has both a narrow therapeutic index and the potential of serious consequences in 
inappropriate dosages warfarin was disallowed in the study.
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Patients were also excluded from the study if they had symptoms and signs suggestive of 
other significant neurological disease or other active and clinically significant systemic 
disease, as follows:
•  coma
• previous stroke with residual deficit
•  seizures and blackouts
•  other serious organic brain disease
•  trauma
•  psychiatric disease
• chronic hepatic dysfunction
• chronic respiratory disease or pneumonia
•  gastro-intestinal disease - including peptic ulceration and G-l bleeding
•  connective tissue disease
•  malignancy within 5 years
•  severe hypertension, valvular heart disease or heart failure
•  investigational drug administration within one month
Withdrawals
CT scanning prior to inclusion was not a prerequisite to study entry but patients found to have 
intra-cerebral haemorrhage were replaced but carried on with study medication and full 
safety data were collected. Patients had study medication discontinued if CT scanning 
demonstrated any of the following:
•  abscess
•  sub-arachnoid haemorrhage
• tumour
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6.5.3 Dosing regimen
Drug doses given to individual cohorts are documented in the table below. Only the first 
cohort received orally administered remacemide: subsequent dosing was exclusively 
intravenous.
1 100mg over 120mins tw ice daily 100 mg
100mg over 120mins 12 hrly stroke 
until day 7
2 200mg over 120m ins x 6 nil
every 12 hrs
3 300 over 120mins x 6 nil
every 12 hrs
4 400 over 120mins x 6 nil
every 12 hrs
5 500 over 120mins x 6 nil
every 12 hrs
6 600 over 120mins x 6 nil
every 12hrs
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6.6 Study procedures
6.6.1 Screening
Following admission to hospital patients were assessed with regard to the entry criteria. On 
initial screening the following assessments were made.
•  Clinical examination
•  Canadian neurological scale247
•  Vital signs
•  Blood samples :-haematoloy, clinical chemistry, remacemide level.
•  urinalysis
•  ECG
Patients with significant abnormalities in any of these parameters suggesting active and 
clinically significant disease, other than acute stroke, were excluded from entering the study.
6.6.2 Safety
Routine biochemistry, haematology, and urinalysis were carried out by standard laboratory 
methods. Blood and urine were taken for analysis at presentation, 24 hours following start of 
drug administration and at 7+2 days. Serious adverse events occurring throughout the study 
period were continuously documented as they occurred.
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Biochemical, and haematological parameters measured are documented in the 
table below.
Biochemistry haematology urinalysis
sodium total white blood cells blood
potassium red cells protein
glucose haematocrit ketones
urea haemoglobin glucose
creatinine platelet count specific gravity
calcium prothrombin time
bilirubin lymphocytes
albumin monocytes
ALT
AST
LDH
alkaline phosphatase
eosinophils
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6.6.3 Tolerability
Adverse events were reported as they occurred and at further clinical follow up appointments 
at 2 weeks and 4 weeks post study entry.
6.6.4 Vital signs
Blood pressure and pulse recordings were made using Marquette semi-automatic 
oscillometric monitoring equipment (Marquette Electronics Inc, Wisconsin U S A ) and 
repeated at frequent intervals during drug dosing as summarised in the plan below.
Protocal summary and 
study design
infusion
ECG * . . .
lab safety ‘ . . .
CNS - * -
■ ■  ■■ ■■ ■■ ■■ ■
BP/pulse every 30 minutes during in fusion " "
 1 1 1 1 1 1
0 24 48 72 96 2 4
week: week!
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6.6.5 Pharmacokinetics
Blood samples (10 mis) were taken from an in situ iv cannula from the non-infusion arm, 
collected in a heparinised tube, centrifuged (3000 rpm for 10 m in s ) and the plasma 
transfered to a polypropylene tube and frozen immediately thereafter.
Blood was taken for pharmacokinetic (PK) analysis 30 mins and 2 hours after the start of the 
first infusion. Sampling was repeated at the end of each infusion and before the final 
infusion.
Times when PK samples were taken are also shown below.
Times in first 24 hours when PK samples taken
♦  ♦ ♦ ♦ ♦  ♦  ♦  ♦  ♦
i------------- 1-------------------- 1--------------1----------------1----------------1----------------1----------------1----------------1----------------1--------------- 1----------------1----------------1
0 2 4 6 8 10 12 14 16 18 20 22 24
time in hours
Pharmacokinetics were assessed utilising solid phase extraction o-phthalaldehyde 
derivatisation followed by HPLC separation and fluorescence detection. Plasma was 
analysed for remacemide and its main desglycine metabolite ARL12495AA. The calibration 
range of the method is 10- 500 ng/mL for both analyses. Results from samples containing > 
500ng/mL were determined after sample dilution in control human plasma to produce a result 
within the calibration range of the method.248
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6.6.6 Outcome
Functional outcome was assessed at the 4 week follow up, using the Barthel functional scale 
(appendix III) Neurological outcome was assessed by the Canadian neurological scale with 
assessments made at baseline, 60 hours, 2 weeks and 4 weeks (appendix II).
6.7 Results
6.7.1 Recruitment and demographics
A total of 61 patients were recruited to the study. Forty-three patients completed the 
treatment course. The demographic details of patients entering the study are shown in the 
table below. All were Caucasian.
Table Patient Dem ographics
pm HIHImHIDR
Num ber of 
Patients
18 10 6 8 6 6 7 61
Age (years):Mean 66.6 66.7 65.7 68.4 67.3 67.2 70.4 67.3
Range 4 9 - 8 4 46 - 83 4 5 - 8 4 41 - 82 4 6 - 8 1 6 0 - 8 0 55-81
41-84
Sex: Male 7 8 5 6 4 3 3 36
Fem ale 11 2 1 2 2 3 4 25
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6.7.2 Compliance
Four patients were withdrawn during the treatment period due to intolerable side effects. A  
further 10 patients failed to complete the protocol: 2 died during the infusion period(see 
below), 3 patients were found to have intracerebral tumours on CT scanning and were 
subsequently withdrawn, 5 patients in the placebo /  100mg dose group developed dysphagia 
and as a result could not comply with oral medication. The protocol was thereafter amended 
to allow all doses to be administered via intravenous infusion.
6.7.3 Serious adverse events 
Mortality
Two patients died during the study infusion period and a further 7 during the 1 month follow 
up period. No deaths were considered to be due to administration of study drug in the 
opinion of the investigator. There was no excess mortality in the remacemide treated patients 
compared with the placebo group (figure 6.7.3.1).
Placebo deaths
Two patients in the placebo group died. Patient OCHA was unable to swallow following a 
large dominant middle cerebral artery infarction and therefore only received 2 iv bolus doses. 
Two days later the patient’s level of conciousness deteriorated and never fully recovered: 
the subject died 11 days later. The clinical deterioration was in keeping with the CT findings 
which confirmed a large infarction with considerable peri-infarction oedema and mass effect.
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Patient 4 died 6 days after receiving remacemide. The patient had been admitted with a
large cerebral infarction with complicating raised intracranial pressure. The patient received
iv drug only. As she never regained consciousness she was unable to comply with oral
medication.
100 mg dose
•  Two out of ten patients in the 100 mg dose group died within 1 month of study drug 
administration: patient 001 received 2 iv doses only as the patient was unable to 
swallow. CT scan demonstrated an intracerebral haemorrhage and the patient was 
withdrawn from the study. The patient was transferred to another hospital but died 
following an episode of bronchopneumonia.
•  Patient 007 died following a massive pulmonary embolism which occurred 3 weeks after 
administration of study drug. CT scan had diagnosed an underlying brain tumour.
200 mg dose
Two of the six patients in the 200 mg dose group died.
•  Patient 010 suffered a sudden cardiorespiratory arrest 4 days after the administration of 
study drug. The cause of death was thought to be pulmonary thrombo-embolism.
•  Patient 016 died on the day after admission as a consequence of a large cerebral 
infarction with raised intracranial pressure and mass effect confirmed on CT. Drug 
treatment was discontinued after 2 iv doses because of the deterioration in the patient’s 
condition.
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300 mg dose
One from a total of 8 patients (024) died 2 days after admission following 4 iv doses. 
Although the death occurred during the infusion there was no evidence to suggest this was a 
drug effect. The cause of death was transtentorial herniation secondary to a large cerebral 
infarction.
400 mg dose
One from six patients (025) died 7 days after the final administration of study drug. The 
cause of death was a combination of congestive cardiac failure and bronchopneumonia.
500 mg dose
Patient 034 died of congestive cardiac failure 3 days after the last dose of study therapy.
No deaths were thought to be attributable to drug therapy. The mortality rate for those 
receiving placebo was considerably lower than expected at 6% whereas active treatment was 
consistent with known previous experience at 16%. There was no excess of deaths at the 
higher doses of remacemide, compared with lower doses.
Non fatal adverse events 
Withdrawals
Four patients given active treatment and one placebo patient were withdrawn after 
developing side effects attributed to drug therapy. One patient in the 200 mg group was 
withdrawn for an infusion site reaction (pain, erythema and swelling). A patient was 
withdrawn after 500 mg with CNS adverse effects (hyperreflexia and agitation) and a further 
2/7 patients withdrew from the highest 600 mg bd dose with CNS adverse effects: 
hallucinations, nausea and vomiting in one case and dizziness, sedation and vomiting in the
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other. Two patients in the first dose cohort were withdrawn from the study due to dysphagia. 
This prevented further compliance with the protocol, which was subsequently amended.
Patient withdrawals are summarised in the table below.
EbhIBEShHiig m H B
4 placebo 2 iv dysphagia: patient died
4A placebo 2 iv dysphagia: patient died
6 placebo 2 iv + 5 oral brain tumour on CT
6A placebo 1 iv dysphagia
24 placebo 4iv died due to stroke: day 4
38 placebo 5 iv confused *
1 100 mg bd 2 iv dysphagia
1B 100 mg bd 2 iv dysphagia
2 100 mg bd 2 iv + 4 oral brain tumour
7 100 mg bd 2 iv + 1 oral brain tumour
11 200 mg bd 4iv intolerance: infusion site reaction *
16 200 mg bd 2 iv died due to stroke: dayl
19 300 mg bd 1 iv diagnosis not stroke
21 300 mg bd 1 iv CT = haemorrhage: withdrawn in error
37 500 mg bd 5 iv intolerance: hyperreflexia and agitation *
43 600 mg bd 2 iv transferred from ward for emergency surgery
43A 600 mg bd 4iv intolerance: hallucinations, nausea and vomiting *
44 600 mg bd 2 iv intolerance: light headed, sleepy and vomiting *
* Patients withdrawn due to drug attributed adverse events.
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Serious adverse events
Reassuringly there was no increase in the number of serious adverse events reported at the 
higher doses of remacemide (figure 6.7.3.2).
Vital signs
There was no difference in vital signs (heart rate, blood pressure) and no excess of ECG  
abnormalities in patients receiving remacemide compared with placebo.
Other adverse events
There was an increase in reported CNS adverse events and gastro-intestinal effects at the 
higher doses of 400, 500 and 600 mg (figures 6.7.3.3, and 6.7.3.4). The most common 
treatment attributed adverse events were neurological. Infusion site reactions and gastro­
intestinal upset, particularly nausea and vomiting were also reported. CNS and gastro­
intestinal events adverse events were frequent in the group receiving 600 mg infusions. CNS  
events increased in frequency during later infusions in the 500 and 600 mg dose groups 
consistent with accumulation of either remacemide or its active metabolite (figure 6.7.3.5).
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H I
n=18 n=43
infusion site 0 17
reaction
neurological 0 5 headache, hyperreflexia, diplopia, dizziness 
tremor
psychiatric 1 6 3x agitation, 2x confusion, 2x hallucinations 
sedation
gastro-intestinal 1 4 4x nausea and vomiting
NB. Some patients reported more than one symptom
6.7.4 Laboratory results
There was no increase in the frequency of abnormal laboratory reports within the patients 
treated with remacemide compared with placebo.
6.7.5 Pharmacokinetics
Pharmacokinetics indicate a short half life of 3-4 hours for remacemide but a more prolonged 
half life (12-18 hours) for its desglycinated metabolite (ARL 12495AA).
Pharmacokinetic analysis demonstrated no accumulation of remacemide during the course 
of repeated infusions at the higher doses but did reveal accumulation of the active 
desglycine metabolite. This suggests the active metabolite is responsible for the onset of
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CNS and gastro-intestinal effects after repeated infusions of remacemide (figures 6.7.5.1 and 
6.7.5.2).
6.7.6 Clinical outcome
There was no significant differencee between neurological and functional outcome between 
the remacemide and placebo receiving groups. Results are summarised in figures 6.7.6.1 
and 6.7.6.2.
6.8 Discussion
Doses of 200 mg bd or higher attained the putative neuroprotective concentrations predicted 
from animal models (250-600ng/mL). Doses of 500 mg bd were well above these target 
levels with an acceptable tolerability profile (only one patient was withdrawn due agitation 
and hyperreflexia). No patients were withdrawn from the 400 mg dose group. Doses of 600  
mg bd iv were associated with an unacceptable side effect profile. 2/7 patients at this dose 
required discontinuation of study drug due to intolerable CNS side effects. Side effects 
reported at this dose were hallucinations, nausea and vomiting in one individual and 
sedation, nausea and vomiting in another.
Side effects, particularly hallucinations, agitation and vomiting were thus reported at the 
higher doses and particularly during the later infusions. These findings would suggest an 
accumulation of either remacemide or active metabolite over time at higher doses. The 
desglycine metabolite accumulated during the course of repeated infusions consistent with 
the clinical findings. Thus, if remacemide was administered over a more prolonged duration 
i.e.greaterthan 72 hours, the maximum tolerated dose may be lower than was observed 
within this study.
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Whether the side effects would preclude therapeutic administration of remacemide is difficult 
to assess in the absence of phase III efficacy data. Clearly if treatment was moderately 
effective in improving neurological and clinical outcome, unpleasant but temporary side 
effects would be acceptable. An analogous example is the use of radiotherapy and 
chemotherapy in the treatment of cancer, where short term side effects are often unpleasant 
but considered acceptable because of the poor prognosis of the untreated condition.
The maximum tolerated dose for use in acute stroke is 400 mg bd. The gradual 
accumulation of active metabolite and the gradual onset of adverse events suggests that 
optimal neuroprotective concentrations are unlikely to be achieved within the early hours of 
treatment at this dose. The most conclusive evidence of neuroprotective effect from the cat 
focal ischaemia model was obtained by pretreatment with remacemide.246 For this reason, 
remacemide may not be an ideal drug to pursue for acute neuroprotective studies.
148
Fi
gu
re
 
6.
2.
1:
 S
tr
uc
ur
e 
of 
re
m
ac
em
id
e 
an
d 
de
sg
ly
ci
na
te
d 
m
et
ab
ol
it
e
©+■»
o
ncs
©E
■D
©
©
c
o
>*
O)
(/)
<D
T3
O
X
CNJ
o
a>
;o
*vl
O
sz
ooUi
TJ
.C
©
TJE
a
o
©E
©
a:
(A
RL
 
12
92
4A
A)
 
(A
RL
 
12
49
5A
A)
Fi
gu
re
 
6.
2.
2:
 
N
eu
ro
pr
ot
ec
tiv
e 
ef
fe
ct
 o
f 
re
ni
ac
em
id
e 
in 
ca
t 
fo
ca
l 
m
id
dl
e 
ce
re
br
al
 a
rt
er
y 
oc
cl
us
io
n 
m
od
el
. 
V 
ol
um
e 
of 
in
fa
rc
tio
n 
(m
ea
n 
± 
se
ni
) 
wa
s 
m
ea
su
re
d 
hi
st
ol
og
ic
al
ly
 
6 
ho
ur
s 
af
te
r 
th
e 
on
se
t 
of 
is
ch
ae
m
ia
.
|ui :uojtojBj.uj jo  9iun|OA
H
em
is
ph
er
e 
C
or
te
x
Fi
gu
re
 
6.
7.
3.
1:
 
D
ea
th
s 
by 
4 
w
ee
ks
 
in 
pa
tie
nt
s 
tr
ea
te
d 
wi
th
 
re
in
ac
em
id
e 
or 
pl
ac
eb
o.
------
_______
spjaged
do
se
 
gr
ou
p 
(m
g 
bd
)
sjuaged
Fi
gu
re
 
6.
7.
3.
3:
 T
re
at
m
en
t-
at
tr
ib
ut
ed
 
CN
S 
ev
en
ts
 o
cc
ur
ri
ng
 
du
ri
ng
 
in
fu
sio
n 
wi
th
 
re
ni
ac
en
iid
e
________ _ ______ __
sjuaped
pl
ac
eb
o 
10
0 
20
0 
30
0 
40
0 
50
0 
60
0
do
se
 
gr
ou
p 
(m
g 
bd
)
Fi
gu
re
 
6.
7.
J.
4:
 G
as
tr
o-
in
te
st
in
al
 a
dv
er
se
 
ev
en
ts
 
re
po
rt
ed
 
du
ri
ng
 
in
fu
sio
 
1 
re
m
ac
em
id
e
 —
s h a p e d
do
se
 
gr
ou
p 
(m
g 
b
d
)
69
Fi
gu
re
 6
.7
.3
.5
: 
Cu
m
ul
at
iv
e 
CN
S 
ev
en
ts 
ve
rsu
s 
du
ra
tio
n 
of 
tr
ea
tm
en
t 
wi
th 
re
m
ac
em
id
e
<u VI&> Vi© (A CO4>Vi V) <ZJ <« Vi
© © O o o
■o T3 T3 ■o ■o
N rr IT)
□ H E3 n ■
>'* '
s>s&/s*s % /A /W /^
sjuaqed jo jaqiunu
do
se
 
gr
ou
p 
(m
g 
bd
)
Fi
gu
re
 
6.
7.
5.
1: 
C
on
ce
nt
ra
tio
ns
 o
f 
re
m
ac
em
id
e 
(m
ea
n 
± 
se
m
). 
Gr
ap
h 
co
m
pa
re
s 
pl
as
m
a 
co
nc
en
tr
at
io
ns
 o
f 
re
m
ac
em
id
e 
aft
er
 s
ec
on
d 
in
fu
sio
n 
an
d 
aft
er
 s
ixt
h 
an
d 
fin
al 
in
fu
sio
n.
 N
o 
ac
cu
m
ul
at
io
n 
of 
re
m
ac
em
id
e 
at 
hi
gh
er
 d
os
es
 
wa
s 
de
m
on
st
ra
te
d.
|iu/6u apiuiaoemai jo uo;;ej;uaouoo
do
se
 
(m
g)
Fi
gu
re
 6
.7.
5.2
 
: P
las
m
a 
co
nc
en
tr
at
io
n 
(m
ea
n 
± 
se
m
) 
of 
re
m
ac
em
id
e 
de
sg
ly
cin
e 
m
et
ab
ol
ite
 c
om
pa
rin
g 
co
nc
en
tr
at
io
n 
at 
the
 
end
 
of 
se
co
nd
 
in
fu
sio
n 
wi
th 
co
nc
en
tr
at
io
n 
at 
end
 
of 
six
th 
an
d 
fin
al 
in
fu
sio
n.
 
Gr
ap
h 
de
m
on
st
ra
te
s 
ac
cu
m
ul
at
io
n 
of 
de
sg
ly
cin
e 
m
et
ab
ol
ite
 a
t 
the
 e
nd
 
of 
in
fu
sio
n 
pe
ri
od
.
|iu/6u ap|oqej8iu 
ainoAibsap epjoiaoeuiaj jo uopejjuaouoo
do
se
 
(m
g)
o
-Q
CJ
cj
03
-S £
yCj <5 
-o 3
i  |CJ 3
cj S
53 O
E ~
“  =  '- 3
WD «H
S =
>
*33
cj
CJ
CJ o-D
<u 3 CJk. V CJ
Vi-*—3
v«l
tS ig " a
. £ ■3 -a«— o 353 g 53O.
_S Vi53
CJ
TJ
CJ £ s3 CJ CJs U CJO CJ 53CJ
3
-3
H £CJ
O v*
1 5
CJ ©£r*
c o Ko CJ
Vi
CJ 1 3
*CJ
CJc CJ3 im
b Vi Vi53
F-< c a 3. £vo -o *■£353
-a Cl.
s> CJ 3
cj J3 CJ—
V
CJ
53 >
£
CJ
£
-Cj
CJ»Q
O)
"J&. v'- N 'i- ,i-.; O
o
CD
O)
■ ; . . . : . .
D)
o
o
D)
O
O
CO
O )
O
O
CM
O)
O
O
Q .
CO OCDO CO CD OCM
-O
-Q
<1>CO
o
TJ
<1)
~o
E
(DO
CO
E
<D
CM
0JOOS |8L|^Ba
Fi
gu
re
 
6.
7.
6.
2:
 
N
eu
ro
lo
gi
ca
l 
ou
tc
om
e 
ex
pr
es
se
d 
in
te
rm
s 
of 
th
e 
C
an
ad
ia
n 
N
eu
ro
lo
gi
ca
l 
Sc
al
e 
in 
pa
tie
nt
s 
re
ce
iv
in
g 
pl
ac
eb
o 
or 
re
m
ac
em
id
e.
 T
he
re
 
wa
s 
no
 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 
be
tw
ee
n 
re
m
ac
em
id
e 
an
d 
pl
ac
eb
o 
pa
ti
en
ts
.
®i§p
9J0DS SNO
pla
ce
bo
 
10
0 
mg
 
20
0 
mg
 
30
0 
mg
 
40
0 
mg
 
50
0 
mg
 
60
0 
m
g
Chapter 7
149
Chapter 7
A Double-Blind, Randomised, Placebo Controlled, Safety and 
Tolerability Study of Single Doses and Extended Infusions of Aptiganel 
HCI in Patients After an Acute Ischaemic Stroke.
7.1 Background
Neuronal damage after stroke is at least partly mediated by the build up of neurotoxic 
excitatory amino-acids. In physiological conditions glutamate acts as a neurotransmitter and 
its levels are regulated by reuptake and by conversion to glutamine in glial cells. Following 
ischaemic brain injury excess glutamate release coupled to a failure of these regulating 
processes leads to massive increase of glutamate concentrations. This activates the post- 
synaptic N-methyl-D-aspartate (NMDA) receptor, a ligand gated ion channel which in turn 
mediates influx of sodium and calcium leading to neurotoxicity. Cell culture of neurones with 
excess glutamate leads to loss of neurones that can be alleviated by antagonism of the 
NMDA receptor site. Similarly in animal models of stroke, administration of antagonists of 
the NMDA receptor can reduce the volume of cerebral infarction obtained after a 
standardised vascular insult by about 50%. Several NMDA antagonists are in preclinical and 
clinical development but as yet none are licensed for use outwith clinical trials.
Aptiganel (CNS1102; proprietary name ’Cerestat’) has been developed as a neuroprotective 
agent for the treatment of ischaemic and traumatic brain injury. In all subsequent references 
the compound will be named as aptiganel.
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7.2 Preclinical pharmacology
Aptiganel [N-(1-naphthyl)-N-(3-ethyl phenyl)-N-methyl guanidine hydrochloride is a selective 
non-competitive antagonist within the ion channel pore of the NMDA receptor. In-vitro 
studies show it to be a high affinity antagonist that is neuroprotective in cultures of brain cells 
exposed to toxic concentrations of the excitatory amino acid glutamate.
Aptiganel reduced cerebral volume measured histologically and by diffusion-weighted MRI 
scanning after permanent MCA occlusion in rats. In this study reductions of 66%  in infarct 
volume were reported suggesting aptiganel was a potent neuroprotective within this model. 
The putative neuroprotective dose was 3mg/kg and the minimal therapeutic concentration 
was 10ng/mL.249 Similar results were obtained in other permanent and reperfusion models of 
rat brain ischaemia. The neuroprotection achieved within these animal models was
250 251comparable with other neuroprotective compounds currently undergoing development.
Neurological effects similar to those seen with other NMDA antagonists in animals and man 
(ataxia and tremors) were observed after single intravenous infusion of 3mg/kg in rats and 
2mg/kg/day in cynomolgus monkeys. Vacuolisation of the retrosplenium of the rat brain is 
induced by doses of aptiganel >10mg/kg. These changes are associated with the 
appearance of behavioural disturbances in animals equivalent to the psychotomimetic effects 
seen in humans. Aptiganel is however 10 times less potent at inducing such changes than 
the NMDA antagonist M K-801. The clinical significance of these pathological changes is 
unknown but vacuolisation is reversible. There are no data available at present on the ability 
of these drugs to induce vacuoles in humans or sub-human primates. The anaesthetic agent 
ketamine, which has similar vacuole inducing properties has been used safely as an 
anaesthetic agent for many years with no long term sequelae.
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Intravenous administration of aptiganel caused hypotension in anaesthetised rats but rises in 
blood pressure in conscious pigs and baboons. In animals, experimental interactions of 
agents active at the NMDA recptors with the regulation of the cardiovascular system are 
complex and dependent on the site of administration and the state of anaesthesia. Non­
competitive NMDA receptor antagonists prevent glutamate stimulated blood pressure rises in 
the rat when administered intrathecally.252 This is thought to be mediated by blockade of 
spinal NMDA receptors which mediate sympathetic vasoconstrictor outflow from the medulla. 
Direct injection of NMDA antagonists into the dorsal ventrolateral medulla is however
253associated with a rise in blood pressure.
Cardiovascular effects of aptiganel in animals are therefore variable and are both species 
and conscious level specific.
7.3 Clinical experience
Aptiganel has been given as a 15 minute bolus to 21 healthy male volunteers within a double 
blind ascending dose study. Doses of up to 30pg/kg were well tolerated with only mild 
symptoms reported. Clinically significant sedation, raised mean arterial pressure and pulse 
rate were reported at doses > 30 jig/kg. Symptoms progressed to disinhibition, nystagmus, 
diplopia and severe sedation at 45|a.g/kg. Doses of 60-100|xg/kg were associated with 
paranoid ideation, hallucinations, peripheral vasoconstriction and catatonia (a state of severe 
sedation, unresponsiveness and immobility but preserved eye opening). Dose dependent 
rises in blood pressure were noted. Blood pressure began to rise within minutes of the 
infusion being commenced, peaked at 40  minutes after the end of the infusion, and resolved 
by 4 hours.181
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Similar results were found when prolonged 4 hour infusions were given to male volunteers. 
Lightheadedness, dizziness, paraesthesia and euphoria were all reported at total doses of 
32|ig/kg. Doses higher than this (50 or 73^g/kg ) were associated with intolerable side 
effects including motor retardation, perceptual disturbance and hallucinations. Giving 
aptiganel as a prolonged infusion therefore did not increase the total dose which could be 
safely administered to volunteers (~30|ig/kg).
Pharmacokinetics of aptiganel obtained from volunteer data are summarised in the table 
below. Clearance was 125 ±  55 L/hr (mean ±  SD) and the terminal t i /2 was 4.6 ±  2.9 h (mean 
+ SD).
The use of weight adjusted doses did not reduce the variability in the Cmax and AUC. 
Pharmacokinetic analysis indicated little correlation between subject weight and volume of 
distribution (Vdss) [ r 2 = 9.1%] or between weight and clearance (CL), suggesting dose 
adjustment for weight would not be necessary.
Sum m ary o f pharm acokinetics from  bolus + 4  hour infusion study in healthy male  
volunteers
number of volunteers 3 6 3 3
Vdss(L) 639 500 596 452
Cmax (ng/m l) 4.2 7.2 9.1 21.1
AUC(h.ng/m l) 6.3 20.4 48.7 52.5
Clearance(L/h) 198 125 82 97
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The CNS symptoms and signs seen with aptiganel are similar to those seen with ketamine 
and phencyclidine. Symptoms closely resemble the dissociative anesthetic state reported 
with these drugs.254
Blood pressure effects of ketamine have been attributed to activation of catecholamines but 
in these volunteer studies there was no evidence of catecholamine excess or activation of 
the renin-angiotensin system.255 The hypertensive effect of aptiganel remains incompletely 
understood but is thought to be centrally mediated.
In a phase II clinical study in stroke patients tolerability was better than in volunteers with 
doses of up to 110 ug/kg tolerated without significant neurological and haemodynamic 
effects.256
Significant rises in blood pressure could potentially increase blood flow to an ischaemic area. 
While this may be of benefit in terms of reperfusing the penumbral zone it may conversely 
increase infarct size by exacerbating reperfusion injury and cerebral oedema. In theory 
increases in blood pressure could increase the risk of haemorrhage into infarction by the 
same mechanism. Total cerebral blood flow as measured by carotid Doppler was unaffected 
by the haemodynamic changes but middle cerebral artery velocity was increased. Peripheral
255vasoconstriction was seen in those volunteers exhibiting blood pressure rises.
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7.4 Aims and objectives
Primary
Results from experimental animal models of stroke suggest plasma concentrations > 1 0  
ng/ml are required for neuroprotection. The purpose of the study was to determine the 
maximally tolerated non-weight adjusted bolus dose of aptiganel and to define an appropriate 
infusion to maintain plasma levels at steady state.
Secondary
The study was not powered to demonstrate efficacy but preliminary data were collected. The  
use of weight-independent doses was also being explored to confirm the independence of 
clinical effects on patient weight.
7.5 Patients and methods
7.5.1 Study design
This was a multi-centre, double-blind, randomised, placebo-controlled safety and tolerability 
study of ascending doses of aptiganel in two phases. The first phase (part A) consisted of 
single ascending doses and the second (part B) a bolus dose followed by an extended 
infusion.
Ethics and consent
Ethical approval was gained from the local W est Ethics committee. Patients gave written, 
witnessed informed consent whenever possible. W here patients were unable to write, 
witnessed verbal consent was accepted from the patient. All witnesses were independent and
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had no connection with the study. If the patient was unable to give consent verbally written 
informed assent was accepted from the next of kin or other close family member.
7.5.2 Patient selection 
Inclusion criteria
All patients with acute neurological deficit consistent with a diagnosis of carotid artery 
territory stroke were considered eligible for the study, providing they met the criteria 
described below.
•  Acute neurological deficit of at least one hour’s duration but ^ 24 hours (for night-time 
stroke time of onset taken as last time patient was known to be free of stroke symptoms)
•  Males or non-fertile females (post-menopausal or surgically sterilised)
•  Requiring hospitalisation
•  21 years of age or older
•  Weight 50-150 kgs inclusive
• Minimum of 4 and maximum of 20 on the baseline NIH scale
• Symptoms consistent with carotid artery territory stroke
•  Witnessed informed consent or consent from an authorised representative.
•  CT scan consistent with diagnosis of ischaemic stroke
(scan was performed prior to study entry)
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Exclusion criteria
Patients with any of the following were excluded from the study:
•  Coma or stupor (unable to localise pain)
•  Evidence of brain tumour, cerebral oedema or haemorrhage on initial CT scan prior to 
entry
•  Malignant hypertension defined as bilateral fundal haemorrhages and/or papilloedema + 
hypertension i.e. blood pressure > 200/110 on at least 2 separate readings
•  Significant hypotension i.e. blood pressure below 90/50 mm Hg
•  Any other unstable medical condition which would interfere with the assessment of study 
treatment
•  Involvement in any other investigational drug study within 3 months
7.5.3 Dosing regimen
In the first phase of the study patients received drug or placebo diluted to 10 mis with normal 
saline. This was administered over 3 to 5 minutes by bolus intravenous injection. Bolus 
doses were as follows: 3m g, 4.5m g, 6mg and 7.5m g. Patients were randomised to receive 
active drug or placebo in a ratio of 3:1 active/placebo for part A. Randomisation was by a 
telephone accessed central computerised system.
In part B two well tolerated bolus doses were chosen from the first phase and followed by a 
continuous infusion. Patients were randomised in a ratio of 4:1 active/placebo. The constant 
infusion was administered for 6 hours initially with an option to continue to 12 hours if well 
tolerated. Rates of infusion in part B were based on pharmacokinetic data already available
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from part A and previous studies. The first group of patients received a 6mg bolus dose 
followed by 1 mg/hour. Further assessment at this dose was abandoned due to the high 
frequency of intolerable side effects. A lower dose was then administered and these patients 
received a 4.5mg bolus followed by 0.75mg/hour. Both continuous infusion doses were 
predicted to achieve and maintain plasma aptiganel levels above the projected 
neuroprotective concentration of 10 ng/ml.
7.6 Study procedures
7.6.1 Screening
Patients were screened at the time of admission. This assessment ensured that all inclusion 
and exclusion criteria were met. Baseline clinical haematology, biochemistry and ECG  
assessments were carried out. The patients were examined by a member of the medical 
staff who documented the neurological deficit and ensured the diagnosis was consistent with 
an acute stroke.
7.6.2 Safety
Routine biochemistry, haematology, and urinalysis were carried out by standard laboratory 
methods. Blood and urine were taken for analysis at presentation, 24 hours following start of 
drug administration and at 7±2 days. Serious adverse events occurring throughout the study 
period were continuously documented as they occurred.
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Biochemical, and haematological parameters measured are documented in the 
table below.
Biochemistry haematology urinalysis
sodium total white blood cells blood
potassium red cells protein
glucose haematocrit ketones
urea haemoglobin glucose
creatinine platelet count specific gravity
calcium prothrombin time
bilirubin lymphocytes
albumin monocytes
ALT
AST
LDH
alkaline phosphatase
eosinophils
7.6.3 Tolerability
Adverse events were continuously documented as they occurred. An assessment was made 
of the treatment’s acceptability 24 hours after each administration by the individual 
investigators involved. This took into consideration the overall impression of the 
symptomatic and haemodynamic side effect profile.
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7.6.4 Vital signs
Patients were monitored by repeated physical examinations and recording of vital signs. 
Lead II ECG and vital signs were recorded at the following times.
•  0 (bolus injection time)
•  5, 10, 15, 20, 25, and 30 minutes from bolus injection time.
•  40, 50 and 60 minutes from bolus injection time.
•  2, 2.5, 3, 3.5, 4 hours from the bolus injection time.
In part B additional recordings were made at:
•  5, 6, 7, 8, 9, 10, 11 and 12 hours from bolus injection time and at
1, 2, 3, 4 hours after the end of the infusion.
7.6.5 Pharmacokinetics
Pharmacokinetic (PK) data were collected during part A to allow prediction of appropriate 
doses for part B. Samples were drawn from an indwelling catheter sited in the contralateral 
arm from that being used to infuse drug at:
•  30 minutes, 2, 6 and 12 hours from the bolus infusion time.
In part B, PK samples were taken at:
•  30 minutes
•  2, 6, 12, 24 hours from the start of the infusion.
Plasma was obtained by collecting supernatant following centrifugation at 3000 revs/ minute 
for 10 minutes after which samples were frozen and stored at -20 ° C.
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Plasma drug concentrations were determined by HPLC with UV detection, validated in the 
range 1.25 - 100 ng/ml. Intra-assay coefficients of variation were ranged from 1.0 to 2.5%. 
Inter-assay coefficients of variation were under 4%.
7.6.6 Outcome
The study was not powered to demonstrate efficacy but neurological outcome was measured 
using NIH (appendix I). Functional outcome was assessed by the Barthel Index (appendix 
III). NIH Stroke Scale assessments were made at screening, 24 hours after bolus dosing and 
at 7 ±  2 days. Functional Barthel index was carried out on day 7 ±  2.
7.7 Results
7.7.1 Recruitment and demographics
Four clinical sites participated in the study: three in the US and one in the United Kingdom. 
Forty six patients were admitted to the study: 36 received aptiganel and 10 were given 
placebo.
Part A
Four dose groups were evaluated in an arithmetic progression i.e. 3mg, 4.5mg, 6mg and 
7.5mg. A total of 21 patients were recruited to this initial part of the study: 16 received 
aptiganel and 5 placebo. At least four patients were evaluated in each dose group prior to 
dose escalation. Demographic details of patients entered into Part A are summarised in the 
table below.
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Demographics of patients admitted to part A of the study.
Bolus administration only.
number o f patients 5 3 3 4 6 16
male 2 2 1 3 1 7
female 3 1 2 1 5 9
w eight (kg)
mean | 69
ij_
66 71 94 80 79
range | 51-91 51-84 57-99 84-113 64-124 51-124
Age (years)
mean 78 | 69 59 74 67 67
range 71-84 47-81 28-83 69-76 47-77 28-83
Part B
The dose initially considered to be the most appropriate for further study was a 6mg bolus 
followed by an infusion of 1 mg/hour.
Twenty-five patients were recruited to part B of the study: 20 received drug and 5 placebo. 
Eight received a 6mg bolus followed by an infusion of 1mg/ hour for a maximum of 12 hours. 
Due to side effects at this dose recruitment was discontinued and a new lower dose assessed 
i.e. 4.5mg followed by 0.75mg/hour. A total of 12 actively treated patients were evaluated at 
this lower dose. Demographic details from part B are summarised in the table below.
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Demographics of patients admitted to part B of the study. Bolus plus infusion.
H H H H I Il8 Sli9 S I ^ H h H hbsmI
number o f patients 5 8 12 20
male 1 2 6 8
female 4 6 6 12
weight (kg)
mean 95 76 72 73
range 59-118
i
50-119 43-126 43-86
age (years)
mean 77 69 71 70
range 67-86 43-85 44-86 43-86
7.7.2 Compliance
Compliance with the protocol was satisfactory. Four patients were discontinued from the trial 
following the serious adverse events documented below. Two patients had the infusion 
discontinued for a short period to allow resiting of iv access but in both cases the correct 
volume of infusate was given by the end of the study.
All appropriate clinical and Stroke Scale assessments were carried out at the appropiate 
time. Biochemistry and haematology at discharge were omitted in patient 301 (6+1mg dose).
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7.7.3 Part A Serious adverse events
Mortality
There were three deaths in part A of the study. No deaths were thought likely to be 
attributable to study treatment.
Placebo
One placebo patient died from a recurrent stroke on day 21 after treatment.
Aptiganel
The other two deaths received active treatment at the 6mg dose and both died 3 days after 
treatment. One 78 year old patient suffered a stroke following pacemaker insertion. He was 
known to have complicating congestive cardiac failure, pulmonary and systemic hypertension 
and coronary heart disease. He died of respiratory failure following an episode of 
pneumonia. A 75 year old male with a history of coronary heart disease died as a result of a 
respiratory arrest following a large hemispheric cerebral infarction.
Part B
There were no deaths during either the study or the follow up period.
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Part A Serious Non fatal events
CNS effects
CNS effects were reported equally frequently throughout the placebo, 3, 4 .5  and 6mg dose 
groups. CNS effects were both more frequent and severe in the 7.5mg dose group (tables 
7.7 .3 .land 7.7.3.2). Six patients were treated at this dose. Catatonia or marked eyes open 
sedation previously reported in volunteer studies at a dose of 100 mcg/kg was reported in 
one patient and hallucinations in another. Three patients became significantly confused. 
Severe sedation and hallucinations in addition to BP effects discussed below precluded 
further evaluation of this dose and thus the lower bolus dose of 6mgs was chosen for initial 
assessment in part B.
Haemodynamic effects
Rises in systolic blood pressure were noted in several patients receiving active treatment 
compared with a BP fall in those receiving placebo. Rises in systolic blood pressure became 
increasingly frequent at the higher doses. One patient (102) out of 3 patients at the 3mg 
dose had a significant rise in blood pressure (>35 mmHg). Blood pressure, in this individual, 
rose from 122/76 mmHg to a peak of 198/88 one hour after dosing (figure 7.7.3.1). One of 3 
patients at the 4.5mg dose (203) exhibited a less dramatic increase in BP from 148/73 at 
baseline to 202/95 at 2.5 hours (figure 7.7.3.2). Two of three patients at the 6mg dose had 
rises of 44 (302) and 38mmHg (303) respectively (figure 7.7.3.3). In the highest dose group 
(7.5mg) 3/6 actively treated patients suffered significant rises in BP. Patient 404 had a rise 
from 133/74 baseline to 182/76 (49 mmHg rise in systolic blood pressure); 407 rose from 
164/83 to 224/114 (60 mmHg); 403 from 154/74 to 216/80 (62 mmHg). Patient 403 was 
given a single sub-lingual dose of nifedipine to reduce blood pressure 40 minutes after the 
bolus injection. The remaining three patients’ blood pressure varied consistent with expected 
fluctuations (figure 7.7.3.4). The average rise in BP within the 7.5mg dose group (34 mmHg)
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was considered too high for further evaluation in part B (figure 7.7.3.5). There were no 
significant rises in blood pressure within the placebo group.
PartB Withdrawals 
During infusion
In total 4 patients had their medication discontinued. Three received the 6mg bolus/ 1mg per 
hour infusion and 1/8 was withdrawn from the lower 4.5mg bolus followed by 0.75mg/ hour 
group. The AE details and times of stopping study drug are described in the table below.
903 HS 6mg+1 m g/hr 11 hours Patient became rigid and unresponsive
908 KSB 6mg+1 m g/hr 43 minutes Patient developed marked subendocardial 
ischaemia associated with 30mmHg rise in mean 
blood pressure
910 BT 6mg+1 m g/hr 60 minutes 50mmHg rise in blood pressure with numerous 
PVB’s on ECG monitoring
961 RDD 4 .5m g+0.75m g/hr 4 hours 15 
minutes
Patient respiratory function deteriorated: cyanosis, 
reduced respirations and oxygen saturation
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C N S  effects
CNS and psychotomimetic effects were severe and frequent at the 6mg/1mg per hour dose 
(tables 7.7.3.1 and 1 .7 .72 ). Six out of eight patients in this group developed profound 
sedation. Five patients developed symptoms within 2 hours of administration and 4 of these 
5 required discontinuation of study drug infusion. One patient in the high dose group had late 
onset of sedation 11 hours following administration.
Further recruitment to this group was terminated and a lower dose selected for further study. 
Only one patient in the 4.5mg /  0.75mg group developed significant sedation but symptoms 
were severe and prolonged lasting 4 days (patient 958). In this individual sedation was also 
associated with agitation and hallucinations. It is unclear whether this duration of symptoms 
was due to a drug associated event, or a neurological deterioration related to the underlying 
stroke.
Vital signs
In the group receiving 6mg+1m g/ hr three out of eight patients were treated for hypertension 
due to blood pressure increases resulting in systolic BP of > 210 mm Hg. Patient 909 is one 
such patient who required iv labetolol for control of blood pressure. The BP profile is 
summarised in figure 7.7.3.6 as an example. There was a significant rise in the mean 
arterial blood pressure in this group of patients (figure 7.7.3.7).
Within the 4.5mg + 0.75mg/hr dose group there was an average 30 mm Hg rise in systolic 
blood pressure. Four out of eight of the patients recruited to this lower dose infusion group 
required anti-hypertensive treatment. Patients within this group who received anti­
hypertensive therapy had dramatic reductions in blood pressure following treatment. Figure 
7.7.3.8 gives an example of the blood pressure profile in a patient requiring sub-lingual
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nifedipine for control of blood pressure and figure 7.7.3.9 summarises the mean blood 
pressure changes over time.
Other adverse events
Systemic adverse events were no more frequent in the treated patients compared with 
placebo.
Gastrointestinal upsets were more common in the lower4.5mg + 0.75mg dose group 
compared with placebo or 6+1 mgs. 5 patients complained of dyspepsia while 3/12 had 
episodes of vomiting. Urinary complaints were more commonly reported as adverse events 
in patients receiving extended infusions. This was associated with the insertion of Foley 
catheters leading to discomfort, irritation, infection and abnormal urinalysis results.
7.7.4 Laboratory results
Analysis of haematology, urinalysis and biochemistry did not reveal an excess of 
abnormalities in the aptiganel receiving patients. Urinalysis were positive for blood and 
protein in those patients who required catheterisation but there was no excess in those 
receiving drug rather than inactive placebo. No significant excess of ECG abnormalities 
were reported in the actively treated patients.
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7.7.5 Treatment acceptability
All treatment allocations were determined to be either acceptable or unacceptable based on 
the safety and tolerability profile for each individual. This assessment was made by the 
investigator personally responsible for the management of that individual patient and took 
into consideration the patient’s own perception of acceptability as well as the physician’s.
Part A
All placebo receiving patients treatments were considered acceptable as were ail patients 
receiving active treatment with bolus doses of 3, 4.5, and 6mg. 2/6 individual treatments at 
the 7.5mg bolus dose were considered unacceptable. Patient 406 found psychotomimetic 
effects unacceptable as did patient 407 who also experienced an asymtomatic rise in blood 
pressure of > 30/15 mmHg which was of concern to the treating physician.
Part B
Four out of seven treatments in the 6 + 1mg group were deemed to have been unacceptable 
by the investigating physicians. Patient 904 developed a hypertensive crisis, generalised 
catatonia and hallucinations. Patient 903 developed catatonia and rigidity 11 hours after the 
maintenance infusion had been commenced. Patient 908 developed generalised 
subendocardial myocardial ischaemia and the maintenance infusion was stopped after 43  
minutes. This was asociated with a significant rise in systolic blood pressure. Patient 910  
developed catatonia and multiple ectopic beats on cardiac monitoring.
Of those treated at the 4.5 + 0.7mg dose; patient 953 developed significant sedation and 954 
developed nausea and vomiting. Both effects were considered to be acceptable with
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reservation expressed by the investigators concerned. It is possible that the nausea and 
vomiting were not drug effects as these symptoms are frequently reported in stroke patients 
including the placebo receiving patients in the control group.
7.7.6 Pharmacokinetics 
Part A
Mean concentrations of aptiganel for the bolus doses are shown in figures 7.7.6.1, 7.7.6.2,
7.7.6.3 and 7.7.6.4. Patient weight did not correlate with plasma concentrations achieved. 
Concentrations above the putative neuroprotective drug concentration were obtained in 
patients receiving the 4.5mg doses and above.
Part B
Plasma levels achieved during the two prolonged infusion regimens did not differ significantly 
from each other (p = 0.35 ANOVA). Concentrations achieved by both doses exceeded 
putative neuroprotective levels (figure 7.7.6.5). Infusions were, however, prematurely 
discontinued in the 6mg + 1mg infusion group in 3 /  8 patients. Plasma pharmacokinetics 
remained linear and clearance was unaffected by the duration of infusion. Patient weight did 
not influence concentrations achieved. There was no correlation between plasma levels 
achieved and the severity of side effects reported. The Cmax ranged widely, from 10-21 
ng/ml, in those patients whose side effects required discontinuation of infusion. 
Pharmacokinetics are summarised in the table below.
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Summary of clinical pharmacokinetics
E B
m m
3 5.8 1565 371 3
sem (0.6) (536) (53)
4.5 11.1 1557 367 2
sem (1.8) (101) (34)
6 13.5 1557 480 4I
sem (3.4) (493) (112)
7.5 16.3 1532 365 6
sem (1.5) (137) (31)
6+1 16.5 1228 540 8
sem (1-4) (129) (57)
4.5+0.7 | 14 1224 547 11
sem (2.1) (208) (91)
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7.7.7 Clinical outcome
The NIH stroke scale was assessed at admission and then at discharge. Most recordings 
were obtained between 5 and 7 days post treatment, but the variability in time to discharge 
was wide. The power of the study was not sufficient to test for drug efficacy. There was no 
significant difference between placebo and actively treated groups in terms of the NIH Stroke 
Scale or Barthel index (figures 7.7.7.1 and 7.7.7.2).
7.8 Discussion
In a population of stroke patients a non-weighted adjusted dose of 4.5mg followed by an 
infusion of 0.75mg/hour achieves and maintains plasma levels thought to be neuroprotective 
in animals (10 ng/ml). This dosing schedule appears reasonably well tolerated, but is 
associated with notable haemodynamic effects (a mean rise in systolic blood pressure of 
30mmHg). Sedation was reported in 1/12 individuals but the syptoms were both prolonged 
and severe. W hether or not the reported sedation was a true drug effect will only be 
answered by a larger study.
Higher dose infusions of 6mg + 1mg per hour infusions were associated with more dramatic 
increases in blood pressure and frequent reporting of intolerable CNS side effects of agitation 
and catatonia. The assessment of this dose was abandoned as the haemodynamic and side 
effect profile was unacceptable to both investigators and patients.
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It is always possible that a study with an ascending dose design will be prematurely 
discontinued due to clustering of chance adverse events. Similarly the acceptable tolerability 
obtained at a lower dose may not be repeated in a larger study. This potential bias can be 
addressed by treating larger numbers of patients at the doses of interest. In this particular 
study the side effects and adverse events reported at the 6mg+1mg/h dose were so dramatic 
and consistent with experience from C N S-1102 volunteer and other NMDA antagonist studies 
as to suggest further evaluation of the 6mg + 1mg/ hr dose to be unwise, if not unethical. It 
remains conceivable that a larger phase III trial could report a higher frequency of adverse 
events at the 4.5+0.75m g /hr dose.
Most patients within the 6mg + 1 mg/hr dose group had increases in blood pressure. Blood 
pressure was also increased to a lesser extent within the 4.5mg + 7.5mg group and settled to 
levels comparable with placebo after 4 hours.
Haemodynamic changes are likely to influence cerebral haemodynamics which could 
positively or negatively influence stroke outcome. At the time of cerebral ischaemia, 
cerebral autoregulation is lost. Thus changes in blood pressure could directly influence 
changes in local cerebral perfusion particularly in penumbral areas. Reductions in blood 
pressure, i.e. those induced by treatment that may be given to counteract the effects of 
aptiganel could potentially reduce the local cerebral perfusion of the ischaemic area. While 
moderate rises in blood pressure may be beneficial by increasing blood flow to ischaemic 
areas of brain dramatic increases in blood pressure such as those obtained with higher doses 
of aptiganel could potentially lead to an increased risk of reperfusion injury and even 
haemorrhagic transformation of infarction.
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While studies of aptiganel in human volunteers suggest that as blood pressure is increased 
there is no change in total cerebral blood flow, this may not be the case in stroke patients. In 
addition total cerebral blood flow may be unaltered while local perfusion to ischaemic areas 
changes significantly.
Treatment which lowers blood pressure in the acute stroke phase has been reliably 
demonstrated to worsen clinical outcome. This was reported in the INW EST trial of 
intravenous and oral nimodipine therapy in patients with acute stroke54 and also in a study of 
the neuroprotective ion channel blocker lifarizine.55 As yet the clinical effects of a moderate 
increase in blood pressure similar to that observed in the lower infusion dose group is 
undefined.
In conclusion the 4.5mg/0.75mg/hour dosing regimen was not associated with excess CNS or 
psychotomimetic effects when compared with placebo, but was associated with a 
hypertensive effect. Further evaluation of the efficacy of the 4.5mg + 0.75mg/hour schedule 
is merited within a Phase III clinical efficacy study, but haemodynamic effects should 
continue to be carefully addressed.
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Final conclusions and future prospects
The prevention and treatment of cerebrovascular disease remains a major challenge for 
physicians and researchers. While antihypertensive therapy is established as an effective 
form of primary prevention, studies continue to investigate its effectiveness in secondary 
prevention. Controversy exists regarding when anti-hypertensive therapy should be 
instituted. Our study indicates that commencing ACE inhibition between 3 and 7 days 
following stroke is both effective and safe.
There were two limitations of that study. First, patients with severe carotid disease were 
excluded on safety grounds that were valid at the time the study was designed. Knowing that 
the treatment was safe in patients with normal carotid arteries now allows us to consider 
extending treatment to patients with stenosis. Second, we confirmed that total carotid flow 
was unaltered by treatment but have not excluded effects on local perfusion in the peri- 
infarct region, as Doppler would be insensitive to flow redistribution. A further study has now 
been designed and ethics approval gained, that will deal with these points. It will also 
consider a third, previously disregarded, issue: it will investigate the incidence of clinically 
important renovascular disease in patients with cerebrovascular disease who are to be 
treated with an ACE inhibitor.
Patients with recent cerebrovascular disease will be recruited. They will be stratified 
according to presence or absence of moderate to severe occlusive carotid disease. After 
baseline screening of cerebral blood flow by both Doppler and SPECT scanning and after 
assessment of renal function by radio-isotope methods, patients will be randomised to
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receive perindopril or placebo once daily for two weeks. The effect of perindopril on renal 
function, on total cerebral blood flow and on local perfusion will each be assessed.
The PROGRESS secondary stroke prevention study continues to study patients who may 
have occult carotid or renal artery stenosis. The results from the above proposed trial may 
assist in interpretation of the results of PROGRESS, and assuming that blood pressure 
lowering is proven beneficial, may guide selection, investigation or monitoring of patients in 
future years.
The work described in chapter 3 arose from a more general examination of risk factors in our 
patient population, and from testing of a hypothesis that patients with raised cholesterol had a 
greater risk of secondary events and should be offered cholesterol-lowering treatment. Our 
counter-intuitive results have certainly stimulated debate within the medical literature.257'261 
More important, most correspondents agree that a trial of cholesterol-lowering in elderly 
patients with cerebrovascular disease is not only ethical but essential. Debate continues 
over the entry criteria for such a study: should it be restricted to patients without evidence of 
ischaemic heart disease, should there be fixed age limits, should there be baseline 
cholesterol limits, which drug should be used to lower the cholesterol? W e  plan to resolve 
these issues in discussion with colleagues throughout the UK and to initiate a multicentre 
study within the next 12-18 months.
Chapter 4 has considered the role of hyperglycaemia in determining outcome after acute 
stroke. No single study can resolve the issue of whether the hyperglycaemia is truly 
independent of stroke or is a stress response. The study that we have published has, 
however, stimulated further debate and has prompted ourselves and others finally to initiate 
pilot trials of intervention for hyperglycaemia complicating stroke. Thus, we are randomising 
patients who present with a blood sugar of > 8mmol/L to receive standard medical care or 
tight control of blood sugar with insulin (target range 5 - 8  mmol/L). W hen possible, patients
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also have a baseline MRI scan with diffusion- and perfusion-weighted imaging, followed after 
1 month by a T2-weighted MR scan. If insulin improves outcome, the imaging may assist in 
deciding whether it acts via a local effect to restrict infarct size or a systemic effect. Clearly, 
a multicentre study is likely to be required, and we have started to seek grant funding to 
collaborate on this with other European centres.
In chapter 5, I have described the initial administration to stroke patients of a novel glycine 
antagonist, GV150526. The results of that study have provided the essential information on 
which a choice of loading infusion and selection of maintenance doses have been based for 
two large phase 3 trials with this drug. The phase 2 study that I have undertaken not only 
demonstrated the good tolerability of GV150526 in comparison with other means of 
manipulating the NMDA receptor, but also confirmed the pharmacokinetics of GV150526 in 
stroke patients. When coupled with the new information on an effect of G V150426 on 
bilirubin transport/metabolism and/or hepatic function, it is now clear what the dose-limiting 
effects of this drug are in man, and clear that it is possible to administer sufficient drug to 
maintain putative neuroprotective plasma concentrations of GV50526 for several days after 
acute stroke. The fact that a single centre can establish so much information in under a year 
is impressive, and offers a lesson to other pharmaceutical companies. Only the phase 3 trials 
will answer whether outcome can be improved.
The lessons from remacemide, in chapter 6, have also been of considerable importance for 
future drug development. This was also a single centre study. W e  showed early on, that oral 
drug administration is impractical after acute stroke. W e  have established a maximum  
tolerated dose of remacemide that could be considered for future stroke trials. The study 
also suggested strongly that continued development of remacemide for this indication may 
be unwise: the adverse effects of the drug appear to be related to the active metabolite.
The neuroprotective effects are probably also related to the metabolite. Since, with the 
administration regime that was used, the metabolite concentrations and the adverse effects
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accumulated during repeated daily dosing, it is likely that neuroprotective concentrations 
were not attained until many hours after treatment was initiated. The use of a pro-drug such 
as remacemide would therefore delay effective neuroprotection and render it ineffective.
The sponsoring company, Astra, have recognised this shortcoming and have since switched 
their interest to a related compound that has inherent activity, ARL15896AR. Studies with 
ARL15896AR have been conducted in our unit over the last year.
Finally, in chapter 7, another potential neuroprotective drug, aptiganel hydrochloride, was 
assessed. This study was crucial in confirming that weight-independent dosing was practical 
and safe, and in identifying the maximum tolerated loading and maintenance doses for future 
phase 3 stroke trials. Since then, a phase 3 stroke trial has been underway. At present, 
recruitment is on hold pending and interim safety and efficacy analysis.
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Table 7.7.3.1: CNS Adverse events in patients receiving bolus doses of 
aptiganel. All CNS adverse events reported within 7 days of drug treatment. 
Number of specific events reported in each dose group.
llllllBSIII1PPPff
n=5 n=3 n=3 n=4 n=6
headache 1 1 1 0 4
visual disturbance 0 0 1 1 2
sedation 1 1 1 1 4
anxiety 2 1 2 1 2
confusion 2 2 2 1 3
hallucinations 0 0 0 0 2
paranoia 0 0 0 0 1
nystagmus 0 0 0 0 2
anarthria 0 0 0 0 1
lightheadedness 1 1 2 0 3
total 7 6 9 4 24
A E’s per patient 1.4 2 3 1 4
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Table 7.7.3.3: CNS adverse events reported in patients receiving bolus
aptiganel followed by infusion.
m
headache 1 3 2
visual disturbance 0 3 1
sedation 1 5 10
anxiety 2 5 3
agitation 1 3 4
confusion 0 5 4
hallucinations 0 1 4
insomnia 0 0 1
lightheadedness 1 1 1
total 6/5 26/12 30/8
A E’s per patient 1.2 2.2 3.8
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Appendix I
NIH Stroke Scale
The NIH Stroke Scale is an established reliable tool for the assessment of patients 
with acute stroke. It can be reliably performed by trained nursing and medical 
staff.129
NIH Scale N,H
Level of Consciousness Score
0 = Alert, keenly responsive
1 = Drowsy, but reusable by minor stimulation to obey, answer or respond
2 = Stuporous, requires repeated stimulation to attend, or lethargic or obtunded, [__|
requiring strong or painful stimulation to make movements
3 = Coma, responds only with reflex motor or autonomic effects, or unresponsive
Level of Consciousness - Questions
Ask patient the month and his/her age. Score first answer.
0 = Answers both correctly
1 -  Answers one correctly_________________________________________________________ j__ j
2  =  I n c o r r e c t
Level of Consciousness - Commands
Ask patient to open/close hand and eyes. Score if he or she makes unequivocal attempt.
0 = Obeys both correctly
1 -  Obeys one correctly___________________________________________________________ I__I
2 = Incorrect
Pupillary Response
0 = Both reactive
1 = One reactive
2 *  Neither reactive
Best Gaze
0 = Normal
1 = Partial gaze palsy, abnormal but not forced deviation________________________________]__|
2 = Forced deviation/total gaze paresis
Best Visual
Confrontation testing using finger movements, including double simultaneous 
stimulation. Use visual threat if consciousness or comprehension limit testing, scoring '1' 
for any asymmetry demonstrated
0 = No visual loss .
1 = Partial hemianopia I— I
2 = Complete hemianopia, to within 5 degrees of fixation
continues
217
NIH Scale, continued
Facial Palsy
0 = Normal
1 = Minor
2 -  Partial
3 *= Complete
Best Motor - Arm
Arms held for 10 seconds at 90 degrees if sitting, 45 degrees if lying. Grade weaker 
arm. Place arms in position If comprehension reduced.
0 -  No drift in 10 seconds
1 = Drift, after brief hold
2 = Cannot resist gravity, falling immediately but some effort made
3 = No effort against gravity
Best Motor Leg
While lying, patient to hold weaker leg raised 30 degrees for 5 seconds. Place leg if 
comprehension reduced.
0 = No drift in 5 seconds
1 = Drift, lowering within 5 seconds
2 ” Cannot resist gravity, falling to bed but some effort made
3 = No effort against gravity
Plantar Reflex
0 = Normal
1 = Equivocal
2 = One extensor
3 ~ Bilateral extensor
Limb Ataxia
Finger-nose and heel-to-shin tests performed; ataxia is scored only if out of proportion to 
weakness. If total paralysis, score as absent.
0 -  Absent
1 -  Present in arm or leg
2 = Present in arm and leg
NIH
Score
u
u
u
u
u
cantiniNS
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NIH Scale, continued
Sensory
Tested with pin; only hemisensory loss record. If comprehension or consciousness 
reduced, only score if obvious evidence.
0 = Normal
1 = Partial loss, subjectively different but still felt
2 = Dense loss, unaware of being touched
Neglect
0 -  No neglect
1 = Partial neglect; visual, tactile or auditory
2 a Complete neglect; affecting more than one modality
Dysarthria
0 *  Normal articulation
1 = Mild to moderate dysarthria, slurring some words
2 = Near unintelligible or worse
Best Language
Assessed from responses during evaluation.
0 = No aphasia
1 = Mild to moderate aphasia; naming errors, paraphrasia, etc
2 = Severe aphasia
3 = Mute
Total Score (0-36)
Canadian Stroke Scale 
1. M E N T A T IO N
L e v e l o f Consciousness: A le rt =  N o rm al; D ro w sy — A w ake  bu t dozes;
O rien tatio n : O rien tated  =  P lace +  T im e
N o t A pp licab le  =  Com prehension or Speech D e fic it
Speech: Repeat 3 com m ands (tw ic e  each i f  necessary).
R eceptive D e fic it -  O beys 2  o r less com m ands.
I f  recep tive d e fic it, proceed to  testing m otor function .
I f  obeys, ask p a tien t to  nam e 3  objects (p en c il, w atch, ke y ).
Expressive D e fic it =* N am es 2  o r less objects.
I f  can nam e objects, ask "W h at do  you do w ith  a p e n c il/ 
w atch/key?"
N o rm a l — A nsw ers 3 questions correctly.
Expressive D e fic it -  A nsw ers 2  o r less questions correctly. 
2 A . N O  C O M P R E H E N S IO N  D E F IC IT  -  M O T O R  F U N C T IO N  
W E A K N E S S
N on e — N o  detectab le w eakness.
M ild  -  N o rm a l m ovem ent against g rav ity  bu t succumbs to  resistance. 
S ign ifican t =  C annot co m p lete ly  overcom e g rav ity .
T o ta l A bsence o f m otion o r o n ly  contraction o f m uscles w ithou t m ovem ent o f  
lim b .
2 B . C O M P R E H E N S IO N  D E F IC IT  - M O T O R  F U N C T IO N
Face: S ym m etrical =  S ym m etrical response to  pa in , eg sternal pressure.
Arm s: E qual
Legs: E qu al
M a in ta in  fix e d  posture fo r  a few  seconds o r w ith d raw  equally to
pain.
M a in ta in  fix e d  posture fo r  a few  seconds o r w ithdraw  equally to  
pa in .
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Appendix III 
Barthel index
The Barthel is a functional evaluation of recovery following stroke129
Barthel Index barthel
Bowels Score
0 = Incontinent (or needs to be given enemata) . .
1 -  Occasional accident (once/week) '— ‘
2 = Continent
Bladder
Q = Incontinent or catheterised and unable to manage alone
1 - Occasional accident (max once/day) I— I
2 = Continent (for over 7 days)
Grooming
0 = Needs help with personal care I |
1 -  Independent face/hair/teeth/shaving (implements provided)
u
Toile t Use
0 = Dependent
1 = Needs some help, but can do something alone
2 = Independent (on and off, dressing, wiping)
Feeding
0 = Unable
1 = Needs some help, but can do something alone 1— I
2 = Independent (food provided in reach)
Transfer
0 = Unable - no sitting balance
1 = Major help (one or two people, physical) can sit I— I
2 = Minor help (verbal or physical)
3 = Independent
Mobility
0  -  Immobile
1 ® Wheelchair independent, Including comers, etc i i
2 = Walks with help of one person (verbal or physical)
3 = Independent (but may use any aid, eg stick)
Dressing
0 -  Dependent , ,
1 = Needs help but can do about half unaided '— '
2 = Independent (including buttons, zips, laces, etc)
Stairs
0  *  Unable
1 = Needs help (verbal, physical, carrying aid)
2 = Independent up and down
Bathing
0  « Dependent |__ |
1 = Independent (or in shower)
Total Score (0  - 2 0 )
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